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ABSTRACT 
Parenchyma and stroma represent the functional and structural units in every organ of the body 
respectively. Stromal cells of mesenchymal origin (MSC) have traditionally been associated with a 
structural support activity within the tissue, but it is only recently that more complex functions have 
been unveiled. Subsets of MSC have been shown to play a fundamental role in self-renewal and 
differentiation of haematopoietic stem cells (HSC). Recent findings show that MSC and bone marrow 
(BM) macrophages represent fundamental components in the niche, modulating egress and 
mobilization of HSC during normal or emergency myelopoiesis. Therefore, I have decided to 
investigate whether and how MSC contribute to the formation and function of myeloid cells. In an in 
vitro co-culture model I have observed that MSC have the ability to induce the expansion and 
differentiation of different subsets of mature myeloid cells from haematopoietic BM cells. Based on 
the differential expression of CD11b and Gr-1, three cell subsets recapitulating myeloid 
differentiation could be identified. MSC induced differentiation targets common myeloid progenitors 
(CMP) or granulocyte/macrophage progenitors (GMP) but not the primitive HSC. CD11b+ sorted 
cells obtained at the end of the co-culture exhibited a functional profile characterised by high levels of 
both anti- and pro-inflammatory markers, such as nitric oxide synthase 2 (NOS2) and arginase-1 
(ARG-1). In order to identify the mechanisms involved in this phenomenon I have chosen to 
investigate a number of molecules involved in the regulation of haematopoietic differentiation by the 
microenvironment. I have demonstrated that whilst NOS2 and agrin, an ECM protein, play a key role 
in the differentiation of CD11b+ Gr-1- F4/80+ cells, complement appears to be primarily involved in 
the generation of CD11b+ Gr-1int-low F4/80- cells. My studies have shown that MSC differentiating 
activity is not confined to the BM but can also be detected in MSC from other tissues like skin and 
kidney. Overall these results suggest a key role for stromal cells as regulators of myeloid 
differentiation. Further investigation is under way to assess the importance of such a function in vivo. 
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CHAPTER 1.  
INTRODUCTION 
Tissues can be generally defined as consisting of two main components – parenchyma and stroma – 
that represent the functional and structural element, respectively, of an organ. Whilst parenchymal 
cells effect the specific function of the organ in which they reside, stroma comprises all other 
‘accessory’ components, and thus includes cells of both mesenchymal and haematopoietic origin. 
Mesenchymal stromal cells (MSC) have been traditionally related to supportive functions, with 
macrophages being accounted for modulating inflammation. Such a notion has recently been 
challenged by numerous studies indicating that an interaction between MSC and macrophages might 
play a fundamental role in tissue homeostasis. 
1.1 MESENCHYMAL STROMAL CELLS 
1.1.1 Definition of mesenchymal stromal cells 
The definition of mesenchymal stromal cells (MSC) according to the criteria outlined before present a 
substantial overlap with the traditional concept of tissue fibroblasts (Figure 1.1). However, the last 
decade has seen a renewed interest in MSC because, irrespective of the tissue from which they can be 
sourced, they contain a large proportion of cells capable of differentiating into mature mesenchymal 
tissues such as adipocytes, chondrocytes and osteoblasts [2, 3]. MSC can be isolated from the bone 
marrow (BM) and virtually all tissues, both in adult and foetal life [3-9]. They have been described to 
be capable of differentiating also into endothelial cells [10], neural cells [11] and cells of endodermal 
origin [12], but the evidence available is limited.  
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These findings have led to introducing the misleading terminology of ‘mesenchymal stem cells’. The 
same confusing terminology is used to include other ‘stromal cells’ [13, 14], like reticular cells, 
pericytes.  Although the origin of such confusion is primarily semantic, there is a need to unravel the 
complex question of their developmental origin. 
1.1.1.1 Source and ontogeny of MSC 
Several studies have attempted to identify MSC progenitors that would possess embryonic stem cell 
(ESC) features. In this way, the existence of mesodermal progenitor cells (MPC) [15], and marrow-
isolated adult multilineage inducible cells (MIAMI) [16] was discovered, augmenting the poor 
approaches used in the many attempts to define MSC. Very small embryonic like stem cells (VSEL) 
represent another population identified in vivo that expresses markers of pluripotent stem cells [17]. 
Furthermore, in the BM other cells with precursor characteristic were isolated, such as multipotent 
adult progenitor cells (MAPC), showing ability to differentiate in vitro into various lineages and to 
contribute to haematopoiesis upon transplantation [18].  
A recent work from Vodyanik has suggested that MSC might share the same precursor with 
haematopoietic and endothelial cells, the so called ‘mesenchymoangioblast’ [19]. Indeed, it has been 
proposed that MSC are associated with blood vessels in vivo [20, 21]. Several reports suggest that 
pericytes, cells that are located on the abluminal side of blood vessels in close contact with 
endothelial cells, show great similarity with MSC in vitro [22], and may behave as tissue specific 
stromal cells in vivo [23, 24]. In line with these findings, transplantation of MCAM/CD146+ 
subendothelial cells from human BM stroma established a haematopoietic niche to heterotopic sites, 
through specific interactions with developing sinusoids [25].  
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FIGURE 1.1. Mesenchymal stromal cells phenotype and related tissue-specific entities.  
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1.1.1.2 Phenotype of MSC 
MSC are defined as plastic adherent cells expressing stromal markers like CD73, CD105, CD90, 
CD106 and CD44, and lacking haematopoietic and endothelial markers (CD45, CD11b, CD34, CD14 
and CD31) (Figure 1.1) [4]. A trypsin resistant antigen, STRO-1, has been proposed as marker for 
human MSC [26], although its expression is shared by endothelial progenitors and is lost by MSC 
during culture [27]. Neuronal markers, such as low-affinity growth factor receptor-1 (LNGFR1) [28] 
and ganglioside GD2 [29], have been identified in human MSC. Indeed, the notion of a possible 
neuroepithelial ontogeny of MSC has been supported also by a work from Takashima et al. [30], thus 
confuting their broadly accepted mesodermal origin. 
Different markers associated with an embryonic phenotype have been proposed to identify mouse 
MSC, like stage-specific embryonic antigen-1 (SSEA-1) [31]. More recently, Morikawa et al. 
suggested the expression of platelet derived growth factor receptor α (PDGFRα) and stem cell 
antigen-1 (Sca-1) in the absence of TER119 and CD45 to characterise the subset with higher 
differentiation potential [32]. This subset of cells could generate colonies in vitro at high frequency, 
and differentiate into haematopoietic niche cells, osteoblasts and adipocytes after in vivo 
transplantation [32].  
Despite few differences in markers that identify them, human and mouse MSC share the expression of 
several receptors associated with specific functions. Growth factor receptors, adhesion molecules, 
cytokine and chemokine receptors can be detected on their cell surface, although expression varies 
with prolonged in vitro culture. Indeed, large in vitro expansion of MSC is consequential to the 
absence of markers that can unequivocally identify these cells ex vivo in their original tissues. 
PDGFR, epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), insulin 
growth factor receptor (IGFR), hepatocyte growth factor receptor (HGFR), and transforming growth 
factor-β receptor I (TGFβRI) and TGFβRII have been detected on MSC [33, 34]. Pattern recognition 
receptors, such as Toll-like receptors (TLR), that detect microbial pathogen associated molecular 
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patterns, are expressed by both human (TLR1 to TLR10) and mouse MSC (TLR1 to TLR8) [35]. Cell 
adhesion molecules including intercellular adhesion molecule 1 (ICAM-1), ICAM-2, vascular cell 
adhesion molecule 1 (VCAM-1, also known as CD106), and lymphocyte function-associated antigen 
3 (LFA-3) can also be detected on their surface [36, 37], as well as various integrin α and β subunits 
[38]. Chemotaxis assays showed that cultured MSC express a broad range of chemokine receptors 
that play a crucial role in their migratory abilities. The list of chemokine receptors includes 
chemokine (C-X-C motif) receptor 4 (CXCR4), as well as chemokine (C-C motif) receptor 1-5 
(CCR1-5), CCR7, CCR9, CXCR3-6 and chemokine (C-X3-C) receptor 1 (CX3CR1) [34, 36, 39, 40]. 
1.1.2 Role of MSC in haematopoiesis 
Haematopoietic stem cells (HSC) are the self-renewing, multipotent progenitors that give rise to all 
mature blood cells. They persist in adult life, and their maintenance and regulation of self-renewal and 
differentiation depends upon both cell-intrinsic and cell-extrinsic mechanisms. The contribution of a 
specific microenvironment to the regulation of HSC is a concept firstly introduced by Curry et al. in 
1967 [41] and then by Schofield et al. in 1978 [42], who referred to a ‘haematopoietic inductive 
microenvironment’ and ‘stem cell niche’, respectively. Although such concept has been known for 
several decades, only recent work shed light to the structure and localization, and also to molecules 
and cell types involved in the formation of the HSC niche.  
Currently, two models of niche are being proposed: the endosteal niche near bone surfaces, and the 
vascular niche associated with sinusoidal endothelium [43]. The endosteum, the cellular lining of 
bone surfaces separating the bone from the BM, has long been viewed as the environment regulating 
HSC.  Osteoblasts, osteoclasts and other stromal cells of mesenchymal origin are associated with the 
endosteum. On the other hand, the vasculature has an important role for the formation and expansion 
of HSC during development. Sinusoidal endothelial cells, perivascular reticular cells, and other cells 
of mesenchymal origin are associated to the perivascular niche. Although it has been proposed that 
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endosteal components maintain the HSC in a quiescent, dormant state, whereas BM endothelial cells 
are responsible of dividing, self-renewing HSC [43], it is still unclear whether these two niches are 
physically and functionally separated or if they contribute to a ‘common’ niche influenced by both 
endosteal and perivascular stimuli [44]. 
1.1.2.1 The endosteal niche 
The first study describing the relationship between haematopoiesis and bone development 
(osteogenesis) dates back to 1970s. After subcutaneous transfer of total BM, Patt and Maloney 
demonstrated that bone was forming before vascularized BM [45, 46]. In the same years, it was 
shown that HSC reside close to the bone surface [47]. It is well known that osteoblasts are directly 
implicated in HSC maintenance. For instance, mouse and human osteoblast cell lines can secrete a 
large number of cytokines that promote the maintenance of HSC in vitro [48].  
The direct proof of the involvement of osteoblasts in HSC regulation came from two simultaneous in 
vivo studies. Both studies were aimed at increasing the number of osteoblasts. The first study utilised 
a constitutively active form of parathyroid hormone (PTH) or the PTH/PTH-related protein receptor 
(PPR) [49], whilst the other employed mice deficient for the bone morphogenetic protein (BMP) 
receptor 1A (BMPR1A), normally expressed on osteoblasts lining the endosteum. In both cases, the 
increase in osteoblast number was associated with parallel increment in HSC [50].   
Amongst the various osteoblast populations, a subset expressing N-cadherin has been proposed to 
directly interact with HSC [51]. This notion was further supported by the finding that an overall 
increase in the number and function of osteoblasts without a concomitant increase in N-cadherin+ 
cells is not sufficient to enhance HSC numbers [52].   
 23 
1.1.2.2 The vascular niche 
Haematopoiesis and vasculature have an intimate relation during embryonic and foetal development. 
HSC are indeed able to self-renew and differentiate before the formation of BM cavities, and they 
undergo haematopoiesis in association with the blood vessels of placenta. Although it is arguable that 
such association could be present only during development and not in the adult, several studies 
suggest the existence of a perivascular niche.  
Similar to osteoblasts, BM sinusoidal endothelial cells can promote the maintenance of HSC in vitro, 
constitutively expressing cytokines such as chemokine (C-X-C motif) ligand 12 (CXCL12, also called 
stromal-derived factor- 1, SDF-1) and adhesion molecules like endothelial-cell (E)-selectin and 
VCAM-1 that are important for HSC mobilization, homing and engraftment [53]. Furthermore, 
endothelial cells are known for supporting the survival, proliferation and differentiation of myeloid 
and megakaryocyte progenitors, suggesting that development of these lineages could be initiated at 
the perivascular niche [54]. Apart from in vitro studies, it has been shown that reticular cells, 
specialised pericytes of BM sinusoids within the vascular medullary network, make contact with HSC 
and more mature blood cells [55]. Several studies have shown that, after myeloablation or stress, HSC 
are mobilized from their quiescent state near the endosteal niche and migrate towards the centre of the 
BM to the vascular zone, near the sinusoidal endothelium [53]. This notion of vascular BM niche as a 
site where HSC are dividing and highly proliferating has recently been confuted by the discovery of 
early precursors attached to the endothelium of BM sinusoids [56].  
1.1.2.3 Contribution of mesenchymal cells to endosteal and perivascular niches 
Mesenchymal progenitors have long been studied for regulating HSC (Figure 1.2). As previously 
discussed, several studies have demonstrated that transplantation of BM stromal cells under the 
kidney capsule results in the formation of bone-like structures, in which osteoblasts, adipocytes and 
reticular cells could be detected [57].  
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Recent findings, based on the adoptive transfer of BM derived mesenchymal precursors, showed that 
a human CD146+ subendothelial subset could give rise to haematopoietic bone upon transplantation in 
mice [25]. Furthermore, two main studies identifying mesenchymal derived candidate niche cells 
strengthen the concept of MSC as fundamental niche components. The first study from Sugiyama et 
al. [58] proposes that reticular cells expressing high levels of the chemokine CXCL12, called CAR 
(CXCL12 abundant reticular) cells closely interact with HSC. Deletion of CXCR4, receptor for 
CXCL12 in mice, determined a reduction in HSC numbers [58]; depletion of CAR cells also led to a 
reduction of HSC numbers, accompanied by a quiescent status and increased myeloid differentiation 
[59].  
Another subpopulation of mesenchymal cells residing on the walls of BM sinusoids proposed as 
candidate niche cells has been characterised in mice by the expression of the cytoplasmic filament 
protein nestin [60]. Nestin-expressing MSC are subendothelial cells spatially associated with HSC 
and sympathetic nerve fibres, expressing HSC maintenance genes such as CXCL12 [60]. Their 
depletion results in an increased mobilization of HSC to the periphery, and poor homing of HSC after 
transplantation. Although it could be argued that CAR cells and nestin+ cells represent overlapping 
cell types, two theories are being diffused: nestin-expressing MSC might represent a functional 
subtype of CAR cells that are found in the perivascular location [61], or CAR cells might represent a 
more committed precursor regulating haematopoietic progenitors rather than HSC [62]. In fact, CAR 
cells depletion was lethal within 5 days, affecting the numbers of various haematopoietic cell types, 
whereas depletion of nestin+ cells only affected HSC numbers.  
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FIGURE 1.2. MSC in the haematopoietic niche. HSC can be found near the endosteal surface, in 
association with CXCL12 abundant reticular (CAR) cells, and near perivascular nestin+ cells. Each niche 
provides signals to support HSC functions, although there is no consensus yet about the specific activity of 
each niche (dotted arrow). Nestin+ MSC are innervated by SNS, which regulates their cell cycle, 
differentiation and expression of HSC retention genes. The relation between nestin+ cells and CAR cells is 
still under investigation. Ang1, Angiopoietin-1, CXCL12, chemokine (CXC motif) ligand 12; CXCR4, 
chemokine (CXC motif) receptor 4; SCF, Stem cell factor (Modified from Mercier et al.). 
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1.1.2.4 Role of MSC in HSC transplantation 
Not only MSC progenitors have been studied for their ability to give rise to niche cells, but also for 
their possible role in favouring the engraftment of HSC. In fact, a large number of studies investigated 
the potential application of cultured MSC in the treatment of graft failure or in HSC transplantation. 
In several experimental mouse models [63, 64] the simultaneous injection of BM derived MSC and 
HSC determined acceleration and increase in the engraftment after total body irradiation. Such effect 
was shown to be MHC-restricted, as the formation of cobblestone colonies of HSC under MHC-
mismatched stromal cells was demonstrated to be decreased in comparison with MHC-matched 
stromal cells [65]. These data prompted investigations also in clinical transplantation, although the 
results obtained were inconsistent [66, 67].  
The first clinical trial on breast cancer patients undergoing autologous HSC transplantation in 
combination with culture-expanded MSC showed that haematopoietic recovery was accelerated [67]. 
However, this beneficial effect has not been confirmed in allogeneic HSC transplantation even when 
donor and recipient are HLA identical siblings [68]. Furthermore, there is no evidence of long-term 
engraftment of adoptively transferred MSC in the host stroma [69].  
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1.1.3 MSC and the immunomodulatory function 
In recent years, much attention has been paid to a unique property of MSC, apparently unrelated to 
their primary function in regulating haematopoietic differentiation. MSC have been found to exhibit a 
potent immunosuppressive activity that can target virtually every cell of the immune system (Figure 
1.3). 
1.1.3.1 MSC and T lymphocytes 
The first indications on the immunosuppressive action of MSC come from studies on humans [70-73], 
baboons [74], and mice [75, 76] demonstrating that MSC are able to suppress the activation and 
proliferation of T cells in vitro. This inhibition affects CD4+ and CD8+ T cells, independently of 
whether they are naïve or antigen-experienced [76], and regardless of the stimulus utilised, whether 
putative or allo-antigens [71-74], mitogens such as phytohaemagglutinin (PHA) [70, 71, 77], 
Concanavalin-A (ConA) [71, 75], and tuberculin [78], or CD3/CD28 agonists [73, 76, 79]. The effect 
is dose-dependent, as inhibition increases with increasing amount of MSC, but it has been proposed 
that low concentration of MSC may stimulate rather than inhibit mixed leukocyte reactions (MLR), 
although the experimental approaches utilised are questionable [71, 72, 78].  
MSC have been reported to inhibit the cytotoxic effects of cytotoxic T cells (CTL) [72], although it 
seems to be related to their ability to suppress proliferation rather than inhibiting the effector function 
[80, 81]. Suppression of T cell proliferation is not MHC restricted, as similar effects are being 
observed whether MSC were autologous or allogeneic to the responder cells [76, 82, 83]. 
Interestingly, it appears that MSC inhibitory effect can overcome also species barriers [75].  
MSC induce the arrest of T cell cycle in G0/G1 phase, strongly inhibiting cyclin D2 and up-regulating 
cyclin dependent kinase inhibitor p27kip1 [84]. Although it has been proposed that MSC can induce T 
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cell apoptosis by converting essential amino acid tryptophan into its breakdown products [85], this 
notion is still controversial [71, 77]. It is instead broadly accepted that MSC can induce T cell anergy. 
Whether anergy is the consequence of the absence of co-stimulatory molecules, such as CD80 or 
CD86, on MSC surface remains to be convincingly demonstrated [73, 75, 82]. In fact, a study by 
Klyushnenkova et al. [82] showed that up-regulating co-stimulatory molecules in MSC did not result 
in increased T cell proliferation. Several studies have shown that the unresponsiveness of T cells is 
transient and can be restored after removal of MSC [70, 76], whereas others suggest that T cell anergy 
is induced [86].  
1.1.3.2 MSC and B cells 
T cells are not the only target of MSC mediated immunosuppression. Consistent with the non-specific 
anti-proliferative activity also the proliferation of pokeweed mitogen stimulated B cells can be 
inhibited by murine MSC [87]. Spleen derived B cells stimulated with T cell dependent stimuli, such 
as CD40 and IL-4, can also be suppressed by MSC [84]. In an experimental model of human systemic 
lupus erythematosus (SLE), BXSB mouse, allogeneic MSC can inhibit the proliferation, activation 
and immunoglobulin G (IgG) secretion of B cells [88]. Also human MSC have been described for 
their inhibitory effect on B cells previously activated either with anti-Ig antibodies, soluble CD40 
ligand or cytokines. Not only were they able to suppress the proliferation of B cells, but MSC also 
affected the differentiation, antibody-production and chemotactic activity in response to CXCL12, 
CXCL13, and chemokine (C-C motif) ligand 19 (CCL19) [89]. In a murine model of multiple 
sclerosis, the production of antigen specific antibodies was inhibited by the infusion of MSC, as well 
as T cell responses [90]. However, other in vitro studies showed that MSC support the proliferation 
and differentiation into Ig secreting cells of naïve B cells, either isolated from healthy donors or from 
pediatric SLE patients [91].  
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1.1.3.3 MSC and natural killer cells 
MSC can modulate also the activity of natural killer (NK) cells. MSC can inhibit IL-2 or IL-15 driven 
proliferation of NK cells, and also their cytokine [interleukin-10 (IL-10), interferon-γ (IFN-γ), tumour 
necrosis factor-α (TNF-α)] production [79, 92]. The cytotoxic activity of resting [93] and IL-2 
activated NK cells is also reduced in culture with MSC [94]. Furthermore, a short-term culture with 
MSC reduces NK cell cytotoxicity against HLA class I expressing tumours, but not on HLA class I 
negative tumours [92].  
As MSC express very low levels of HLA class I molecules, they can be lysed by IL-2 activated NK 
cells [92]. MSC also express several ligands for activating NK cell receptors, such as UL16-binding 
proteins, polio virus receptor (PVR) and nectin-2 [93]. Nevertheless, IFN-γ exposed MSC are not a 
target of NK mediated lysis, as IFN can up-regulate the expression of HLA molecules on MSC 
surface [93]. Adoptively transferred MSC could therefore be protected from lysis by activated, IFN-γ 
producing NK cells during inflammatory conditions. 
1.1.3.4 MSC, monocytes and dendritic cells 
Antigen presenting cells (APC) are also a target of MSC. In vitro studies have demonstrated that MSC 
can inhibit the differentiation of DC from monocytes [95, 96] or from IL-4 and granulocyte-
macrophage colony stimulating factor (GM-CSF) induced CD34+ precursors [97] [98]. As a result of 
this, DC ability to induce allogeneic T cell responses is impaired [79, 95-99], as MSC induce a down-
regulation of MHC molecules of class II, CD11c, CD83, a decrease in the production of TNF-α and 
IL-12 and an increase in the production of IL-10 [79, 95, 96, 98, 99].  
It has recently been shown that MSC-treated DC are unable to form immune synapses with T cells 
because of a rearrangement of actin distribution [100]. As for T cells, monocytes are inhibited to enter 
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the cell cycle, as they are retained all in G0 phase, due to a down-regulation of cyclinD2 and p27kip1 
[96]. Recently, it was observed that the adoptive transfer of MSC decreased the migration of 
subcutaneously administered ovalbumin-pulsed DC to the draining lymph nodes. This effect could 
thus explain the decreased number of CSFE-labelled DC in draining lymph nodes and the impaired 
priming of ovalbumin specific CD4+ T cells [101].  
1.1.3.5 MSC and macrophages 
MSC have been shown to stimulate the entry of monocytes into the bloodstream during infections 
[102]. An elegant work by Shi et al. demonstrated that BM MSC progenitors and CAR cells 
expressed monocyte chemotactic protein 1 (MCP-1) after sensing microbial pathogens through their 
TLR, thus inducing CCR2-dependent monocyte entry into the bloodstream. Human and mouse MSC 
are able to recruit monocytes and macrophages in inflamed tissues also through the release of 
chemokines CCL3, CXCL12 and CCL12 [103].  
Monocytes co-cultured with human or mouse MSC are turned into M2 type of macrophages, 
increasing the production of anti-inflammatory cytokines like IL-10, and down-regulating TNF-α and 
IFN-γ [104-106]. The in vitro data have been confirmed by in vivo studies. In a sepsis model, the 
injection of BM derived MSC effectively improved survival. The mechanisms responsible for the 
therapeutic efficacy have been related to the ability of MSC to temporarily reprogram monocyte and 
macrophage functions, inducing IL-10 production from M2 macrophages that were able in turn to 
reduce neutrophils infiltration in tissues [107]. Further evidence has been provided by the work of 
Gupta et al., in which the intrapulmonary administration of MSC in an endotoxin-induced lung injury 
model reduced TNF-α and CXCL12, and increased the production of IL-10 by alveolar macrophages 
[108]. In a zymosan peritonitis model, human MSC produce the anti-inflammatory protein TNF-α 
stimulated gene 6 (TSG-6), which interacts with resident macrophages to decrease zymosan-mediated 
nuclear translocation of nuclear factor-κB (NF-κB) [109]. Not only MSC can recruit monocytes and 
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induce M2 macrophages, but also they produce interleukin 1 receptor antagonist (IL1RA), that 
prevents the release of TNF-α and IL-1 from activated macrophages [110].  
1.1.3.6 MSC and neutrophils 
Naïve or TLR3-triggered MSC are able to promote the survival of resting or IL-8 activated 
neutrophils in vitro. The recent work of two Italian groups suggests that MSC protect neutrophils of 
the storage pool in the BM niche from apoptosis, through an IL-6, IFN-β and GM-CSF dependent 
mechanism [111, 112]. Neutrophils co-cultured with MSC up-regulate the expression of anti-
apoptotic factors, such as myeloid cell leukaemia sequence 1 (MCL1), and down-regulate pro-
apoptotic factors, such as BCL-2 associated X protein (BAX) [111]. Also stimulation with 
lipopolysaccharide (LPS), a TLR4 ligand, induces human MSC to increase the production of IL-6, IL-
8 and macrophage migration inhibitory factor (MIF), thus attracting neutrophils and enhancing their 
lifespan and pro-inflammatory activity [113]. These in vitro results were confirmed in a work in 
which LPS activated human MSC embedded in Matrigel and subcutaneously injected in a mouse 
model were able to recruit neutrophils in vivo [114]. 
1.1.3.7 Mechanisms involved in immunomodulation 
The mechanisms underlying MSC anti-proliferative effect are only partially known, although the 
secretion of soluble factors is now widely accepted as fundamental for MSC immunosuppressive 
ability. Contact-dependent mechanisms and soluble factors are likely to act in concert and/or in 
alternate fashion. For instance, suppression of T cell, B cell and NK cell proliferation can be mediated 
by soluble factors as demonstrated by transwell experiments [70, 73, 81] [89] [92]. Only supernatants 
coming from co-cultures of MSC and lymphocytes are able to deliver the same immunosuppressive 
effect [75, 78], whereas human or mouse MSC conditioned media are not [72, 77, 78, 87], suggesting 
that the suppressive factor requires a dynamic cross-talk between MSC and T cells. Similarly, the 
 32 
inhibitory effect of MSC on DC differentiation is mediated by soluble factors produced only upon 
interaction between MSC and monocytes [98].  
It is arguable that a concert of molecules is responsible for the inhibitory effect, as selective 
inactivation of only one molecule does not have any restoring effect. TGF-β1, hepatocyte growth 
factor (HGF) [70], indoleamine 2,3-dioxygenase (IDO) [115], prostaglandin E2 (PGE2) [79], nitric 
oxide (NO) [116], heme oxygenase-1 (HO-1) [117], and insulin-like growth factor binding proteins 
[118] are some examples of candidate factors proposed to be involved in MSC mediated 
immunosuppression. IDO seems to play an important role in human MSC, whereas NO is more 
important in the mouse system and rat MSC use preferentially HO-1.   
IDO is one of the mechanisms believed to control T cell responses to autoantigens and alloantigens 
[119, 120], and has been implicated in the inhibition of proliferation of T cells [115], NK cells [93] 
and B cells [94] mediated by MSC. Its activity causes tryptophan depletion and synthesis of toxic 
catabolites like kynurenine, thereby inhibiting the growth and function of immune cells [121]. IDO is 
not constitutively expressed by MSC, as it is produced only after exposure to inflammatory 
conditions, such as IFN-γ [94].  
Prostaglandin E2 (PGE2) is a synergistic partner of IDO [79, 93]. It has been shown that MSC-derived 
PGE2 is involved in skewing an inflammatory environment into an immunological tolerance state, as 
shown by the down-regulating effect on TNF-α and IFN-γ production by DC and T cells [79]. MSC 
constitutively express PGE2, but upon co-culture with PBMC they up-regulate it [73]. PGE2 has also 
been studied as a mechanism involved in MSC-macrophage interaction, with MSC-derived PGE2 
binding to the prostaglandin receptors EP2 and EP4 on macrophage surface [105, 107]. 
Nitric oxide (NO) is another important mediator of MSC properties, although its role seems to be 
confined in the mouse system. It is synthesized by the inducible isoform of the NO synthase (NOS2, 
NOS2), which is induced in MSC by contact with activated CD4+ or CD8+ lymphocytes [116], mainly 
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due to the presence of IFN-γ or the combined presence of TNF-α, IL-1α and IL-1β [122], and inhibits 
the proliferation of T cells via the phosphorylation of Stat5 [123]. Interestingly, NOS2-/- MSC are less 
effective in suppressing T cell proliferation than wild type MSC, and this is demonstrated also by the 
blocking effect of N-nitro-L-arginine methyl ester, a specific inhibitor of NOS2, on MSC 
immunomodulatory potential [116].  
Other cytokines that have been studied for their role in the immunomodulatory properties of MSC are 
represented by IL-6, IL-11, IL-10, CXCL12, receptor activator of NF-κB ligand (RANK-L) and 
osteoprotegerin (OPG). Di Nicola et al. have shown that IL-6 and IL-11, although up-regulated by 
MSC, are not important to deliver immunosuppression [70]. IL-10 is not secreted by MSC, but it has 
been investigated because its levels are always up-regulated in the co-cultures of immune cells with 
MSC [82, 99, 124]. Blocking IL-10 partially restores the inhibitory effect on cytokine release and 
proliferation of T cells [99]. CXCL12 has been investigated for its known activity in BM and thymic 
stroma [125]. Low doses of CXCL12 are chemoattractive, but high doses repel T cells [126]. Even 
though low levels of CXCL12 are detected in culture, blocking antibodies do not have any effect on 
the MSC mediated immunomodulation. RANK-L and OPG were studied for their role in promoting 
survival and function of DC, T cell activation and communications between them, but neutralization 
had no effect [77].  
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FIGURE 1.3. MSC immunomodulatory activity. DC, dendritic cell; IDO, indoleamine-2,3-dioxygenase; 
IFN, interferon; IL, interleukin; MCP-1, monocyte chemotactic protein-1; NK, natural killer; NO, nitric 
oxide; PGE2, prostaglandin E2; Tregs, regulatory T cells; VEGF, vascular endothelial growth factor. 
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1.1.3.8 Induction and polarization of MSC immunomodulatory properties 
The immunosuppressive properties of MSC are not constitutive, but they can be acquired after 
exposure to the inflammatory environment. The concept of ‘inflammatory MSC licensing’ was 
initially reported in the context of IFN-γ treatment [94]. Other pro-inflammatory cytokines that can 
license MSC are TNF-α, IL-1α, or IL-1β, and they can also induce an up-regulation of HLA class I 
molecules, ICAM-1, VCAM-1 and de novo expression of HLA class II [122]. Although these changes 
might promote an immunostimulatory function of MSC, they are also critical for their 
immunoregulatory activity [83]. In fact, IFN-γ can enable MSC to acquire APC properties and 
stimulate the generation of cytotoxic CD8+ T cell in vivo when present at low concentrations. High 
concentrations of IFN-γ instead induce immunosuppressive properties of MSC [127, 128]. However, 
further investigation is required in order to clarify the physiological relevance of these studies.  
Recently it has been proposed that TLR may control MSC ‘plasticity’. Human and mouse MSC 
express TLR on their surface, and their expression can be up-regulated under hypoxia [129] or 
inflammatory conditioning [130]. TLR2 and TLR4 are stimulated by bacterial components, such as 
LPS; TLR1, TLR2 and TLR6 by lipoproteins; TLR3 by double stranded RNA; TLR9 by bacterial or 
viral unmethylated CpG DNA. Different TLR agonists influence differently MSC survival, 
proliferation and differentiation, as well as their migratory and immunoregulatory functions. The 
stimulation with LPS protects human MSC from oxidative stress by enhancing the expression of 
cellular antioxidants [131, 132]. TLR2 or TLR4 ligands promote cell division, whereas TLR9 agonists 
induce cell cycle arrest in MSC [35]. TLR activation is known to increase antigen presentation and 
stimulation of immune cells, but apparently this does not apply to MSC. Although MSC up-regulate 
the expression of MHC molecules, they probably maintain their immunoprivileged status. However, 
long term engraftment of MSC after transplantation is not supported by the literature. TLR3 triggering 
is known to stimulate the migration of MSC, which is a prerequisite for an efficient function of 
transplanted MSC [133]. TLR signalling has also been investigated for the immunosuppressive 
functions of MSC. As an example, TLR2 has been shown to up-regulate the secretion of T cell 
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suppressive protein galectin 3 on human MSC [134]; TLR2, TLR3 and TLR4 signalling promotes the 
production and release of IL-6 [134], which is involved in neutrophils modulation and inhibition of 
DC maturation [112]. Nevertheless, the relationship between TLR stimulation and MSC properties is 
still open to further investigations. It has been proposed, in analogy with the M1 and M2 macrophages 
paradigm, that also MSC can be induced by TLR signalling into a pro-inflammatory MSC1 and an 
anti-inflammatory MSC2 phenotype [135]. In this model, TLR4 activation would promote the 
generation of an IL-6, IL-8 and TGF-β producing pro-inflammatory phenotype, whereas TLR3 would 
favour the up-regulation of IDO, cyclooxygenase 2 (COX2), IL-4 and IL1RA, typical of an anti-
inflammatory phenotype. It remains to be determined if these populations exist in vivo.  
1.1.4 MSC therapeutic applications 
The immunosuppressive properties and tissue repair function of MSC have prompted investigations 
into many disorders in the last decade. Indeed, MSC are a promising population of cells for the 
treatment of immune-mediated diseases, promotion of tissue repair, delivering anti-cancer agents, and 
facilitating the engraftment of HSC transplantation.  
Bartholomew and colleagues were the first to investigate the ability of MSC to modulate immune 
responses in vivo, showing that injection of donor MSC prolonged allogeneic skin-graft survival in 
primates [74]. This result has been later confirmed also in a murine model of skin graft, where 
infusion of syngeneic MSC reduced the rejection of allogeneic skin transplant [136]. 
Another study on allogeneic islet transplantation tested MSC in a rat model of streptozotocin-induced 
diabetes for the induction of chimerism and islet allograft tolerance [137]. The effect of in vivo 
administration of MSC has been successfully tested also in autoimmune diseases. MSC have been 
shown to ameliorate experimental autoimmune encephalomyelitis (EAE), decreasing inflammation 
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and demyelination in the central nervous system due to the induction of peripheral T cell tolerance 
[86].  
MSC could affect the capacity of encephalitogenic T and B cells directed against the immunizing 
antigen to adoptively transfer the disease into naïve recipients [90]. MSC have also been investigated 
for their effect in collagen induced arthritis (CIA), a model of rheumatoid arthritis; although initially it 
was shown that MSC did not have a beneficial effect for curing arthritis [138], it has recently been 
demonstrated that a single injection of MSC in a CIA model can prevent the damage to bone and 
cartilage [139]. Sepsis [107] and colitis [140], for their inflammatory nature, have been tested for the 
effect of MSC, showing that activated MSC can induce in vivo the production of higher amounts of 
IL-10 from macrophages [107, 140] by releasing PGE2, and prevent neutrophils from migrating into 
tissues and causing oxidative damage [107].  
Besides their effects on immune responses, MSC are known for their ability to promote tissue repair. 
Rather than trans-differentiating into parenchymal cells, the anti-proliferative and anti-apoptotic 
activity of MSC on parenchymal cells [141] and the anti-inflammatory activity might effect a 
cytoprotective action that preserves residual stem cells from destruction, thus favouring their recovery 
and spontaneous tissue repair. In a streptozotocin-induced diabetes model, MSC were able to promote 
endogenous repair of pancreatic islets and renal glomeruli [142]. As far as their cytoprotective action 
is concerned, it has been demonstrated that the co-infusion of MSC and BM cells inhibited the 
proliferation of antigen specific T cells, restored insulin levels and, importantly, induced recipient-
derived pancreatic β cell regeneration [143].  
MSC orchestrate the resolution of acute inflammation, which is crucial for tissue repair. Although 
several studies have demonstrated that MSC mediate a direct immunosuppressive effect, it is more 
probable that they act through the release of cytokines and/or in concert with other cells in order to 
resolve inflammation. As shown in a model of ischaemic renal failure, MSC ameliorate tissue injury 
by reducing the expression of IL-1β, TNF-α, IFN-γ and NOS2, and up-regulating anti-inflammatory 
 38 
cytokines [144]. Similarly, MSC can protect from bleomycin-induced lung fibrosis by releasing 
IL1RA [110]. As previously discussed, MSC favour the generation of anti-inflammatory 
macrophages, which are equally important to promote tissue repair [145]. Also, endothelial cells and 
myofibroblasts are recruited from MSC at the injury site to help the tissue repair through the release 
of several growth factors [146]. 
Graft-versus host disease (GvHD), a severe condition that develops after allogeneic haematopoietic 
stem cell transplantation (HSCT), has been the most extensively studied application for MSC in the 
clinical setting. The use of MSC in GvHD has produced different outcomes. After the anecdotal 
report [147], a phase II trial involving 55 patients [148] suffering with steroid resistant grade IV acute 
GvHD, demonstrated the clinical efficacy of MSC in improving the overall survival. In contrast, in a 
multicentre phase I/II clinical trial, the infusion of MSC at the time of HSCT did not impact on the 
frequency of developing GvHD, as no difference was observed between the group receiving MSC and 
the controls [68]. The findings in the preclinical studies can possibly explain these discrepancies. A 
single infusion of MSC given at the time of the transplant did not prevent GvHD in MHC-mismatched 
donor-recipient pairs [149]. Instead, when given in multiple doses, MSC could fully prevent the 
development of GvHD [150]. Furthermore, an interesting study by Polchert et al. suggested that MSC 
could significantly increase the survival rate when administered at day +2 or +20, when IFN-γ levels 
are at their peak [151].  
These findings confirm and strengthen the concept of MSC ‘licensing’, showing that not only in vitro 
but also in vivo MSC need the appropriate inflammatory environment in order to exert their 
immunomodulatory properties. Inflammation can also facilitate the recruitment of MSC at the site of 
lesion, as shown by in vivo studies [144, 150, 152]. The IFN-γ produced by the inflammatory event 
causes the accumulation of antigen-specific T cells by inducing MHC molecule expression on the 
endothelium [153], thus enabling MSC and effector T cells to get in close proximity [154].  
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1.2 HAEMATOPOIETIC STROMA 
1.2.1 Development of myeloid lineages  
In murine haematopoiesis, the multipotent activity resides within a small fraction of BM cells, lacking 
the expression of lineage-associated surface markers (Lin) but expressing Sca-1 and c-Kit [155], 
termed ‘LSK’ fraction. In this population, the most primitive self-renewing HSC having long term 
reconstituting ability (LT-HSC) can be isolated. [156].  
LSK population comprises also cells with transient reconstituting activity, called short-term HSC (ST-
HSC) or multipotent progenitors (MPP). LT-HSC can be identified in the CD34- CD38+ fraction of 
LSK [157]. ST-HSC and MPP reside instead in the CD34+ CD38- fraction of LSK [158]. More 
recently, cell surface receptors of the signalling lymphocyte activation molecule (SLAM) family were 
discovered to selectively distinguish primitive HSC from non-self-renewing MPP. HSC were defined 
as CD150+ CD244− CD48− cells while MPP were CD244+ CD150− CD48− and most restricted 
progenitors (myeloerythroid and B cell progenitors) were CD48+CD244+CD150− [56]. In contrast 
with such clear definition, there is still no phenotypic and functional distinction between ST-HSC and 
MPP. It is instead widely accepted that LT-HSC give rise to ST-HSC, which in turn give rise to 
committed progenitors that differentiate into end stage blood cells [156].  
The lineage-committed progenitors are the common lymphoid progenitor (CLP) and myeloid 
progenitors (CMP). The CLP population is defined within the Lin- Sca-1low c-Kitlow population by the 
up-regulation of interleukin 7 receptor α (IL-7Rα), and it has clonogenic T, B and NK cell potential, 
but lacks of myelo-erythroid differentiation ability [159]. In contrast, the CMP population, is defined 
as Lin-Sca-1-c-Kit+IL-7Rα-, and possesses myelo-erythroid colony forming activity. This subset of 
cells can be further fractionated upon the expression of Fc gamma receptor II/III (FcγR, CD16/32), 
and CD34: FcγRlow CD34+ CMP, FcγRlow CD34- megakaryocyte/erythrocyte progenitors (MEP), and 
FcγRhigh CD34+ granulocyte/macrophage progenitors (GMP) [160]. CMP differentiate into GMP and 
 40 
MEP, and can generate all types of myeloid colonies, whereas GMP and MEP produces only 
granulocyte/macrophage and megakaryocyte erythrocyte colonies, respectively [161, 162].  
Among the myeloid precursors, macrophage/DC progenitor (MDP) has been identified as a subset of 
BM cells sharing the same phenotype of GMP, lacking the expression of Lin, Sca-1 and IL-7Rα, but 
positive for FcγR and c-Kit [160], and that specifically expresses colony stimulating factor 1 receptor 
(Csf-1R, also called CD115) and the chemokine receptor CX3CR1 [163, 164]. Monocytes, several 
macrophages subsets and the two main subsets of dendritic cells, splenic ‘classical’ dendritic cells 
(cDC) and plasmacytoid dendritic cells (pDC), are generated from the MDP. cDC are generated 
without a monocytic intermediate [164], whereas monocytes give rise to other types of DC, such as 
inflammatory DC or mucosal DC [165]. The chemokine receptor CX3CR1 is firstly detected on 
MDP, but not on CMP or GMP, thus it is strictly associated with the commitment of myeloid 
progenitors to the monocyte/macrophage/DC lineage.   
Adding complexity to the origin of monocytes and DC, it has been reported that another progenitor, 
termed common DC precursor (CDP), is able to generate cDC and pDC but not monocytes [166]. 
CDP shares the same phenotype of MDP, but its existence is still controversial (Figure 1.4).  
1.2.1.1 Transcription factors controlling myeloid development 
Lineage commitment and differentiation of multipotent cells involves the selective activation and 
silencing of a number of genes. Cell intrinsic and extrinsic signals, or the combination of both, can 
trigger cell fate decisions, which are ultimately controlled by transcription factors. Transcription 
factors, in turn, can activate specific lineage commitment on the basis of their relative expression, 
timing, and collaborative or competitive relations with other transcription factors.  
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1.2.1.1.1 Transcription factors involved in formation of HSC 
Several transcription factors involved in the formation of HSC are also required at later stages within 
the differentiation of individual blood lineages. Therefore, such a distinction is arbitrarily used for 
discussion purposes. Mixed lineage-leukaemia gene (MLL), runt-related transcription factor 1 
(Runx1), ets variant gene 6 (TEL/ETV6), T cell acute lymphocytic leukaemia 1 (SCL/tal1) and LIM 
domain only 2 (LMO2) are some of the transcription factors discovered for being fundamental for the 
formation of HSC as they account for leukaemia-associated translocations.  
Transcription factors SCL/tal1 and LMO2 are essential for the development of both primitive and 
definitive haematopoiesis [167]. A deregulated expression of the locus of these two transcription 
factors has been identified in T cell acute leukaemia.  
MLL and Runx1 are essential for the generation of HSC in the aorta-gonad-mesonephros (AGM) 
region [168].  In the absence of Runx1, no hematopoietic clusters form in the dorsal aorta in mice. 
Mouse and zebrafish models show that Notch is required for aortic HSC production [169], and in 
zebrafish Runx1 lies downstream of Notch signalling. MLL instead seems to be fundamental for 
maintaining the expression of HOX genes, and in particular lies upstream of HOXB4, one of the most 
extensively studied HSC transcription factors [170].   
1.2.1.1.2 Transcription factors controlling granulocyte and monocyte lineage commitment  
One of the most important transcription factors controlling myelopoiesis is PU.1. Not only PU.1 
induces myeloid commitment in ST-HSC [171] and generates CMP [172], but also is engaged in 
antagonistic interactions with other transcription factors. Its inhibitory interaction with GATA binding 
protein 1 (GATA-1) shuts down the megakaryocytic/erythroid pathway, and antagonizing GATA-2 
blocks mast cell development [173].  
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PU.1 interaction with CCAAT/enhancer-binding protein α (C/EBPα) is instead critical for inducing 
monocyte development at the expense of the granulocyte compartment [174]. A current model 
proposes that C/EBPα activates Gfi-1, indispensable for granulocytic differentiation, whereas PU.1 
activates Egr transcription factors to induce monocyte/macrophage differentiation [175]. 
Nevertheless, this model is far from being complete, and might involve other transcription factors. For 
instance, IFN consensus sequence binding protein/IFN regulatory factor 8 (ICSBP/IRF-8) [176] and 
Krueppel-like factor KLF4 [177] have been also demonstrated to be involved in driving monocytic 
differentiation, at the expense of the granulocyte compartment.  
 As demonstrated by the drastic reduction in the numbers of monocytes in knockout models, the 
development of monocytes depends on the growth factor receptor Csf-1R (CD115) [178]. CD115 is 
expressed by all the cells of the mononuclear phagocyte system (MPS), which comprises monocytes, 
macrophages, DC and their precursors [179]. The two known ligand of CD115, Csf-1 and IL-34, are 
both important for MPS development. PU.1 trans-activates CD115 promoter [180], as confirmed by 
CD115 lack of expression in PU.1 deficient myeloid progenitors [181]. However, CD115 expression 
is not sufficient by itself to drive macrophage differentiation [181].   
Monocytes and macrophages highly express MafB and c-Maf transcription factors [182], which 
selectively drive monocyte fate in myeloid progenitors. Expression levels of PU.1 are fundamental to 
drive the differentiation of monocytes into macrophages or DC. Monocyte-derived macrophages 
express MafB and moderate levels of PU.1, whereas DC show high levels of PU.1 and no MafB 
expression [182].  
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FIGURE 1.4. Development of myeloid lineages in mouse. In the BM, HSC produce CMP and CLP 
precursors. CMP give rise to MDP precursor. MDP give rise to monocytes, some populations of 
macrophages (dotted arrow). CDP (whose existence is still controversial (dotted arrow)) give rise to pre-
cDC and pDC; pre-cDC and pDC circulate in blood and enter lymphoid tissue. Under homeostatic 
conditions, two monocyte subsets, Ly- 6C+ and Ly-6C–, leave the bone marrow to enter the blood, and 
transmigrate to nonlymphoid tissues, where they may give rise to tissue resident MФ. During inflammation, 
Ly-6C+ monocytes give rise TipDC, inflammatory macrophages, and may contribute to MDSC associated 
with tumors (dotted arrow) It is unclear whether CLP contribute to CDP (dashed arrow). CDP, common DC 
precursor; CLP, common lymphoid progenitor; CMP, common myeloid progenitor; DC, dendritic cell; 
MDP, macrophage/DC precursor; MDSC, myeloid derived suppressor cells; MФ, macrophage; pDC, 
plasmacytoid DC; pre-cDC, preclassical DC; ST-HSC, short-term haematopoietic stem cell; TipDC, TNF-α 
iNOS producing DC. (Modified from Geismann, Science) 
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1.2.2 The mononuclear phagocyte system 
1.2.2.1 The monocyte system 
Monocytes in mice represent a morphologically distinct population distinguished by their irregular 
shape, presence of cytoplasmic vesicles and high cytoplasm to nucleus ratio. A number of markers 
have been used to better characterise different subsets according to their origin and functional activity. 
Mouse monocytes are identified in blood by the expression of the integrin CD11b (macrophage-1 
antigen, Mac-1), CD115, F4/80 (member of EGF-TM7 family of leukocyte plasma molecules), 
Dectin-1 (β-glucan receptor), the chemokine receptor CX3CR1, and a variable expression of the Gr-
1/lymphocyte antigen 6C (Ly6C) and 7/4 antigen [183, 184]. Anti-Gr-1 monoclonal antibody (RB6-
8C5) binds with different specificity two molecules, Ly6C and Ly6G. The epitope Ly6C is not only 
expressed by monocytes, but also by NK cells, granulocytes and pDC, whereas the epitope Ly6G is 
expressed only by granulocytes [185].  
Two main subsets of blood monocytes have been identified in mice, the Gr-1+ Ly6Chigh 
‘inflammatory’ subset, and the Gr-1- Ly6Clow ‘resident’ subset [184]. The developmental relationship 
between these two subsets remains incompletely defined. Many investigators have proposed that Gr-
1+Ly6Chigh shuttle between the blood and the BM and lose Ly6C expression, thus becoming Ly6C- 
monocytes [165, 186, 187]. However, genetic defects impairing the presence of Gr-1+Ly6Chigh 
monocytes, such as cyclin-dependent kinase inhibitor p21 [188] and the transcription factor KLF4 
[189], do not impair the presence of Gr-1-Ly6Clow monocytes. In an attempt to define their 
relationship, additional subsets have recently been proposed, such as the Gr-1+Ly6Cint subset [190].  
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1.2.2.1.1 Inflammatory Gr-1+ Ly6Chigh monocytes 
The main subset of blood monocytes is represented by the inflammatory subset, expressing CD115, 
Ly6C, CCR2 and CD62L (adhesion molecule L-selectin), but low CX3CR1. These cells egress from 
the BM in CCR2-CCL7/CCL2 dependent fashion and are recruited to inflamed tissues and lymph 
nodes in vivo [184, 191-193].  
Monocytes differentiate into TNF-α iNOS producing DC (Tip-DC) via a MyD88 dependent 
mechanism [194] associated with the production of high levels of TNF-α and NO, and the up-
regulation of CD86, CD80, CD11c and MHC class II [195-197]. CCR2 appears to be a key molecule 
because CCR2-deficient mice have a severe reduction in the number of Tip-DC, associated with a 
reduced control and clearance of bacterial infection [195].  
Inflammatory monocytes have also been shown to replenish the macrophage and DC populations in 
skin [198], digestive tract [165] and lung during inflammation [199, 200]. 
Cells sharing the same phenotype of inflammatory monocytes have been found increased in spleen of 
tumour-bearing hosts [201]. These cells have the peculiar capability of inducing the recruitment of 
tumour-induced T regulatory cells (TREGS) and inducing T cell anergy, and they are referred to as 
‘myeloid derived suppressor cells’ (MDSC) [202-204]. It is still under investigation the hypothesis 
that Gr-1+ Ly6Chigh circulating monocytes could give rise to these cells. It could also be suggested that 
inflammatory monocytes can give rise to MDSC in the tumour and Tip-DC in the inflammatory 
environment, but this remains to be confirmed. 
1.2.2.1.2 Resident Gr-1- Ly6Clow monocytes 
The second subset of circulating monocytes is smaller in size and defined by the Gr1- Ly6Clow 
CD115+ phenotype. Characteristically, it exhibits high expression of the chemokine receptor 
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CX3CR1, lymphocyte function associated antigen 1 (LFA-1) and CD43, and lacks Gr-1, CCR2 and 
L-selectin (CD62L) [184]. This subset has been termed ‘resident’ because of its longer half-life and 
its presence in both resting and inflamed tissues.  
During homeostasis, Gr-1- Ly6C- monocytes patrol blood vessels as demonstrated by intravital 
microscopy, and the process is mediated by the LFA-1/ICAM-1 interaction and CX3CR1 [205]. 
During tissue inflammation such as Lysteria monocytogenes infection, instead, these ‘resident’ 
monocytes extravasate and start to develop a peculiar transcriptional program with the up-regulation 
of cytokines, lysozyme, defensins, complement, and chemokines [205]. Interestingly, this type of 
monocytes is participating only in a transient response, as they are replaced by inflammatory 
monocytes within few hours after the infection [205]. After myocardial infarction, it as been observed 
that Gr-1- Ly6Clow cells are recruited to the damaged tissue via CX3CR1 and, after its digestion, they 
express vascular endothelial growth factor (VEGF) and promote healing through myofibroblast 
accumulation, angiogenesis and deposition of collagen [191]. 
Studies performed on extravasated Ly6Clow resident monocytes demonstrate that the transcriptional 
program initiated by these monocytes resembles the one of M2-like (alternatively activated) 
macrophages [206]. Conversely, extravasated inflammatory monocytes start a transcriptional program 
similar to Tip-DC or M1 (classically activated) macrophages [205]. This concept of fate-defined 
subsets of monocytes is in apparent contradiction with the accepted view of monocytes as plastic cells 
[207]. Combinations of cytokines and growth factors can determine in vitro the differentiation of 
monocytes and macrophages. For example, monocytes can be induced to become DC by IL-4 and 
GM-CSF [185]; macrophages, in presence of macrophage colony-stimulating factor (M-CSF) [208]; 
M1 macrophages, with M-CSF and IFN-γ, or M2 macrophages, with M-CSF and IL-4 [209, 210]. It is 
therefore accepted that both the microenvironment and the transcriptional programs play a role in 
determining the fate of monocytes.  
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1.2.2.2 The macrophage system 
Macrophages are scattered in almost every lymphoid and non-lymphoid tissue, where they exert 
fundamental effects in tissue homeostasis. They are responsible for clearing 200 billion erythrocytes 
per day, removing cell debris deriving from apoptotic and senescent cells, and remodelling the tissue 
after inflammation. Most of their actions are mediated independently of other immune responses. 
When stimulated by danger signals, such as heat shock proteins, DNA, histone proteins, macrophages 
alter their physiology, surface protein expression and production of cytokines, stimulating in such 
way an immune response.  
1.2.2.2.1 Tissue distribution of macrophages 
Macrophages are divided into subpopulations on the basis of their anatomical location and functional 
phenotype. Several specialized macrophages reside in tissues throughout the body, and these include 
osteoclasts in the bone, alveolar macrophages in the lungs, Langerhans cells in the epidermis, Kupffer 
cells in the liver, microglia in the brain. The gut and secondary lymphoid organs are also populated by 
distinct populations of macrophages with different phenotype and function. For instance, 
macrophages found in the thymus and in the white pulp of the spleen (called ‘tingible-body’ 
macrophages) are important for clearance of apoptotic lymphocytes generated during an immune 
response. High phagocytic and bactericidal activity is instead exhibited by lamina propria 
macrophages [211]. These tissue-specific macrophage subpopulations ingest foreign materials and 
recruit additional macrophages from circulation during an infection or following injury. 
1.2.2.2.2 Phenotype of murine macrophage subsets 
The phenotype of macrophages in mouse is hard to define. Although several molecules are in use to 
characterise macrophages (Table 1.1), their distinction from DC is still imprecise. CD11b and CD18 
(Mac-1), F4/80, macrosialin (CD68), mannose receptor (MR, CD206) are some of the molecules used 
 48 
to distinguish macrophages and DC. However, macrophages also express low amounts of CD11c, a 
marker that is used to identify DC, and, in turn, some DC but not all the macrophages express F4/80. 
Also, the nomenclature defying some subsets of DC or macrophages is misleading. As an example, 
the subset of Tip-DC is more similar to an inflammatory macrophage than an antigen-presenting cell 
(APC), whereas the subset of CD169+ macrophages has APC functions [212]. However, few 
combinations of markers can distinguish DC from macrophages, probably because they exist in a 
continuum and they arise from a common precursor.  
Functionally, macrophages have been schematically classified in several subsets, which present a 
great overlap in surface marker expression. Table 1.2 represent the markers used to distinguish the 
different subsets through gene expression. M1, or ‘classically activated’ macrophages, mediate 
defence of the host from bacteria, parasites and viruses, and have roles in antitumor immunity. M2, or 
‘alternatively activated’ macrophages [213], have anti-inflammatory functions and regulate tissue 
remodelling. ‘Regulatory’ macrophages produce high levels of the anti-inflammatory cytokine IL-10 
in response to TLR and immune complexes [214]. Further subsets are the tumour-associated 
macrophages (TAM), which suppress antitumour immunity and are closely linked to myeloid derived 
suppressor cells (MDSC). Although these subsets are distinguished functionally and phenotypically, it 
is generally believed that macrophages consist in a spectrum of activated phenotypes rather than 
discrete stable subpopulations. 
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Marker Gene Comments
CD1150 Csf1r Expressed(on(all(monocytic(cells,(including(macrophages(and(osteoclasts
CD11b Itgam Expressed(on(all(myeloid(lineage(cells,(including(neutrophils(
CD11c Itgax Expressed(on(many(monocytic6derived(cells,(including(macrophages.(
Enriched(in(certain(populations(of(dendritic(cells(
CD169 Siglec1 Expressed(on(DC(and(on(macrophages(with(APC(functions;(recently(
identified(in(a(subset(of(BM(macrophages(regulating(niche(activity
CD206 Mrc1 Expressed(on(all(tissue6specific(macrophages(but(also(on(mesangial(cells(
and(hepatic(endothelium;(not(clear(if(expressed(by(DC(in(vivo
CD62L Sell Expressed(by(neutrophils,(monocytes,(and(subsets(of(T,(B,(and(NK(cells,(
mediating(the(rolling(of(blood(cells
CD68 Cd68 Expressed(on(all(macrophages
F4/80 Emr1 Expressed(on(most(tissue(macrophages(in(the(mouse.(
ILE4Ra Il4ra Expressed(on(most(macrophages,(but(also(on(lymphocytes(and(other(cell(
types(that(are(responsive(to(IL64(and(IL613(
LyE6C Ly6c1
Enriched(on(monocytic(myeloid(lineages.(A(useful(marker(system(when(
used(together(with(LY6G(to(determine(relative(amounts(of(granulocytes(
and(monocytes(or(macrophages.(
LyE6G Ly6g
Enriched(on(granulocytes.(A(useful(marker(system(when(used(together(
with(LY6C(to(determine(relative(amounts(of(granulocytes(and(monocytes(
or(macrophages(
MAC2 Lgals3 Distributed(in(epithelia(of(many(organs(and(various(inflammatory(cells,(
including(macrophages,(as(well(as(dendritic(cells(and(Kupffer(cells
TABLE 1.1. Cell surface markers of murine macrophages. Csf1r, colony stimulating factor 1 receptor; 
Emr1, EGF-like module containing, mucin-like, hormone receptor-like sequence 1; Il4ra, interleukin-4 
receptor, alpha; Itgam, integrin alpha-M; Itgax, integrin alpha-X; Lgals3, lectin, galactose binding, soluble 3; 
Ly6, lymphocyte antigen 6; Mrc1, mannose receptor, C type 1; Sell, selectin, lymphocyte; Siglec, sialic acid 
binding Ig-like lectin 1, sialoadhesin. Modified from [1]. 
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Marker&type Gene Comments
M1&markers Cox2%(Ptgs2) Highly%induced%in%M1%activation%
Ido1 Useful%marker%of%exposure%to%type%1%and%2%interferons%
Il12b Highly%induced%in%M1%activation%
Il23a%(Il23p19) Highly%induced%in%M1%activation%
Marco CalmodulinDassociated.%Also%found%in%other%activation%scenarios%
Nos2
Highly%upregulated%in%M1%and%mediator%of%immunosuppressive%
properties
Socs3 Induced%by%ILD10%and%ILD6
M2&markers Arg1
Highly%upregulated%in%M2%and%mediator%of%immunosuppressive%
properties
Ccl12 Chemokine%linked%to%TH2%cell%responses%
Ccl24 Chemokine%linked%to%TH2%cell%responses%
Chi3l1%(Gp39,%Ykl40) Highly%induced%by%ILD4%and%ILD13.%Not%macrophageDspecific%
Chi3l3%(Ym1) Highly%induced%by%ILD4%and%ILD13
Chia%(Amcase) Highly%induced%by%ILD4%and%ILD13.%Not%macrophageDspecific%
Cxcl13 Chemokine%linked%to%TH2%cell%responses%
Fizz1%(Relma,%Retnla) Highly%induced%by%ILD4%and%ILD13
Irf4 Highly%induced%by%ILD4%and%ILD13.%Not%macrophageDspecific%
Klf4 Transcription%factor%induced%by%ILD4%
Socs2 Highly%induced%by%ILD4%and%ILD13.%Not%macrophageDspecific%
TABLE 1.2. M1-M2 markers for activated macrophages. Arg1, arginase 1; Ccl, CC-chemokine ligand; 
Chi3l, chitinase 3-like; Chia, chitinase, acidic; Cxcl13, CXC-chemokine ligand 13; Ido1, indoleamine 2,3-
dioxygenase 1; Il, interleukin; Irf4, interferon regulatory factor 4; Klf4, Krüppel-like factor 4; Marco, 
macrophage receptor with collagenous structure; Mrc1, mannose receptor, C type 1; Nos2, nitric oxide 
synthase 2, inducible; Ptgs2, prostaglandin-endoperoxide synthase 2; Relma, resistin-like molecule alpha; 
Socs, suppressor of cytokine signalling. Modified from [1]. 
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1.2.2.2.3 Classically activated macrophages 
The term ‘classically activated’ refers to the effectors that are produced during cell-mediated immune 
responses (Figure 1.5). M1 cells have an IL-12high, IL-23high, IL-10low phenotype, and they produce 
other inflammatory cytokines, such as IL-1β, TNF-α and IL- 6. They participate as inducers and 
effectors of Th1 immune responses, and mediate resistance against bacteria, protozoa, viruses and 
tumours. M1 macrophages are activated by IFN-γ, either alone or in combination with other 
cytokines, such as TNF-α and GM-CSF, or TLR stimulation by microbial products [215]. IFN-γ can 
be produced either by other cells of the innate immune system, such as NK cells, or by cells of the 
adaptive response, like Th1 cells. Once macrophages sense IFN-γ, they secrete pro-inflammatory 
cytokines, produce increased amounts of superoxide anions, oxygen and nitrogen radicals to increase 
their microbicidal activity [216]. However, if not tightly controlled, the amount of inflammatory 
cytokines produced by these cells can lead to host-tissue damage. M1 macrophages have been 
involved in several autoimmune diseases, such as rheumatoid arthritis [217] and inflammatory bowel 
disease [218].  
1.2.2.2.4 Alternatively activated macrophages 
‘Alternatively activated’ macrophages refer to various forms of macrophages sharing an IL-12low, IL-
23low, IL-10high phenotype, but with variable production of inflammatory cytokines (Figure 1.5). They 
are induced by IL-4 and IL-13, immune complexes, IL-10, glucocorticoids and secosteroid hormones 
[213], but also activin-a (member of TGF-β family) [219] and IL-21 [220]. They generally express 
high levels of scavenger, mannose and galactose receptors, and they up-regulate the enzyme arginase-
1 (Arg-1) for the production of ornithine and polyamines. M2 macrophages differ from their M1 
counterpart also in the regulation of components of the IL-1 system, with low levels of IL-1β and 
caspase-1, and high levels of IL-1RA and IL-1II receptor. They participate in parasite encapsulation 
[221], tissue remodelling and angiogenesis [222], and they promote tumour progression. Such actions 
are promoted through the production of growth factors, such as TGF-β1 and PDGF [223], but also 
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matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP), which regulate 
extracellular matrix turnover, and immunoregulatory proteins, such as IL-10, Arg-1 [224] and resistin 
like α (Retnla, Fizz1) [225]. Although M2 wound healing and fibrosis-promoting activities contrast 
M1 responses, they can originate from M1 converted macrophages [226].  
Based on their wide variety of physiological statuses, several classifications of M2 macrophages have 
been proposed. Mantovani et al. [227] have suggested the existence of three types of M2 
macrophages, based on the stimuli needed to activate them. M2a are induced by IL-4 and IL-13; M2b 
by immune complexes and agonists of TLRs or IL-1R; M2c by IL-10 and glucocorticoid hormones. 
Other have proposed that ‘wound healing’ macrophages, activated by IL-4, are the one responsible for 
tissue remodelling, producing minimal amounts of pro-inflammatory cytokines and inducing 
regulatory effect on lymphocytes, whereas ‘regulatory’ macrophages, induced by glucocorticoids, 
TGF-β, IL-10, prostaglandins, and immune complexes, exert immunoregulatory functions by up-
regulating IL-10 [228].  
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FIGURE 1.5. Macrophage subsets. M1 macrophages have a pro-inflammatory phenotype characterised by 
the expression of IL-12 and IL-23, and the up-regulation of NOS2, and they are induced by several pro-
inflammatory stimuli. M2 macrophages have an anti-inflammatory phenotype, with high expression of IL-
10, and characterised by the up-regulation of the enzyme Arg-1. They are induced by IL-4, IL-10 and other 
anti-inflammatory stimuli, and they are characterised by the up-regulation of scavenger (SR), mannose (MR) 
and galactose receptors (GR) on their surface. 
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1.2.2.2.5 Intrinsic and environmental regulation of macrophages 
A complex interplay of intrinsic differentiation factors and environmental signals determines the 
existence of many different phenotypes and functions of macrophages. So far, there is not a 
comprehensive knowledge of the complex relation between transcriptional regulation and external 
cues.  
PU.1 is a fundamental transcription factor for induction and maintenance of macrophage 
differentiation. A genome-wide role has been suggested for PU.1, which controls the formation and 
access of macrophage specific regulatory genomic regions and promotes the binding of other 
macrophage-specific transcription factors by acting through the methylation pattern of histone 
proteins [229]. Nevertheless, the interaction between PU.1 and macrophage-specific transcription 
factors needs to be further investigated.  
Distinct signalling pathways determining M1 and M2 fates have been identified. IFN-γ, known to 
induce M1 macrophages, acts through the Janus kinase signal transducer and activator of transcription 
(JAK-STAT). Subsequently, STAT1 binds to ‘γ-activated sequences’ in the promoters of genes 
encoding NOS2, MHC class II transactivator (CIITA), and IL-12 [230]. STAT-1 and STAT-2 are also 
involved in TLR4 mediated signalling. LPS induces in fact the autocrine production of IFN-β, which 
acts through the induction of a heterodimer of STAT-1 and STAT-2 on interferon stimulated response 
elements (ISRE) that are found in several M1 genes [231].  
STAT6, which can be induced by IL-4 [232], is instead regulator of M2 signature genes such as Arg-
1, Fizz1, CD206, and chitinase-3 like 3 (Chi3l3).  
Another important factor for the induction of M2 macrophages is the nuclear receptor peroxysome 
proliferator activated receptor-γ (PPAR-γ). Macrophages of adipose tissue constitutively express 
PPAR- γ, where it acts as an important regulator of macrophage-mediated lipid metabolism [233]. 
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Nos2 expression is inhibited by PPAR- γ partly by antagonizing the activities of several transcription 
factors, including STAT. The activity of PPAR- γ can be augmented by IL-4 signalling through an 
interaction between PPAR-γ and STAT6 on promoters of PPAR-γ target genes [234].  
C/EBP-β is another important transcription factor for M2 macrophage induction, and in particular it 
can induce Arg-1 expression in response to TLR signalling [235]. The induction of Arg-1 is not made 
redundant by C/EBP-β and STAT-6, as these two transcription factors are activated by different 
stimuli, and act on different cis-elements of Arg-1 promoter.  
1.2.2.2.6 Macrophages and tissue injury 
During inflammation, the number of resident macrophages is insufficient to mediate microbial control 
and tissue repair, and circulating monocytes are recalled from the blood (Figure 1.6). Tissue stress, 
acute or chronic inflammation, and sterile inflammation can induce ‘emergency myelopoiesis’, 
dependent on cytokines such as granulocyte colony stimulating factor (G-CSF), and chemokines like 
CCL5 and MCP-1 [192].  
Inflammatory monocytes are recruited at the sites of inflammation in several types of acute infections. 
Rapid migration to the inflammatory tissue is induced by chemokines, such as MCP-1, produced by 
local inflamed tissues [236] or by BM MSC that sense low circulating amounts of TLR [102]. Once 
recruited at the site of inflammation, monocytes differentiate into macrophages or DC, and their 
activity is likely to be switched off by IL-10 [236].  
It has not yet been elucidated if and how monocytes differentiate into macrophages. On the other 
hand, it has been recently demonstrated that macrophages are able to proliferate in situ in response to 
IL-4 [237]. In a Th2 type of inflammatory process, induced with infection from nematode 
Litomosoides sigmodontis, macrophage proliferation in situ was induced also after depleting 
circulating monocytes by treatment with clodronate liposomes.   
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FIGURE 1.6. Macrophages are recruited during tissue injury. Ly6C+ monocytes egress from the BM and 
extravasate into the blood, in response to the chemokine MCP-1 produced by CAR cells and by inflamed 
tissues. Once in the tissue, monocytes differentiate either in Tip-DC or in M1 macrophages in order to help 
resolution of inflammation and tissue repair. 
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1.2.2.2.7 Macrophages and cancer 
Macrophages play a key role in cancer (Figure 1.7) [238]. TAM are major components of the tumour 
leukocyte infiltrate. They are recruited by M-CSF, CCL2 and VEGF [238].  
TAM express many genes typical of the M2 phenotype, and have therefore been described as ‘M2-
skewed’. However, recent findings suggest that their phenotype varies with the stage of tumour 
development. M1-like cells have been found at the tumour site, whilst M2-like cells predominate 
during the stage of invasion, associated with vasculogenesis [239]. 
Accordingly, TAM promote angiogenesis [240], facilitate tumour invasion and metastasis [241], and 
protect tumour cells from chemotherapy-induced apoptosis [242]. They are also able to inhibit M1 
tumouricidal responses, impair T cell activation, and produce IL-10 to stimulate Th2 and CCL22 to 
attract TREGS [243]. T cell apoptosis is mediated through the expression of PD1 ligand 1 (PDL1) 
binding on programmed-death 1 receptor (PD1) on T cell surface [244] and by depleting L-arginine 
through up-regulation of Arg-1 [245].  
1.2.2.2.8 Myeloid derived suppressor cells 
Tumour cells also recruit a highly heterogenous myeloid population from BM and spleen with 
important functions for the promotion of neovascularization and metastasis of the tumour. This 
population, defined as myeloid derived suppressor cells (MDSC), [246] consists of progenitor and 
immature myeloid cells that exhibit immunoregulatory properties. They are present also in healthy 
individuals, where they differentiate into mature granulocytes, macrophages or DC without causing 
immunosuppression.  
In the normal mouse BM, MDSC represent 20-30% of the total population, and 2-4% of the spleen, 
whereas they cannot be found in draining lymph nodes. During pathological conditions, such as 
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cancer, infectious diseases, trauma, sepsis, BM transplantation or autoimmune diseases, a block in the 
differentiation of immature myeloid cells causes their expansion [247].  
Two main subsets of MDSC have been identified, both in mice and humans: monocytic MDSC and 
polymorphonuclear or granulocytic MDSC [248]. Polymorphonuclear MDSC, whose phenotype is 
defined as CD11b+ Gr-1high Ly6Clow Ly6G+ CD49d–, are the most represented subset in tumour-
bearing mice, and also the major subset of circulating MDSC. They inhibit CD8+ T cell responses by 
activation of reactive oxygen species (ROS), and they are less immunosuppressive than their 
monocytic counterpart [249, 250]. Monocytic MDSC are defined as CD11b+ Gr-1mid Ly6Chigh Ly6G- 
CD49d+, and they have variable expression of F4/80, CD115, 7/4 and CCR2. They inhibit CD8 T 
cells through the induction of NOS2 and Arg-1, and the production of ROS [249, 250].  
Corroborating the evidence that MDSC are a population of immature cells, some similarities with 
other myeloid cells can be found and MDSC have been shown to differentiate into mature myeloid 
cells, both in vitro and in vivo. Polymorphonuclear MDSC and neutrophils have a similar morphology 
[251], whereas monocytic MDSC are similar to inflammatory monocytes for their phenotype and 
morphology. Not only are MDSC distinguished for their immunosuppressive activity, but also for the 
coordinated up-regulation of enzymes such as NOS2 and Arg-1 [252]. Furthermore, MDSC includes 
progenitors of DC, macrophages and granulocytes. Several in vitro experiments have shown that 
MDSC can differentiate into mature cells. For instance, polymorphonuclear MDSC can differentiate 
into neutrophils [251], and culture of tumour-derived MDSC can give rise to mature macrophages and 
DC in absence of tumour soluble factors [253]. Finally, it has been shown that MDSC in the hypoxic 
microenvironment become TAM [254].  
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FIGURE 1.7. Myeloid cells in cancer. Factors produced in the tumour microenvironment by tumour cells 
and stromal cells promote the aberrant differentiation of myeloid cells. Immature myeloid cells normally 
differentiate into DC, monocytes, macrophages and granulocytes (dotted arrows). During cancer, aberrant 
differentiation gives rise to various immunosuppressive populations, such as monocytic MDSC (M-MDSC), 
polymorphonuclear MDSC (PMN-MDSC), and TAM. It is still unclear whether monocytes and neutrophils 
can give rise to M-MDSC and PMN-MDSC respectively. MDSC, myeloid derived suppressor cells; TAM, 
tumour-associated macrophages. (Modified from [286]) 
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The mechanisms of modulation of innate and adaptive immune responses by MDSC are several and 
include depletion of nutrients [245], oxidative stress [255], inhibition of lymphocyte trafficking, 
induction of T cell apoptosis [256], and activation and expansion of TREGS [257]. 
Stimulation of myelopoiesis and the subsequent inhibition of differentiation of mature myeloid cells 
cause MDSC expansion. The mediators are myelopoietic growth factors (GM-CSF, G-CSF, M-CSF, 
stem cell factor - SCF, and VEGF) [247], and pro-inflammatory cytokines (IL-6, IL-1β, and IFN-γ, 
IL-4, IL-10 and IL-13) [258]. Most of these factors involve STAT3 signalling, which, amongst other 
functions, induces C/EBPβ, fundamental for the differentiation of MDSC [259] and myelopoiesis in 
general. However, it is not clear whether the first wave of immature cells recruited to tumours is 
immunosuppressive. Continuous stimulation of myelopoiesis and activation of immature cells from 
soluble factors could therefore be fundamental to drive the accumulation and differentiation of 
MDSC.  
1.2.2.2.9 Macrophages in the haematopoietic niche 
BM contains at least two populations of macrophages, namely osteoclasts and tissue resident 
macrophages (Figure 1.8). Osteoclasts differentiate from a precursors found in the GMP population, 
and their development depends on the presence of M-CSF. Tissue resident macrophages as well as 
osteoclasts are fundamental components of the HSC niche.  
The function of BM macrophages has recently been investigated. Rare activated BM monocytes and 
macrophages with high expression of α-smooth muscle actin (α-SMA) and COX2 have been 
identified adjacent to haematopoietic stem/progenitor cells (HSPC). This myeloid population is 
thought to prevent HSPC exhaustion by limiting the production of ROS through the expression of 
PGE2 [260]. Macrophages can also act as positive regulators of MSC and osteoblasts to retain HSC in 
the BM. In vivo depletion of endosteal macrophages, either in macrophage Fas-induced apoptosis 
(Mafia) transgenic mice in which a suicide fusion protein (made of the cytoplasmic domain of Fas and 
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the FK506-binding protein) is expressed under CD115 promoter, or with clodronate administration, 
recapitulated effects similar to administration of G-CSF: depletion of osteoblasts, suppressed 
endosteal bone formation, decreased expression of factors required for HSC retention and self-
renewal, and HSC mobilization into the blood [261]. A seminal study showed that the selective 
depletion of a specific subset of Gr-1- CD115int F4/80+ CD169+ macrophages was sufficient to induce 
HSPC egress. Interestingly, this subset localises in the vicinity of Nestin+ MSC niche cells, and its 
depletion induces a selective down-regulation of HSC-retention genes in niche cells [262]. There is 
still controversy regarding the mechanisms underlying such activity of macrophages in the niche. G-
CSF receptor signalling has been suggested to induce HSPC mobilization and osteoblast suppression 
either by monocytes [263], or through the expansion of neutrophils [264].  
The role of osteoclasts in the niche seems more direct and essential for its constitution as 
demonstrated by the increased proportion of MSC progenitors in osteopetrotic mice [265] and the 
reduction of HSC after bisphosphonate treatment [266]. Also osteoclast activation, resulting into the 
secretion of proteolytic enzymes, can mediate progenitor mobilization in the peripheral blood. 
Stimulation of osteoclasts with RANK-L recruits mainly immature progenitors to the circulation, and 
this is mediated by cathepsin K mediated degradation of niche molecules such as CXCL12, OPN and 
SCF. On the other hand, inhibition of osteoclasts with calcitonin reduced progenitor egress in 
homeostatic conditions, G-CSF mobilization and stress [267].  
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FIGURE 1.8. Macrophage role in the haematopoietic niche. Osteoclast activity is fundamental for 
osteoblast differentiation and MSC precursors capacity to retain HSC. BM monocytes and macrophages with 
high expression of α-SMA and COX2 (α-SMA+ mono/ϕ) maintain the primitive phenotype of HSC by 
regulating Akt induction of ROS through PGE2. In addition, PGE2 results in higher CXCR4 expression on 
HSPC and higher CXCL12 expression in the nearby nestin+ MSC. A population of CD169+ macrophages is 
also fundamental to maintain nestin+ HSPC retention genes, and possibly to promote osteoblast survival 
(dotted arrow). The relationship between α-SMA+ cells and CD169+ macrophages has not yet been 
investigated (dotted arrow). CAR, CXCL12 abundant reticular cell; COX2, cyclooxygenase 2; OPN, 
osteopontin; PGE2, prostaglandin E2; ROS, reactive oxygen species; SCF, stem cell factor; α-SMA, α-
smooth muscle actin. 
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1.3 THE ROLE OF NITRIC OXIDE IN IMMUNOSUPPRESSION 
L-arginine is a conditionally essential amino acid in adult mammals, which must be supplied in the 
diet during some pathological conditions in which L-arginine biosynthesis cannot compensate for 
depletion or inadequate supply. It is mainly metabolized by arginase and nitric oxide synthase (NOS) 
enzymes to produce urea and L-ornithine, and nitric oxide (NO) and L-citrulline, respectively. Not 
only myelomonocytic cells, but also MSC exploit the metabolism of the amino acid L-arginine to 
restrain T lymphocyte proliferation [122] [268].  
1.3.1 Nitric oxide synthase regulation 
NOS is a family of enzymes present in three isoforms with different intracellular localization, 
regulation and catalytic properties: neuronal (nNOS, NOS1), inducible (iNOS, NOS2), endothelial 
(eNOS, NOS3). NOS1 and NOS3 are constitutively expressed in a variety of cell types at low levels, 
whereas NOS2 is expressed in various cells of the immune system, such as macrophages, eosinophils, 
neutrophils, DC and NK cells.  
NOS enzymes are dimers that require the presence of calmodulin and the cofactors (6R)-5,6,7,8-
tetrahydrobiopterin (BH4), iron–protoporphyrin IX (haem), flavin-adenine dinucleotide (FAD) and 
flavin mononucleotide (FMN) for full activity. Each isoform consists of an amino-terminal oxygenase 
domain and a carboxy-terminal reductase domain. Electron carriers FAD and FMN transfer the 
electron resulting from the conversion of NADPH to NADP to the oxygenase domain of NOS. The 
oxygenase domain then uses the cofactors haem and BH4 to catalyse the reaction between oxygen and 
L-arginine, which generates L-citrulline and NO [269].  
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NOS2 expression is regulated by environmental cues. Th1-cytokines, such as IFN-γ, either alone or in 
combination with LPS, TNF-α, IFN-α, IFN-β and IL-1 up-regulate NOS2. In contrast, NOS2 
transcription is down-regulated by steroids [270], anti-inflammatory cytokines (e.g., transforming 
growth factor-β [TGF-β], IL-10) [271], p53 [272], and NO itself [273]. IFN-α, β and γ mediate NOS2 
induction by activating IRF-1, whereas LPS can induce NOS2 expression through stimulation of the 
mitogen-activated protein kinase (MAPK) pathway [274]. Hypoxia is another relevant factor in 
induction of NOS2 transcription due to the presence of hypoxia-responsive enhancer (HRE) on NOS2 
promoter [275]. Several transcription factors have been shown to be required for NOS2 gene 
expression, such as nuclear factor NF-κB, Jak3/Stat1, and c-Jun NH2-terminal kinase (JNK) [276]. 
The promoter sequence of NOS2 also contains a number of binding sites for transcription factors 
regulating cell proliferation, apoptosis and cell differentiation, such as C/EBP and hypoxia-inducible 
factor (HIF) [277]. The bioavailability of L-arginine, which is in turn influenced by the activity of 
arginase, is another important modulator of its function. 
1.3.2 The immunoregulatory role of NO 
NO is a diatomic free radical mediating a host of physiological events such as smooth muscle 
relaxation, vasodilatation, neurotransmission, inhibition of platelet aggregation, and 
immunomodulation [278-280]. Furthermore, at the cellular level, NO regulates cell growth, survival, 
apoptosis, proliferation, and differentiation [280]. As a result, NO is involved in the pathophysiology 
of several diseases [279].  
Its downstream effects are mediated through either cyclic guanosine monophoshate (cGMP)-
dependent or independent mechanisms. cGMP-independent effects of NO are mediated through its 
interactions with metal complexes, oxygen, and superoxide, DNA and proteins [281].  The reaction 
with other oxidants generates reactive nitrogen species (RNS), which can directly cause apoptosis or 
mutagenesis by damaging DNA and proteins [282]. Therefore, NO has a critical role in host-defence 
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against pathogens, but also in several immunological responses by regulating cytokine production, 
leukocyte chemotactic responses, cell survival, and thymic selection [269, 283, 284]. NO can also be 
involved in the pathogenesis of infectious diseases, chronic degenerative disorders and tumour growth 
[282, 285, 286]. 
The immunoregulatory activities mediated by NO on T cells [283, 287] are effected through the 
induction of apoptosis and/or by impairing cell activation. T lymphocyte apoptosis has been 
implicated in the regulation of T cell ontogeny both during thymic maturation and peripheral 
expansion [288].  
The NO effects on the signalling cascade downstream of IL-2 are responsible for the impairment of T 
cell activation [289-291]. Phosphorylation and activation of signalling intermediates in the IL-2R 
pathway (JAK1, JAK3, STAT5, Erk, and Akt) are inhibited [255, 291].  
NO exerts its effects also on other cells of the immune system. It impairs immunoglobulin expression 
on B cells [269, 292] and is required for NK IFN-γ mediated cytotoxic activity [293]. Th1 
lymphocytes expansion is suppressed by high concentrations of NO, whereas low levels of NO induce 
their proliferation [294, 295]. 
During acute bacterial or parasitic infections, NO is described as a resistance factor elaborated by the 
host to fight pathogens. Persistent infection with parasites, such as Tripanosoma, Chlamidya, 
Schistosoma, or Leishmania, are instead commonly characterised by an increase in arginase 
expression concomitantly with the prevalent production of IL-4, IL-10, and TGF-β [296]. Recent 
results obtained in models of Candida albicans and Tripanosoma cruzi infections demonstrated the 
existence of an immunosuppressive mechanism depending on IFN-γ-induced secretion of NO by 
myeloid cells that colonize the spleen during the acute phase of infection [297-299].  
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1.3.3 NO and cancer 
Tumour growth is often associated with an altered metabolism of the amino acid L-arginine, due to 
the activity of both NOS and arginase enzymes. The consequences of such activities by tumour-
recruited myeloid cells and cancerous cells consist in L-arginine deprivation and/or release of NO, 
supporting tumour growth and inhibition of anti-tumour T cell responses.  
Neoplastic transformation is a key step in cancer initiation. NOS2 mediates neoplastic transformation 
in oncogene- and chemical-induced tumourigenesis models, although conflicting results are reported 
in literature.  
Oxidative and nitrosative stress are known for inducing DNA damage and inhibition of DNA repair 
enzymes through direct or indirect mechanisms. p53 tumour suppressor mutations, or S-nitrosylation 
of caspases, can induce apoptosis-resistance and facilitate the accumulation of further mutations. NO 
can also initiate and promote tumourigenesis. For instance, fewer polyps were found in the small and 
large intestines of mouse with genetic mutations in adenomatous polyposis coli (Apc) alone compared 
with mice carrying mutations in both Apc and NOS2 [300]. In addition, NOS2-/- mice showed 
decreased incidence of gastric carcinogenesis that is induced by Helicobacter pylori [301].  
Another important effect of NO on tumour progression is determined by expression of angiogenic 
factors [302]. By up-regulating VEGF expression, several studies have shown that NOS2 induction in 
tumour cells promotes angiogenesis and consequently tumour progression. NO activates the 
transcription factor HIF1α, and in turn the hypoxic microenvironment in growing tumours lesions 
induces both NOS2 and arginase enzymes through the stabilization of HIF1α [303, 304], in particular 
in the populations of macrophages and immature myeloid cells associated with the tumour.  
In contrast to these findings, NO has also been shown to inhibit tumour progression. DNA damage 
induces the accumulation of p53 and results in death of transformed cells, and relatively low levels of 
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NO up-regulate DNA-dependent protein kinase (DNA–PK), which maintains the integrity of the 
genome. Furthermore, in contrast with previous studies, increased intestinal adenomas in Apc and 
NOS2 double-mutant mice were shown as compared to Apc-mutant mice [305].   
A controversial effect of NO is also found in host stromal-cell derived NO, which inhibits the growth 
of NO-sensitive tumours and promotes the growth of NO-resistant tumours. For example, Wei et al. 
showed that NOS2-deficient tumour cells in a NOS2-/- host grew faster and produced more lung 
metastases than those injected in wild type mice [306]. However, similar studies produced instead 
conflicting results. For example, lower VEGF expression and slower growth of B16 melanoma were 
shown in NOS2-/- mice [307]. 
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1.4 MESENCHYMAL AND HAEMATOPOIETIC STROMA INTERACTION 
1.4.1 Interaction in peripheral tissues 
The stroma of every lymphoid and non-lymphoid tissue is constituted of MSC, endothelial cells and 
resident macrophages, along with tissue-specific extracellular matrix (ECM) components. Tissue 
MSC, also referred to as tissue-resident fibroblasts, synthesize and remodel the ECM, but also 
regulate self-tolerance, organ development, wound healing, inflammation and fibrosis [308-311]. 
Tissue-resident macrophages have a broad role in the maintenance of tissue homeostasis, through 
clearance of apoptotic cells and resolution of inflammation.  
Recent investigations delineated three main groups of stromal cells on the basis of their origin: MSC 
from mesenchyme, monocyte-derived fibroblasts, also referred to as ‘fibrocytes’, and fibroblasts 
arising from epithelial-mesenchymal transition (EMT).  
As previously discussed, several studies have shown that ‘conventional fibroblasts’ share phenotype 
and immunosuppressive functions with BM MSC [13, 14], although further investigation is required 
to understand their developmental relationship. 
Fibrocytes [312] are defined as a circulating blood leukocyte population with in vitro adherent 
properties, expressing markers of haematopoietic cells (CD34), leukocytes (CD11b, CD13 and CD45) 
as well as fibroblast products (collagens I, III, and fibronectin). Their identity is poorly defined 
regarding their relationship to cells of mesenchymal and haematopoietic origin but it is likely they 
represent a rare subset of macrophages with the ability to recirculate following injury [313, 314]. 
Although recent studies have indicated that macrophages and MSC interact to maintain HSC niche 
functions [262], few studies have addressed whether such interaction occurs also in peripheral organs. 
However, it is arguable that an MSC-macrophage interaction exists in other stem cell niches (Figure 
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1.9). In fact, the stem cell niche concept does not solely apply to the haematopoietic niche, but also to 
other adult tissues, such as liver, kidney, gut, skin and gonads.  
During severe liver injury a cellular niche composed of myofibroblasts, macrophages and endothelial 
cells always surrounds the hepatic progenitor cells [315]. In particular, the interaction between 
Kupffer cells and hepatic stellate cells (which resemble MSC) has been recently investigated for its 
role in the process of hepatic injury and fibrotic progression. Stellate cells differentiate towards a pro-
fibrotic myofibroblast phenotype, which undergoes apoptosis during recovery from fibrosis. In vitro 
and in vivo experiments have suggested that macrophages are able to regulate proliferation and 
apoptosis of stellate cells [316, 317]. Using a transgenic mouse model of liver fibrosis, which allowed 
discrete depletion of CD11b+ cells under the influence of diphtheria toxin, Duffield et al. were able to 
demonstrate that depletion of macrophages during the early phases of recovery resulted in sustained 
accumulation of scarring matrix. However, when macrophages were depleted during the progression 
phase of fibrosis, decreased scarring and fewer myofibroblasts were detected [317].  
Similar results have been obtained in a model of crescentic glomerulonephritis. Depletion of 
macrophages reduced proliferation and apoptosis of tubular cells, and this was associated with a 
reduced number of glomerular crescents and improved renal function. The presence of macrophages, 
instead, supported a population of interstitial myofibroblasts with increased levels of proliferation and 
apoptosis [318]. 
The colonic epithelial niche also harbors myofibroblasts and macrophages. Subepithelial 
myofibroblasts continuously migrate upward from the crypt base, and it has been suggested that they 
assume a strategic position to establish and maintain instructive communications with stem cells. Like 
the myofibroblasts, macrophages have been shown to support and promote the proliferation of colonic 
epithelial progenitors in a model of dextran sodium sulphate (DSS) mediated epithelial injury [319]. 
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Suggestions of interaction between macrophages and MSC are found also in the epidermal niche, in 
which CXCL14 and epidermal tissue have been shown as attractant and niche of differentiation for 
Langerhans cells respectively in a human tissue model [320]. In particular, human epidermal 
equivalents were able to affect the supra-basal positioning, survival and differentiation into 
Langerhans cell-like cells of CD14+ DC precursors. 
Although both MSC and macrophages have been extensively studied for their role in tumour initiation 
and progression, few studies have addressed their interaction. In a murine model of mammary cancer, 
knock-out of specific hypoxia regulatory genes, such as HIF-1α, in tumour stromal fibroblasts, led to 
accelerated tumour growth and reduction of F4/80+ cells infiltration [321]. Furthermore, myeloid 
progenitor cells recruited in a lung tumour have been shown to promote EMT of metastatic tumour 
cells through the expression of versican, an extracellular matrix proteoglycan [322]. Recently, several 
in vitro studies have shown that MSC isolated from tumours support survival and proliferation of 
tumour cells through the recruitment and differentiation of myeloid cells. For instance, MSC obtained 
from follicular lymphoma patients up-regulate CCL2 and exhibit increased ability to recruit 
monocytes compared to MSC from healthy donors [323].  
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FIGURE 1.9. Evidence for a mesenchymal and haematopoietic stroma interaction in peripheral tissues. 
Kupffer cells in the liver regulate the apoptosis and proliferation of stellate cells, which differentiate into 
myofibroblasts during hepatic injury. Macrophages and myofibroblast support and promote the proliferation 
of colonic epithelial progenitor cells under inflammatory conditions. In the epidermal niche, the presence of 
stromal cells is important to promote the differentiation of Langerhans cells. In a model of crescentic 
glomerulonephritis, macrophages support the proliferation of myofibroblasts. 
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1.4.2 Interaction in the haematopoietic niche 
It is still unclear how the cellular components of the BM niche interact together to regulate HSC 
functions. Nevertheless, recent investigations are highlighting the role of several soluble factors, such 
as cytokines, chemokine and growth factors, bioactive lipids, cell adhesion molecules in regulating 
HSPC egress from the BM. The further sections will discuss the involvement of these factors in 
HSPC mobilization and their possible role as candidate molecules involved in MSC and macrophages 
interaction in the niche.  
1.4.2.1 The molecular profile of the BM niche 
The modalities by which the BM niche regulates HSC activities are currently a hot topic, and several 
new investigations have highlighted the role of cellular components of the niche and their 
interactions, as well as the central nervous system, as potential players. 
Osteoblasts and HSC are known to interact through Notch-Jagged-1 signalling, which prevents HSC 
differentiation in favour of self-renewal, and this, in turn, leads to HSC expansion [49]. Another 
important interaction is represented by osteoblast angiopoietin-1 and -2 (Ang-1 and Ang-2) with Tie2 
on HSC [324]. This interaction determines the activation of phosphatidylinositol 3-kinase (PI3-K)/Akt 
signaling pathway, and in turn activates cell survival pathways and cell cycle regulators, which may 
prevent HSC from metabolic exhaustion [324]. 
One of the first studies demonstrating a role of the sympathetic nervous system (SNS) in the HSC 
niche came from Katayama et al. [325], who demonstrated that G-CSF mobilization was reduced in 
mice in which the SNS was impaired. Osteoblasts and nestin+ MSC are innervated by the SNS [60], 
suggesting that SNS acts on several niche components. In particular, SNS inhibits cell cycle and 
differentiation of nestin+ cells, as demonstrated by chemical sympathectomy [60]. Furthermore, β2-
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adrenergic and dopamine receptors on HSC are up-regulated by G-CSF [326], and neurotransmitters 
can attract HSC.  
Fatty acids have also been explored for a role in modulating HSC niches activities. Mice deficient in 
galactocerebrosidase (GALC), an enzyme that synthesizes the lipid components of myelin sheaths, 
have a defective niche in which HSC fail to engraft [327]. HSPC express the receptor for sphingosine-
1-phosphate (S1P), which is part of the GALC metabolic pathway. It has recently been demonstrated 
that S1P induces CXCL12 secretion from BM MSC via ROS signalling, thus modulating steady state 
egress of HSPC [328]. Eicosanoids are also able to regulate haematopoiesis. PGE2 regulates the 
expression of CXCR4 on HSPC and facilitates their attraction to CXCL12 and homing [329]. 
Furthermore, a population α-SMA+ COX2 expressing monocytes and macrophages preserves the 
primitive stem cell phenotype of the progenitors in the BM by controlling their ROS content and 
inducing a higher CXCL12 expression in nestin+ MSC [260]. 
Extracellular matrix proteins (ECM) are structural and functional organizers of the niche, augmenting 
progenitor cell localization within the haematopoietic microenvironment [330], and mediating 
adhesion of HSC to stromal cells [331]. Agrin, an extracellular matrix protein belonging to the family 
of heparan sulphate proteoglycans (HSPG), has recently been demonstrated as a non-redundant signal 
for HSC survival and proliferation mediated by niche MSC [332]. Agrin is a critical regulator of 
neuromuscular synapses where it binds to skeletal muscle Lrp4, leading to activation of MuSK, a 
receptor tyrosine kinase essential for initiating clustering of acetylcholine receptors under the nerve 
terminal [333]. The function of non-neuronal isoforms of agrin, expressed in numerous cell types, is 
poorly understood, although its receptor at the immunologic synapse has been identified as α-
dystroglycan (α-DG) [334], a broadly expressed cell surface receptor critical for the early 
development stages [335]. Recent investigations on the role of agrin in post-natal haematopoiesis 
have shown that the absolute number of total leukocytes in all hematopoietic and peripheral 
compartments is reduced in agrin-deficient mice compared with control mice [332]. In particular, 
agrin-deficient mice show a significantly reduced frequency of monocytic cells in BM, spleen, and 
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peripheral blood, but not in lymphocytes or granulocytes, indicating that the absence of agrin 
specifically affects monocytes and macrophages [336].  The lack of agrin inhibits the differentiation 
of promonocytes into mature monocytes, and monocytes into macrophages, whereas it does not affect 
the differentiation of GMP into neutrophils [336]. LSK cells pre-treated with inhibitor of α-DG co-
injected with control cells into lethally irradiated recipients displayed a reduced reconstitution ability, 
whereas agrin-/- LSK were able to differentiate normally in an agrin-sufficient recipient [332], 
demonstrating that agrin expression is fundamental in the stromal but not in the haematopoietic 
compartment.  
1.4.2.2 Role of pro-inflammatory cytokines 
During inflammation, immune cell are highly consumed, and are replenished by proliferating 
haematopoietic precursors from the BM [337]. Mature blood cells are produced at a rate of more than 
one million cells per second in humans, whereas most of the HSC from which they derive are 
quiescent [338].  
In recent times, it has been demonstrated that inflammatory cytokines can also contribute to shape the 
HSC compartment. In vivo injection of bacterial component LPS increases the proliferation and self-
renewal of LSK through TLR4 binding on the surface of HSC [339, 340]. The role of pro-
inflammatory cytokines, such as TNF-α and IFN-γ, is still controversial. It has been shown that TNF-
α and IFN-γ can induce HSPC to proliferate [341] and determine impairment in self-renewal of these 
cells [342, 343]. In line with this finding, BM cells from TNF-α receptor knockout (TNFR-/-) mice 
have a competitive advantage over wild type (WT) BM cells for their ability to reconstitute a 
myeloablated recipient, indicating that TNF-α may act as a potent suppressor of HSC activity in vivo 
[344]. Similarly, BM of mice deficient for IFN-γ show increased engraftment after transplantation 
when compared to WT mice [345]. In contrast with these data, mice lacking TNFR1 have increased 
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numbers of hematopoietic progenitors at baseline and develop increased marrow cellularity with age 
[346, 347].  
Although it is not clear whether TNF-α and IFN-γ can indirectly act on HSC function, other pro-
inflammatory molecules have been instead shown to modify the cellular components of the niche. 
Exposure to TLR ligands induces a block in the maturation of osteoclasts [348, 349], which have been 
shown to be fundamental for a normal formation of the HSC niche [265]. G-CSF inhibits CXCL12 
production by osteoblasts and leads to increased mobilization of haematopoietic progenitors, in a 
process mediated by G-CSF receptor (G-CSFR) mediated signals in BM monocytes [263]. In a 
similar vein, a recent study provides evidence that the expansion of neutrophils in the BM in response 
to G-CSF, induces MSC progenitors and osteoblasts apoptosis through increased ROS production and 
reduces their expression of factors crucial for HSC retention in the BM [264]. Interestingly, CXCL12 
is not only expressed by osteoblasts but also by CAR cells, affiliated to MSC, which express MCP-1 
in response to circulating TLR ligands or bacterial infection, and induce an egress of monocytes from 
BM into the bloodstream [102].  
The expression of HSC retaining genes, such as CXCL12, angiopoietin 1, SCF and VCAM1 by niche 
MSC is regulated by CD169+ BM macrophages. Accordingly, macrophage depletion promotes the 
egress of HSC in the niche [262]. The macrophage-derived factors mediating these effects are still 
unknown, although pro-inflammatory molecules, such as insulin-like growth factor 1, IL-1, IL-10 and 
TNF-α, have been proposed.  
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1.4.2.3 Role of complement 
During inflammation, the human complement cascade represents a first line defence, not only 
eliminating foreign bodies, but also acting as a surveillance system capable of discriminating between 
host cells and pathogens or cell debris [350].  
Several lines of evidence suggest that complement is also involved in the BM niche. C5a and G-CSF 
can activate granulocytes and monocytes to release proteolytic enzymes that cause detachment of 
HSPC from their niches [351, 352]. C3 fragments inhibit mobilization of HSPC, whereas C5 cleavage 
fragments promote it, as demonstrated by knockout mouse models [351, 353].  
Even more directly, complement factors are involved in HSPC homing and engraftment. C3a can 
potentiate the homing gradient of CXCL12 and increase the responsiveness of HSPC to this gradient 
by including CXCR4 in lipid rafts. C3b instead has been shown to tether HSPC to the stroma [354]. 
C3- and C5-deficient mice show a delayed haematopoietic recovery after transplantation [354]. 
Transplantation of WT HSPC into C3-/- mice resulted in a delay in platelet and leukocyte recovery and 
in a reduced number of BM GMP, whereas HSPC from C3-/- engrafted normally into WT mice, 
suggesting a defect of the niche environment of C3-/- [354]. Furthermore, an accumulation of soluble 
C5b–C9 membrane attack complex (MAC) has been shown after conditioning for haematopoietic 
transplantation by lethal irradiation. This complex has a role in homing and engraftment, as it 
activates signalling in HSPC, enhances adhesion of HSPC to BM MSC through the HSPC-expressed 
CR3 (CD11b/CD18) receptor and increases secretion of CXCL12 from BM stroma [355].  
These data have provided the rationale to tested ex vivo priming of HSPC with C3a before 
transplantation to improve engraftments (Charlottesville, VA; and Minneapolis, MN) [356].  
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1.4.2.4 Role of hypoxia and NOS  
Several pieces of evidence suggest that stem cell niches are prevalently hypoxic [357, 358], a factor 
that is believed to enhance greater self-renewing ability in HSC [261]. Analysis of HSC proteome has 
shown a profile compatible with an anaerobic environment, having increased expression of 
antioxidant enzymes [359]. HIF-1α up-regulates erythropoietin production [360], proliferation and 
survival genes, the angiogenic VEGF [361], and other genes. G-CSF, mediator of HSPC mobilization, 
determines an up-regulation of HIF-1α expression [362], increasing in turn VEGF and CXCL12 
production [363], and CXCR4 expression [364]. Interestingly, a population of MSC precursors [17], 
VSEL, was reported to mobilize as a result of hypoxia, coincident with an increased plasma level of 
CXCL12 [365].  
Hypoxia is also a typical feature of the cancer stem cell niche. It is believed that, like normal stem 
cells, also cancer stem cells self-renew and differentiate, and hypoxia might contribute to sustain these 
properties [366]. HIF-1α can induce the up-regulation of NOS in solid tumours [304], and in neural 
progenitor cells [367], thus suggesting a role for NOS in the tumour niche.  
NO has recently been investigated as a putative regulator of HSPC mobilization in the BM niche. NO 
production by murine BM cells was shown to inhibit the colony-forming ability of isolated Lin- cells 
in vitro [368]. Inhibition of NOS activity in vivo results in an increase in the number of stem and early 
progenitor cells in the BM, followed by an increase in the neutrophil content in the blood [369]. In 
particular, BM cells isolated from mice treated with NOS inhibitors were more efficient in 
repopulating lethally irradiated mice than control cells in a competitive repopulation assay [369].  
Interestingly, stromal cell derived neuronal NOS (nNOS) produces NO that acts as a paracrine 
regulator of HSC [370]. Further studies conducted in eNOS knockout mice demonstrate that eNOS 
expressed by BM MSC influences recruitment of stem and progenitor cells in a hind limb ischemia 
model [371]. Moreover, eNOS knockout mice exhibit markedly reduced capacity to produce 
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endothelial progenitor cells from hematopoietic stem cells [372]. Another confirmation to the ability 
of NO to regulate stem cells divisions come from studies in neurons, where it has been shown that 
infusion of NOS inhibitors impairs the proliferation of neural stem cells [373].  
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1.5 AIMS 
We hypothesized that MSC isolated from BM or peripheral tissues can modulate the recruitment, 
expansion and differentiation of myeloid cells. To test this hypothesis we investigated: 
1. The effect of MSC on expansion and differentiation of haematopoietic cells; 
2. The phenotype, and function of BM mononuclear cells exposed to MSC; 
3. The role of candidate molecules in MSC-driven haematopoietic differentiation; 
4. The cellular players involved in mesenchymal-haematopoietic stroma interaction. 
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CHAPTER 2. 
MATERIALS AND METHODS 
2.1 ANIMALS 
C57BL/6 and BALB/c mice were purchased from Olac, Bicester UK. Nos2-/- mice in C57Bl/6 
background were kindly provided by Prof. Vincenzo Bronte (Verona University Hospital and 
Department of Pathology, Immunology Section, Verona). Tnfr1/r2-/- mice in C57Bl/6 background 
were kindly provided by Dr. Jorge Caamano (Medical Research Council (MRC) Centre for Immune 
Regulation, Institute for Biomedical Research, Birmingham Medical School, Birmingham). C3-/- mice 
in BALB/c background were kindly provided by Prof. Marina Botto (Centre for Complement and 
Inflammation Research, Imperial College, London). Musk-L;Agrn-/- and Musk-L;Agrn+/- mice in 
C57Bl/6 background were kindly provided by Prof. Antonella Viola. Musk-L;Agrn-/- mice have been 
described elsewhere [374]. Briefly, mice lacking all isoforms of agrin were crossed with mice 
overexpressing Musk transgene (Musk-L), increasing Musk expression by 3-fold and achieving an 
adequate level of Musk activation in muscle that prevents neonatal lethality of agrin mutant mice 
[374]. 
BM and spleen cells were obtained from 8-12 week old mice. All procedures were conducted in 
accordance with the Home Office Animals Act of 1986. 
2.2 CELLS AND CELL CULTURE 
All cell culture procedures were performed under sterile conditions in a flow cabinet. Cell cultures 
were incubated at 37°C and 5% CO2 in a humidified incubator. MSC were cultured in Mesencult 
medium with MSC stimulatory supplement (StemCell Technologies, Canada). MDSC were cultured 
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in RPMI 1640 medium supplemented with 10% heat inactivated FBS (Superior, Biochrom), 100U/ml 
penicillin G, 100U/ml streptomycin sulphate and 100U/ml glutamine (Invitrogen). Skin MSC and 
mesangial cells were cultured in RPMI 1640+GlutaMAXTM medium supplemented with 20% heat 
inactivated foetal bovine serum (FBS) (Biosera, South America) 100U/ml penicillin G, 100U/ml 
streptomycin sulphate (Invitrogen). Mesangial cells isolated from C57Bl/6 mice were a gift from Dr. 
Jacques Behmoaras (Centre for Complement and Inflammation Research, Imperial College London, 
London). Briefly, glomeruli from C57Bl/6 mice were isolated by sieving, and digested with 
collagenase type 1 for 20 min. Partially digested glomeruli were cultured in 25-cm2 tissue culture 
flasks at 600 glomeruli/ml in RPMI 1640 medium (Invitrogen) that contained 20% FBS (F-539), 
penicillin (100 U/ml; Invitrogen), streptomycin (100 µg/ml; Invitrogen), and l-glutamine (2 mM, 
Invitrogen) and was supplemented with insulin-transferrin-selenite (Sigma). The cultures were 
maintained at 37°C with 5% CO2 for 6 days, allowing glomerular mesangial cells to grow out.  
BM and spleen cells were cultured in RPMI 1640+GlutaMAXTM medium supplemented with 10% 
heat inactivated FBS (Biosera, South America) 100U/ml penicillin G and 100U/ml streptomycin 
sulphate (Invitrogen). In co-culture experiments with MSC the same medium was used. 
2.2.1 MSC 
MSC were generated from 8 to 12 weeks old mice. Femurs and tibias of C57Bl/6, Nos2-/- and 
Tnfr1/r2-/- mice were directly crushed and plated in Mesencult. After 72 hours non-adherent cells 
were removed and fresh medium was added to the cultures. The medium was changed every 3 to 4 
days for 8 to 10 weeks and a homogeneous cell population was obtained. The identity of MSC was 
confirmed by immunophenotypic criteria based on the expression of PDGFRα and Sca-1, and the 
absence of haematopoietic marker CD45. BM derived MSC isolated from Musk-L;Agrn+/- and Musk-
L;Agrn-/- mice [332] were kindly provided by Prof. Antonella Viola (Istituto Clinico Humanitas 
IRCCS and Department of Translational Medicine, University of Milan, Milan). BM derived MSC 
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isolated from C3-/- (BALB/c background) and BALB/c mice were kindly provided by Prof. Marina 
Botto. 
2.2.2 MDSC 
Tibias and femurs from 8 to 12 weeks old C57BL/6 mice were removed using sterile techniques and 
BM was flushed. Red blood cells (RBCs) were lysed with ammonium chloride (Lonza). To obtain 
BM-derived MDSC, 2.5x106 cells were plated into dishes with 100 mm diameter (Falcon, BD, NJ, 
USA) in 10 ml of medium supplemented with a combination of GM-CSF (40 ng/ml) and IL-6 (40 
ng/ml) cytokines. Cells were maintained at 37°C in 5% CO2-humidified atmosphere for 4 days. 
2.2.3 Skin MSC 
In order to obtain skin MSC, 5 mm skin biopsies were obtained from C57Bl/6 mice, cut into pieces 
and plated in RPMI 1640+GlutaMAXTM medium supplemented with 20% heat inactivated FBS 
(Biosera, South America), and 100U/ml penicillin G, 100U/ml streptomycin sulphate (Invitrogen). 
After 72 hours non-adherent cells were removed and fresh medium was added in the cultures. The 
medium was changed every 3 to 4 days for 2 weeks and a homogeneous cell population was obtained. 
2.2.4 Spleen and BM cells 
Spleen and limbs were removed from freshly euthanized C57BL/6 mice and placed in complete 
RPMI. Spleens were mashed through a cell strainer (70µm, BD Bioscience, UK), washed with 
complete RPMI, and centrifuged at 1500 rpm for 6 minutes. BM cells were obtained by flushing the 
tibia and femur of freshly euthanized mice. For the lysis of RBCs spleen and BM cells were treated 
with ammonium chloride (Lonza) for 5 minutes at room temperature and washed again. 
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2.3 Co-cultures 
For co-cultures experiments with BM cells, MSC were plated at 2x105 cells/well in 24 well plates 
(Costar), and kept at 37°C, 5% CO2 and 95% humidity in a cell incubator. When the MSC were 
attached to the plastic, 1x106 BM cells were added, either directly or in a 0.4µm transwell system 
(Corning, Costar). After 4 days, cells were collected by adding PBS containing 2mM ethylene-
diamine-tetraacetic acid (EDTA). Where stated, cytokines or antibodies were added to the co-cultures: 
murine TNF-α (Peprotech), murine IFN-γ (Peprotech), human complement C3 (Calbiochem), murine 
IL-6 (Peprotech).  
2.4 CD11b+ ISOLATION 
For CD11b+ separation, co-cultures were collected by adding PBS containing 2mM EDTA and 
separated with CD11b+ Microbeads (Miltenyi Biotec) according to the manufacturer’s instructions. 
Purity of isolation was assessed by FACS. 
2.5 IN VIVO EXPERIMENTS 
For adoptive transfer of WT or Nos2-/- MSC, lethally irradiated (800cGy) WT C57Bl/6 recipients 
were transferred (by tail vein injection) with 2*106 BM cells and 0.2*106 WT or Nos2-/- MSC 4 hours 
after the second dose of irradiation.  
For the transplantation experiment, lethally irradiated (800cGy) WT or Nos2-/- recipients received 
liposome-encapsulated clodronate (Dr. Nico Van Rooijen) at day -1 by intraperitoneal injection, and 
were transferred (by tail vein injection) with 2*106 BM cells 4 hours after the second dose of 
irradiation.  
Spleen and BM from transplanted mice were recovered at day 10 (adoptive transfer of MSC) or day 
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14 (transplantation experiment) and analysed by FACS. 
2.6 FACS STAINING AND SORTING 
Cells were blocked with PBS supplemented with 1% FBS, and mouse serum IgG before incubation 
with the respective monoclonal antibody (mAb) at 4°C for 20 minutes. After incubation the cells were 
washed with PBS and analysed by flow cytometry.  
For intracellular cytokine staining, 0.3x106 cells obtained from the co-cultures were plated in 96 well 
U-bottom plates and either non stimulated or stimulated with phorbol 12-myristate 13-acetate (PMA) 
(10 ng/ml) and ionomycin (250 ng/ml) for 4 hours. Golgi stop (BD Pharmingen) was added for the 
subsequent 12 hours. Cells were collected, by adding PBS 2mM EDTA, fixed and permeabilized 
following manufacturer instructions (BD Cytofix/CytopermTM), and stained for intracellular markers. 
A list of antibody used is represented in Table 2.1.  
Samples were acquired with a BD FACSCalibur or with a BD LSRII (BD Biosciences) and data was 
subsequently analysed using FlowJo software (Oregon, USA).  
For sorting primitive HSC and myeloid progenitors, BM cells were stained for Lineage antibody 
Cocktail (CD3e, CD11b, CD45R/B220, TER-119, and Ly-6G and Ly-6C), c-Kit (CD117), IL-7Rα, 
CD34, CD16/32 (FcγR), Sca-1 and Flk2 antibodies. Samples were acquired with a BD FACSAria 
(BD Biosciences).  
For sorting CD11b+ cells and CD11b+ Gr-1high, CD11b+ Gr-1int-low and CD11b+ Gr-1-, BM cells were 
stained for CD11b and Gr-1 antibodies. Samples were acquired with a BD FACSAria (BD 
Biosciences). 
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TABLE 2.1. List of monoclonal antibodies for FACS analysis and sorting. 
Antibody Clone Manufacturer
CCR2 475301 R&D Systems
CD115 (c-fms) AFS 98 eBioscience
CD117 (c-Kit) 2B8 BD Biosciences
CD11b M1/70 Biolegend
CD124 (IL4Rα) mIL4R-M1 BD Biosciences
CD127 (IL-7Rα) A7R34 eBioscience
CD135 (Flk2) A2F10.1 BD Biosciences
CD140a (PDGFRα) APA5 eBioscience
CD16/32 (FcγR) 93 eBioscience
CD169 (Sialoadhesin) 3D6.112 AbDSerotec
CD206 (mannose receptor C type 1) MR5D3 AbDSerotec
CD34 RAM34 eBioscience
CD45 30-F11 eBioscience
CD45.1 A20 eBioscience
CD45.2 104 eBioscience
CD62L (L-selectin) MEL-14 BD Biosciences
CD68 FA-11 Biolegend
F4/80 CI:A31 AbDSerotec
IFNγ XMG1.2 BD Biosciences
IL-10 JES5-16E3 BD Biosciences
IL-12 (p40/p70) C15.6 BD Biosciences
IL-4 11B11 BD Biosciences
Lineage antibody cocktail BD Pharmingen
Ly-6C AL-21 BD Biosciences
Ly-6G 1A8 BD Biosciences
Ly-6G/Ly-6C (Gr-1) RB6-8C5 Biolegend
Sca-1 (Ly-6A/E) D7 eBioscience
TNFα MP6-XT22 BD Biosciences
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2.7 RT-PCR 
Total RNA was extracted from CD11b+ cells from the co-cultures, or from MSC, using the RNeasy® 
plus kit (Qiagen, UK) according to manufacturers instruction. RNA concentration was measured 
using a NanoDrop 1000 spectrometer (Thermo Fisher Scientific, USA). 25 ng of sample were 
analysed with TaqMan® RNA-to-CT™ 1-Step Kit, according to manufacturers instruction. RNA was 
reverse transcribed for 15 minutes at 48°C, and the AmpliTaq Gold® DNA Polymerase (Applied 
Biosystems) was activated for 10 minutes at 95°C. mRNA was quantitated with TaqMan® Gene 
Expression Assay. Samples were run in triplicate and data was analysed using the delta delta CT 
(ΔΔCT) relative quantification method, with each sample normalized to HPRT to correct for 
differences in RNA quantity.  
2.8 IMMUNOSUPPRESSIVE ASSAY 
For immunosuppressive assays of CD11b+ cells isolated from the co-cultures, CD11b+ cells were 
plated at different percentages of the total number of cells in the cultures (12%, 6%, 3% and 1.5%) in 
a 96 well flat bottom plate (Costar), and either 5x105 Concanavalin-A  (ConA) stimulated or non-
stimulated splenocytes were added. For immunosuppressive assays of skin stromal cells or MSC, 
stromal cells were plated at 5x104 cells/well in a 96 well flat bottom plate (Costar), and either 5x105 
Con-A stimulated or non-stimulated splenocytes were added. Cell proliferation was measured by 
incorporation of tritiated thymidine (3H-TdR). Cell cultures were pulsed with 0.5µCi/well of 3H-TdR 
(Amersham, UK) and incubated for 18 hours. Cells were then harvested onto filters (Wallac Perkin 
Elmer, USA) using a 96-well cell harvester. Scintillation fluid (Wallac) was added to the filter, which 
contains fluorophores that absorb radioactive energy and converts it into light that is then detected by 
the beta counter (Wallac). The results of the incorporated thymidine were expressed in counts per 
minute (cpm) and were a mean of triplicate.  
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2.9 DIFFERENTIATION ASSAY 
MSC were tested for their ability to differentiate into adipocytes and osteoblasts. MSC were plated in 
6-well plates at a density of 1x105 cells per well in 2 ml of medium. Adipocytic differentiation was 
induced by 1µM dexamethasone (SIGMA), 0.5 mM methyl-isobuthylxanthine (IBMX) (SIGMA), and 
10µg/ml insulin (SIGMA), whereas 100nM dexamethasone, 10mM β-glycerol phosphate (SIGMA), 
and 50µM ascorbic were used for osteoblastic differentiation. Oil red O and Alizarin red S dyes were 
used to identify adipocytes and osteoblasts respectively after 21 days. 
2.10 CYTOSPIN PREPARATIONS 
After 4 days, BM cultured alone, with cytokines GM-CSF and IL-6 or with MSC were harvested and 
CD11b+ cells were separated. Cytospin preparations of CD11b+ cells were fixed and stained with 
May-Grünwald-Giemsa staining. 
2.11 CONFOCAL 
BM cultured alone grown on coverslips or cytospins of CD11b+ cells sorted from co-cultures of BM 
cells and MSC were rinsed with PBS, fixed in 4% paraformaldehyde (PFA) overnight at 4°C, and air-
dried. The coverslips were incubated with 5µg/ml of wheat germ agglutinin (WGA, AlexaFluor 488, ) 
for 10 minutes, and blocked with PBS containing 1% bovine serum albumin (BSA) and 0.1% Triton 
X-100 for 1 hour. After removing the medium, the coverslips were incubated overnight with a 
solution containing monoclonal antibody anti CD11b (0.5 µg/ml, Abcam) and anti-iNOS (1:100, 
Abcam) or anti-Arginase-1 (1:100, Abcam) in PBS containing 1% BSA. The coverslips were washed 
three times with PBS, and then incubated with a solution containing Dylight 594-conjugated anti-Ig 
directed to the native species of the primary antibody (1:200) in PBS containing 1% BSA. This 
secondary incubation was done for 1 hour at 25°C. The coverslips were washed three times in PBS 
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and mounted to the slides in Vectashield mounting medium containing 4,6-diamidino-2-phenylindole 
(DAPI) (Vector Laboratories, Inc., Burlingame, CA). The slides were then sealed with nail polish and 
stored at 4°C. Confocal images were obtained using a Leica TCS-SP laser-scanning confocal 
microscope (Leica, Heidelberg, Germany). 
2.12 STATISTICAL ANALYSIS 
Data were analysed using unpaired two-tailed Student’s t test with confidence interval of 95%, and 
expressed as mean ± standard deviation (SD). For analysis of in vivo experiments, Mann-Whitney U 
test was used. 
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CHAPTER 3.  
MSC DRIVE MYELOID CELL DIFFERENTIATION  
3.1 INTRODUCTION 
MSC are a heterogeneous population derived from the BM that comprises a large proportion of 
progenitors, capable of differentiating into osteoblasts, adipocytes and chondrocytes [2, 3] and of 
forming a haematopoietic niche when transferred in vivo [32]. MSC precursors have been shown to 
play a fundamental role in the regulation of self-renewal and differentiation of HSC [25, 58, 60]. 
However, cells of myeloid origin play a key role in modulating MSC functions. BM macrophages 
modulate HSPC retention genes in MSC precursors, thus regulating HSPC mobilization from the 
niche [262]. G-CSF mediated HSPC egress correlates with an expansion of neutrophils population in 
the BM, and this in turns reduces MSC expression of factors crucial for HSC retention in the BM 
[264]. Finally, MSC progenitors modulate HSC entry into the bloodstream during infections [102]. 
Therefore, the interaction between myeloid populations and MSC is a crucial regulator of the 
haematopoietic niche. 
An interaction between MSC and macrophages has also been shown in regards to MSC mediated 
immunosuppressive functions. Indeed, MSC can exert potent immunosuppressive activities under 
particular circumstances, which can be potentiated by the presence of monocytes [99, 375].  
On the basis of these notions, we wanted to investigate the ability of MSC to induce the expansion 
and terminal differentiation of myeloid cells from haematopoietic cells of BM origin.  
 90 
3.2 RESULTS 
3.2.1 Characterization of isolated MSC 
The first aim was to establish a reference MSC preparation in order to make the results more 
comparable throughout the project.  
The preparation of BM derived MSC was quantitated at serial intervals during its expansion for the 
expression of PDGFRα, Sca-1 [32], c-kit, and the stromal marker CD90. Any contaminating 
haematopoietic cells were evaluated by the use of CD45. The results of a FACS analysis of a 
representative MSC preparation are reported in Figure 3.1A. MSC were cultured for 8 weeks and 
underwent 8 passages. The preparation was confirmed as CD45-, and the proportion of 
PDGFRα+/Sca-1+ cells within this population was 97.6%. No expression of the marker c-Kit was 
detected in BM derived MSC, whereas 95.6% cells were CD90+. 
In order to assess the multipotent activity of the isolated MSC, we investigated their ability to 
differentiate into adipocytes and osteoblasts in the presence of specific media. After 3 weeks of 
culture, differentiation of our MSC preparation was confirmed by using Oil Red O to stain lipid 
droplets (Figure 3.1C, left panel) or Alizarin Red S (Figure 3.1C, right panel) to stain bone nodules.  
Since BM MSC have been demonstrated to be immunosuppressive [79], we tested the ability of our 
MSC preparations to inhibit T-cell proliferation by culturing escalating concentrations of MSC with 
ConA stimulated splenocytes (Figure 3.1B). T-cell proliferation was evaluated by 3H-thymidine 
uptake. The suppressive activity of our MSC preparation was dose dependent (Figure 3.1B). The 
proliferation of activated splenocytes was completely abolished when MSC were present up to a 1:80 
ratio, whilst the percentage of inhibition was 50% at a 1:160 ratio.  
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FIGURE 3.1. Characterization of BM derived MSC preparation. A. Proportion of CD45- cells is 
represented in the live gate. Proportions of PDGFRα+ Sca-1+ cells and CD90+ c-Kit+ cells are represented in 
the CD45- gate in dot plot. A representative example out of 3 independently derived preparations of MSC is 
shown. B. MSC were plated at 5x104 cells/well, with 1:2 serial dilutions, and splenocytes were added at 
5x105 cells/well and stimulated with 3µg/ml of ConA for 3 days. 3H-thymidine was added for the last 18h. A 
representative experiment out of 3 independent experiments is shown. Each column represents the mean±SD 
of triplicates of cultures. (cpm: count per minute). Results are expressed as the value obtained by subtracting 
the (MSC+Splenocytes) value from the (MSC+Splenocytes ConA) value. C. Adipogenic and osteogenic 
differentiation of BM derived MSC. Adipose droplets and bone nodule mineralization are visualized by oil 
red O and Alizarin Red S staining, respectively. Representative images of 3 independent adipogenesis and 
osteogenesis differentiation experiments. 
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3.2.2 MSC expand and differentiate haematopoietic cells 
In order to investigate the effect of MSC on terminal myeloid differentiation of haematopoietic cells, 
short-term co-cultures of BM derived MSC and unfractionated BM were set up.  
MSC were plated overnight and unfractionated BM cells were added at a 5:1 ratio to the MSC 
cultures and incubated for 4 days. BM cells treated with GM-CSF and IL-6 were used as control 
cultures to differentiate myeloid cells as previously reported [259]. A further control consisted of BM 
cells cultured alone. 
After 4 days the BM cells present in the cell suspension were harvested and assessed for the 
expression of CD11b and Gr-1 to define myeloid cell populations, and F4/80 for macrophages [376]. 
The vast majority of BM cells cultivated in the presence of MSC were CD11b+, thus indicating a 
prominent myeloid differentiation. The analysis of Gr-1 expression within the CD11b+ gated 
population identified three main subsets of CD11b+ cells: CD11b+ Gr-1high, CD11b+ Gr-1int-low and 
CD11b+ Gr-1- (Figure 3.2A, left panel). Cytokine-induced differentiation typically consisted of a 
higher percentage of CD11b+ Gr-1int-low cells (33.8% ± 9.3% versus 24.6% ± 8.6% in BM alone, 
p=0.0346) and a higher percentage of CD11b+ Gr-1- cells (19.7% ± 5.3% versus 4.9% ± 2% in BM 
alone, p<0.0001) as compared to BM cultured alone. The proportion of CD11b+ Gr-1high cells was 
instead decreased (46.9% ± 9.8% versus 70.6% ± 9.1% of BM alone, p<0.0001) (Figure 3.2A and 
Figure 3.2B). Within the CD11b+ population, the presence of MSC induced a decrease in the CD11b+ 
Gr-1high (32.2% ± 10.4%) and in the CD11b+ Gr-1int-low component (17.3% ±6.7%) as compared to 
BM alone or treated with cytokines, respectively (CD11b+ Gr-1high: p<0.0001 versus BM alone, and 
p=0.0044 versus BM+GM-CSF+IL-6; CD11b+ Gr-1int-low: p=0.0465 versus BM alone, and p=0.0003 
versus BM+GM-CSF+IL-6) (Figure 3.2B). The CD11b+ Gr-1- component was highly increased 
(50.6% ± 12.5%) in presence of MSC as compared to BM alone and BM treated with cytokines 
(p<0.0001 versus BM alone and BM+GM-CSF+IL-6) (Figure 3.2B).  
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In line with a marked increase in the proportion of CD11b+ Gr-1-, the expression of F4/80/CD11b+ 
was higher in MSC-induced myeloid cells (39.1% ± 12.3%) than in BM cell cultures (6.9% ± 4.3%) 
or BM with cytokines (14.9% ± 4.9%)  (p<0.0001 and p=0.0003 versus BM alone and BM+GM-
CSF+IL-6 respectively, Figure 3.2C). Cytokine-induced differentiation of myeloid cells was also 
confirmed by an increase in the percentage of CD11b+ F4/80+ cells as compared to BM cultured alone 
(p=0.0044). Representative contour plots for the expression of F4/80 versus Gr-1 are shown in Figure 
3.2A.  
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FIGURE 3.2. MSC induce the differentiation of myeloid cells. BM was cultured alone, with MSC (ratio 
5:1) or with GM-CSF and IL-6 (40ng/ml) for 4 days. A. Contour plots represent the CD11b and Gr-1 
proportion in the live gate, and the expression of F4/80 versus Gr-1 is represented in the CD11b+ gate. A 
representative example out of 10 independent experiments is shown. B. Percentage of Gr-1high, Gr-1int-low and 
Gr-1- in CD11b+ cells. Mean of 10 independent experiments, ± SD *p<0.05 ** p<0.005 *** p<0.001 **** 
p<0.0001 Unpaired t test. C. Percentage of CD11b+ F4/80+ cells, within the CD11b+ cells population. Mean 
of 10 independent experiments, ± SD ** p<0.005 *** p<0.001 **** p<0.0001 Unpaired t test.  
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In order to understand whether MSC could drive not only the differentiation but also an expansion of 
the myeloid population, the absolute number of CD11b+ cells recovered at day 4 was analysed 
(Figure 3.3). The figures were obtained by multiplying the number of cells recovered at the end of the 
cultures by the percentage of CD11b+ cells. The selection of CD11b+ excluded possible 
contaminations by MSC. MSC or the cytokine combination, induced in BM cells an expansion in the 
absolute number of CD11b+ cells (5.7x106 ± 1.8 and 10.3x106 ± 3.4), as compared to the amount of 
CD11b+ recovered from BM cultured alone (1.7x106 ±1.4) (p=0.0014 and p=0.0002 versus BM alone, 
respectively).  
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FIGURE 3.3. MSC induce the expansion of myeloid cells. Absolute number of CD11b+ cells recovered 
from initial seeding from BM cultured alone, with MSC or treated with GM-CSF and IL-6 for 4 days. Mean 
of 10 independent experiments, ± SD ** p<0.005 *** p<0.001 Unpaired t test. 
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To further characterise the profile of the CD11b+ cells obtained after the co-culture, several markers 
preferentially expressed by macrophages (F4/80, CD206, CD68 and CD169) and by monocytes 
(CD115, IL4Rα and CD62L) were analysed in BM cells cultured alone, with MSC or with cytokines.  
CD11b+ cells obtained from BM cultured alone showed low expression of F4/80 (6.9%±4.3%), 
CD115 (4.1%±2.3%), IL4Rα (4.9%±4.1%), and CD206 (1.5%±1.5%) (Figure 3.4A). Very low levels 
of expression of CD169 (0.7%±0.3%), and CD68 (0.8%±0.2%) was detected on BM cultured alone. 
High expression of CD62L was instead documented on BM cultured alone (24.4%±4.2%). The 
presence of GM-CSF and IL-6 produced an increase in F4/80 (14.9%±4.9%), CD115 (33.5%±10.3%), 
IL4Rα (22.9%±4.2%), CD206 (2.8%±0.3%), and CD68 (1.5%±0.4), and a decrease in the amount of 
CD62L (6.8%±2.1%) as compared to BM cultured alone (Figure 3.4A). MSC induced a remarkable 
6-fold increase in F4/80 (36.5%±10.3%), a 3-fold increase in IL4Rα (18.2%±7.5%), and a 2-fold 
increase in CD169 expression (2.3%±0.6%) as compared to BM cultured alone. Also, MSC were able 
to induce the expression of CD115 (48.6%±12.4%), CD206 (20.6%±2) and CD68 (16.5%±4.9%). 
Expression of CD62L was found reduced in BM cultured with MSC as compared to BM cultured 
alone (12.1%±2.2% versus 24.4%±4.2% of BM only). 
The expression of each marker in CD11b+ cells obtained from BM and MSC co-cultures was 
evaluated within the different Gr-1 subset. F4/80, IL4Rα, CD206, CD169 and CD68 were expressed 
only in the Gr-1- subset (Figure 3.4A, right panel), whilst CD115 was detected both in the Gr-1high 
and the CD11b+ Gr-1- subsets.  
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FIGURE 3.4. MSC induce the differentiation of macrophages. A. BM cultured alone, with GM-CSF and 
IL-6 or MSC for 4 days was evaluated for the expression of various macrophage surface markers within the 
CD11b+ gated population (open histograms) against their matched isotype controls (filled histograms). 
Contour plots within the CD11b+ gated population show the expression of the different surface markers 
versus Gr-1 expression in BM cultured with MSC. Percentage of fluorescence ± SD of 6 independent 
experiments is represented in histogram plots. 
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Figure 3.4. MSC induce the differentiation of macrophages. B. May-Grünwald Giemsa staining of 
cytospin preparations of CD11b+ cells isolated from BM cultured alone, with MSC or GM-CSF and IL-6. 
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The morphology of CD11b+ cells isolated from BM cultured alone, with MSC or with cytokines was 
evaluated by May-Grünwald Giemsa staining. The presence of MSC in culture induced an 
accumulation of a fairly homogeneous cell population of large size with abundant pale vacuolated 
cytoplasm with some granules and reniform nucleus (Figure 3.4B). In contrast, cytokine-treated BM 
cells were characterised in majority by segmented neutrophils and myeloid cells mostly at terminal 
stages of their differentiation (pro-myelocytes and meta-myelocytes) (Figure 3.4B).  
3.2.2.1 Kinetic of expansion and differentiation 
In order to determine the kinetics of MSC-induced expansion and differentiation of BM cells, analysis 
of expression of CD11b and Gr-1 markers was carried out at day 1, 2, 3 and 4 on the co-cultures, 
using BM cultured alone or in the presence of cytokines GM-CSF and IL-6 as controls.  
At day 1, BM cultured alone, with MSC or with cytokines showed similar proportions of the three 
populations of CD11b+ cells, with a majority of CD11b+ Gr-1high cells (62.7%, 54.2% and 58.6%, 
respectively), and a very small percentage of CD11b+ Gr-1- cells (3.07%, 7.66% and 6.29%, 
respectively) (Figure 3.5A). By day 2, changes in the proportions of CD11b+ cells were already 
detectable between the three different conditions of culture. A remarkable 2-fold increase in the 
CD11b+ Gr-1- cells percentage (13.8% versus 7.66%) and in the CD11b+ Gr-1int-low percentage (27.6% 
versus 15.5%) was detected in the BM cultured with MSC and with cytokines, respectively (Figure 
3.5A). At day 3, a 2-fold decrease was detected in the percentage of CD11b+ Gr-1high cells in BM 
cultured with MSC (21.1% versus 54.2%), with a commensurate increase in the percentage of 
CD11b+ Gr-1- cells (25.1% versus 7.66%). BM cultured with cytokines, instead, induced a 3-fold 
increase in the percentage of CD11b+ Gr-1int-low cells (45.2% versus 15.5%) as compared to day 1 
(Figure 3.5A). At day 4, BM cultured alone still maintained the same proportions of CD11b+ cells. 
BM cultured with MSC, instead, showed a further expansion of CD11b+ Gr-1- cells (34% versus 
7.66%), and a related decrease in the percentage of CD11b+ Gr-1high cells (16.3% versus 54.2%). 
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Notably, BM cells cultured with cytokines expanded the population of CD11b+ Gr-1- cells only at day 
4 (12% versus 6.29%), with a slight decrease in the percentage of CD11b+ Gr-1high cells (38.7% 
versus 58.6%) (Figure 3.5A). 
Analysis of the absolute number of CD11b+ Gr-1- cells confirmed the expansion induced by the 
presence of MSC (Figure 3.5B). The figures were calculated by multiplying the number of cells 
recovered by the percentage of CD11b+ Gr-1high, CD11b+ Gr-1int-low or CD11b+ Gr-1- cells.  
Furthermore, we assessed the kinetics of MSC induced CD11b+ cell expansion in comparison to BM 
cells alone (Figure 3.5C). The absolute cell number was decreased throughout the days in both 
conditions. At day 1 no difference could be detected in the number of CD11b+ cells recovered from 
the cultures, whereas by day 2 and 3 the number of CD11b+ cells recovered from the co-cultures of 
BM and MSC had increased by 1.5-folds (5.7x106 versus 4.1x106, and 4.8x106 versus 3.9x106). At 
day 4, a greater expansion of CD11b+ cells could be detected in BM cultured with MSC (4.1x106 
versus 1.76x106) (Figure 3.5C).  
In order to mimic a physiological condition in which MSC and myeloid cells interact, different ratios 
of BM and MSC were investigated in the short-term co-cultures. As shown in Figure 3.6, higher 
ratios (up to 40:1) between BM and MSC did not impair the MSC ability to induce the same pattern 
of differentiation as in the lowest ratio of 5:1 (9.28% versus 12.5% of CD11b+ Gr-1high; 22.7% versus 
15.4% of CD11b+ Gr-1int-low; 37.4% versus 38.9% of CD11b+ Gr-1-). It seemed therefore that, as long 
as MSC could grow in a homogeneous layer making contact with BM cells, myeloid differentiation 
was induced. 
 101 
FIGURE 3.5. MSC mediate the differentiation of myeloid cells in 4 days, and maintain BM cells 
viability. A. Kinetic of differentiation of BM cultured alone, with MSC or treated with GM-CSF and IL-6 
(40ng/ml) for 1, 2, 3 and 4 days. Contour plots represent the proportion of CD11b+ Gr-1high, Gr-1int-low and 
Gr-1- cells in the live gate. B. Absolute number of CD11b+ Gr-1high, CD11b+ Gr-1int-low and CD11b+ Gr-1- 
cells recovered from BM and MSC co-cultures at day 1, 2, 3 and 4. A representative result of 2 
independently performed experiments is shown. C. Absolute number of CD11b+ cells recovered from BM 
cultured alone or with MSC after 1, 2, 3 and 4 days. A representative result of 2 independently performed 
experiments is shown.  
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FIGURE 3.6. The differentiation of myeloid cells induced by MSC is not dose dependent. BM was 
cultured with MSC in different ratios (ratio 5:1, 10:1, 20:1, 40:1) for 4 days. Contour plots represent the 
proportion of CD11b and Gr-1 cells in the live gate. A representative example from 2 independent 
experiments is shown.  
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3.2.3 Functional characterization of MSC-induced myeloid cells 
We further characterised the functional and enzymatic profile of CD11b+ cells obtained from 
culturing the BM alone, with MSC or with GM-CSF and IL-6.  
3.2.3.1 Myeloid cells generated by MSC are immunosuppressive 
Immunosuppression of activated T cells is a function that is shared by macrophages and myeloid cells 
generated with GM-CSF and IL-6 [259]. Therefore, we investigated whether CD11b+ cells obtained 
from the co-cultures were able to inhibit the proliferation of ConA activated splenocytes.  
After 4 days of culture, CD11b+ cells isolated from BM cultured alone, with MSC or with cytokines 
were plated at different percentages of the total number of cells in the cultures (12%, 6%, 3% and 
1.5%), and cultured with ConA activated splenocytes. CD11b+ cells from BM cultured with cytokines 
were used as positive control of immunosuppression. CD11b+ cells isolated from BM cultured with 
MSC were able to suppress the proliferation of activated splenocytes (50% of inhibition) even when 
representing only 1.5% of the total number of cells in culture. Furthermore, they were more 
immunosuppressive than CD11b+ cells isolated from BM cultured in presence of cytokines, as shown 
by the inhibitory effect when they represented 3% of the total cells in culture (90% versus 65% of 
inhibition in CD11b+ from BM+GM-CSF+IL-6) (Figure 3.7).  
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FIGURE 3.7. MSC-induced CD11b+ cells are immunosuppressive. BM was cultured alone, with MSC or 
with GM-CSF and IL-6 for 4 days. CD11b+ cells were sorted from the cultures, and plated into 96 well flat 
bottom plate; cells were present at different percentages of the total number of cells in the cultures (12%, 
6%, 3% and 1.5%). ConA stimulated splenocytes were then added for 72 hours, and 3H-thymidine was 
added for the last 18 hours of co-culture. Representative experiment from 3 independent experiments; each 
column represents the mean±SD of triplicates. (cpm: count per minute). Results are expressed as the value 
obtained by subtracting the (CD11b+ cells+Splenocytes) value from the (CD11b+ cells+Splenocytes ConA) 
value.  
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3.2.3.2 M1-M2 profile of MSC-induced myeloid cells 
Murine macrophages are generally classified in two subsets, ‘classically activated’ or M1 
macrophages, and ‘alternatively activated’ or M2 macrophages, mirroring the Th1/Th2 nomenclature 
of pro- and anti-inflammatory T helper subsets. In order to further characterise the molecular profile 
of MSC-induced CD11b+ cells, we investigated the expression of several M1 and M2 markers by 
Real-Time PCR (RT-PCR).  
CD11b+ cells from BM cultured alone, with MSC or with cytokines were isolated and RNA was 
extracted. CD11b+ cells isolated from BM cultured with cytokines were used as control for expression 
of Nos2 and Arg-1 genes [377]. RT-PCR data analysis documented a 30-fold and a 10-fold increase in 
Nos2 and Arg-1 expression after co-culture with MSC as compared to BM alone, respectively 
(p=0.003 and p=0.0023, respectively) (Figure 3.8). The presence of MSC induced a 2-fold 
downregulation of cyclooxygenase 2 (Cox2) (p=0.0004), a 100-fold downregulation of indoleamine 
2,3-dioxygenase 1 (Ido1) (p<0.0001), a 3-fold downregulation of interleukin 12b (Il12b) (p<0.0001), 
a 25-fold downregulation of macrophage receptor with collagenous structure (Marco) (p<0.0001), and 
a 6-fold downregulation of M2 marker interferon factor 4 (Irf4) (p=0.0132), as compared to BM 
cultured alone. The marker Found in inflammatory zone 1  (Fizz1) was expressed only by CD11b+ 
cells isolated from BM cultured with cytokines (Figure 3.8).  
As Nos2 and Arg-1 genes were upregulated in BM after culture with MSC, their protein expression 
was further confirmed with confocal staining. Cytospin preparations of CD11b+ cells isolated from 
BM in culture with MSC were stained for expression of proteins Nos2 or Arginase-1, nuclear DNA 
content (DAPI) and wheat germ agglutinin (WGA, for cytoplasm staining) (Figure 3.9). BM cultured 
alone for 4 days onto a cover glass was used as control. Arginase-1 and Nos2 expression in the 
cytoplasm of BM cells and CD11b+ cells isolated from co-cultures was confirmed. 
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FIGURE 3.8. M1-M2 profile of CD11b+ cells from BM cultures. Quantitative RT-PCR data of CD11b+ 
cells isolated from 4 days cultures of BM alone, with MSC or with GM-CSF and IL-6. Data are expressed as 
normalized to Hprt1 housekeeping gene, and compared to abundance in CD11b+ from BM alone. Mean of 5 
independent experiments, ± SD. * p<0.05, **p<0.005, *** p<0.001, **** p<0.0001 Unpaired t test. Arg-1, 
arginase 1; Ccl12, CC-chemokine ligand 12; Chia, chitinase, acidic; Cox2, cyclooxygenase 2; Fizz1, found 
in inflammatory zone 1 (Relma, resistin-like molecule alpha); Hprt1, hypoxanthine guanine phosphoribosyl 
transferase; Ido1, indoleamine 2,3-dioxygenase 1; Il12b, interleukin 12b; Irf4, interferon factor 4; Marco, 
macrophage receptor with collagenous structure; Nos2, nitric oxide synthase 2. 
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FIGURE 3.9. Confocal analysis of NOS2 and ARG-1 expression in BM cells cultured alone or with 
MSC. Confocal images of BM cells cultured alone (BM only) for 4 days and cytospin preparations of 
CD11b+ cells isolated from BM and MSC 4 days co-cultures stained for either NOS2 or ARG-1 (red), 
nuclear DNA content (DAPI, blue) and wheat germ agglutinin (WGA, light blue). Upper panel, cells stained 
for NOS2; lower panel, cells stained for ARG-1. Scale bar, 25 µm. ARG-1, Arginase-1; NOS2, nitric oxide 
synthase 2. 
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3.2.3.3 Expression of Nos2 and Arg-1 in CD11b+ cells subsets 
We further asked which is the subset of CD11b+ cells that retains the highest expression of the two 
genes Arg-1 and Nos2. For this purpose, BM cultured with MSC or treated with GM-CSF and IL-6 
were sorted in 4 different populations: total CD11b+, CD11b+ Gr-1high, CD11b+ Gr-1int-low and CD11b+ 
Gr-1-. RNA was extracted from the cells obtained and RT-PCR was used to evaluate the expression of 
the two genes. Nos2 was mainly expressed by the CD11b+ Gr-1high subset in BM cultured with MSC 
(3.5±0.9, p=0.0458 versus CD11b+), whereas it was mainly expressed by the CD11b+ Gr-1high and 
CD11b+ Gr-1int-low subset in BM treated with cytokines (2.8±0.3, p=0.0144 and 3.1±0.6, p=0.0439 
versus CD11b+, respectively). Arg-1 was instead mainly expressed by the CD11b+ Gr-1- subset 
(1.2±0.4 versus CD11b+) and the CD11b+ Gr-1int-low subset (4.9±0.8, p=0.0224 versus CD11b+) in BM 
cultured with MSC or with cytokines, respectively (Figure 3.10).  
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FIGURE 3.10. Expression of Nos2 and Arg-1 in CD11b+ subsets from BM cultures. Quantitative RT-PCR 
data of total CD11b+ cells and Gr-1high, Gr-1int-low, Gr-1- subsets sorted from 4 days cultures of BM with 
MSC or with GM-CSF and IL-6. Data are expressed as normalized to HPRT1 housekeeping gene, and 
compared to abundance in the total CD11b+ population. Mean ±SD of 2 independently performed 
experiments. * p<0.05, *** p<0.001, Unpaired t test. Arg1, arginase 1; Nos2, nitric oxide synthase 2. 
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3.2.3.4 Essential aminoacid enzymes are expressed by MSC-induced myeloid cells 
Enzymes sequestering essential aminoacid (EAA) have been recently demonstrated to be one of the 
mechanisms mediating T cell tolerance [378]. In particular, several of these enzymes have known 
roles in mediating MSC and macrophages immunosuppressive abilities. On the basis of these notions, 
we investigated the gene expression of enzymes histidine decarboxylase (Hdc), branched-chain 
aminoacid transaminase 1 (Bcat1), and interleukin 4 induced 1 (Il4i1) on CD11b+ cells isolated from 
BM cultured alone, with MSC or with cytokines GM-CSF and IL-6. As Arg-1 and Nos2 RNA were 
significantly upregulated in CD11b+ after co-culture with MSC, we also investigated the expression of 
other arginase and NOS isoforms, namely arginase-2 (Arg-2), neuronal NOS (Nos1) and endothelial 
NOS (Nos3). 
A 25-fold downregulation was detected in Arg-2 expression in BM cultured with MSC as compared 
to BM alone (p<0.0001) (Figure 3.11). In contrast, a 10- and 2-fold upregulation of Nos1 and Nos3 
was induced in presence of MSC in comparison to the BM alone (non-significant and p=0.0113, 
respectively). Nos1 and Nos3 were not expressed by BM treated with cytokines. A 4-fold increase 
was documented in Bcat1 expression in BM cultured with MSC (p=0.0035 versus BM alone), 
whereas 12- and 8-fold decreases were detected in Hdc and Il4i1 expression as compared to BM alone 
(p<0.0001).  
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FIGURE 3.11. Enzymatic profile of CD11b+ cells from BM cultures. Quantitative RT-PCR data of 
CD11b+ cells sorted from 4 days cultures of BM alone, with MSC or with GM-CSF and IL-6. Data are 
expressed as normalized to Hprt1 housekeeping gene, and compared to abundance in CD11b+ from BM 
alone. Mean of 5 independent experiments, ± SD. * p<0.05, **p<0.005, *** p<0.001, ****p<0.0001 
Unpaired t test. Arg-2, Arginase-2; Bcat1, branched chain aminotransferase 1; Hdc, histidine decarboxylase; 
Hprt1, hypoxanthine guanine phosphoribosyl transferase; Il4i1, Interleukin-4 induced 1; Nos1, nitric oxide 
synthase 1 (neuronal NOS); Nos3, nitric oxide synthase 3 (endothelial NOS).  
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 3.3 DISCUSSION 
In this chapter, we have shown that MSC drive the expansion (Figure 3.3) and differentiation (Figure 
3.2) of BM mononuclear cells into three different subsets of CD11b+ cells, according to a differential 
expression of Gr-1: granulocytes (CD11b+ Gr-1high), early myeloid cells (CD11b+ Gr-1int-low) and 
macrophages (CD11b+ Gr-1-). Since CD11b is a marker expressed also by NK and B cells, we cannot 
exclude the presence of these two populations in the co-cultures. However, since the majority of Gr-1- 
cells were F4/80+, we chose not to further characterise these populations.  
The negligible proportion of MSC in unfractionated BM (estimated around 0.01-0.001% mononuclear 
cells) cannot account for the differentiation of BM cells alone. Therefore, further work is required to 
study the limiting dilution at which the phenomenon of macrophage differentiation can still be seen, 
as the ratio used in the experiments does not represent the physiological ratio between MSC and 
haematopoietic cells in the marrow. However, we argue that this culture system magnifies stromal and 
haematopoietic cell contact in the niche. 
The main subset induced by the presence of MSC is represented by macrophages, as confirmed by 
phenotypical and morphological analysis (Figure 3.4). However, the phagocytic activity of these cells 
should be investigated to confirm their macrophage phenotype. In this population, M1 and M2 
enzymes, such as Arg-1 (Figure 3.10), Ccl12, Marco, Il12b and Cox2 (data not shown), were highly 
up-regulated, suggesting a typical immature ‘M0’ profile.  
Expression of Nos2 was mainly detected in the CD11b+ Gr-1high subset (Figure 3.10), suggesting the 
immaturity of MSC-induced granulocytes. Early myeloid cells (CD11b+ Gr-1int-low) were not 
responsible for the up-regulation of any enzyme. These cells were not able to differentiate into Gr-
1high or Gr-1- cells after a second round of co-culture with MSC (data not shown), suggesting that 
these cells either possess a primitive phenotype lacking of the required ligand/receptor for the 
differentiation induced by MSC or they present an irreversible differentiation stage. Further analysis 
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of expression of M1 and M2 enzymes at a protein level and investigation of the immunosuppressive 
properties of each of these populations is however needed to confirm their phenotype.   
Characterization of the whole CD11b+ population revealed that MSC-induced myeloid cells were able 
to suppress the proliferation of mitogen-stimulated splenocytes (Figure 3.7). The up-regulation of 
Nos2 and Arg-1, which are the two main enzymes exploiting the metabolism of L-arginine, together 
with a high expression of Bcat1, an enzyme that mediates T cell suppression through its catabolic 
activity on essential amino acids valine, leucine, and isoleucine, was consistent with the 
immunosuppressive properties of MSC-induced myeloid cells. However, the technical limitations of 
the assay make it impossible to know if MSC-induced myeloid cells are intrinsically 
immunosuppressive or whether this is the result of having been exposed to the inflammatory 
cytokines released in culture by activated splenocytes. A similar cytokine-dependent activation has 
been described for the immunomodulatory activities of MSC. Further assessment of the 
immunosuppressive properties of MSC-induced myeloid cells in a mixed-leukocyte reaction could 
provide a more physiological system, in order to minimise the confusing effect produced by 
inflammatory cytokines released upon mitogen stimulation of splenocytes. Another important effect 
to study is the profile of these cells after exposure to an inflammatory environment, both at mRNA 
and protein level. 
The differentiation pattern mediated by MSC was similar to the one induced by GM-CSF and IL-6 on 
BM cells (Figure 3.2). The use of these cytokines has been shown to mediate the differentiation of 
MDSC [259]. This population has been characterised by the ability to mediate tumour immune-
evasion through the suppression of T cell responses.  
Neutrophils (CD11b+ Gr-1high) and early myeloid cells (CD11b+ Gr-1int-low) were mainly represented in 
MDSC, as confirmed by analysis of their phenotype and morphology (Figure 3.7). CD11b+ Gr-1int-low 
cells were the main subset expressing M1 and M2 enzymes, and up-regulating IL-4Rα, a marker that 
has been associated to the subset of MDSC in which the immunosuppressive ability resides [258]. 
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Despite differences in the proportions of the three subsets of myeloid cells induced, both MSC and 
cytokines mediated the differentiation of immature cells, as confirmed by the low levels of Hdc 
expression. A recent study has shown that cancer cells down-regulate expression of Hdc expression 
and inhibit myeloid cell maturation [379]. Since the presence of GM-CSF and IL-6 induced a slightly 
higher expression of Hdc as compared to the presence of MSC, it could be inferred that MDSC are 
more mature than MSC-induced myeloid cells (Figure 3.11).  
Nos2 and Arg-1 up-regulation in the CD11b+ Gr-1int-low subset, as well as the up-regulation of Ido and 
Il4i1 in the total population (Figure 3.10 and 3.11), could probably account for MDSC 
immunosuppressive ability [380]. The marker profile that has been used was relatively limited and 
may benefit of further refinement to analyse the differences in the phenotype and function of these 
two populations. 
Taken together, these data suggest that MSC can drive the expansion and differentiation of immature 
myeloid cells with a phenotype and function similar to heterogeneous myeloid populations that 
accumulate in tumour-bearing hosts. It is therefore plausible that stromal cells are one of the 
mechanisms by which macrophages are recruited and differentiated at the BM and in peripheral sites, 
thus opening a major line of investigation on the possible modulation of stromal cell activity in 
peripheral tissues under physiological and pathological conditions.  
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CHAPTER 4. 
INVESTIGATING THE MOLECULAR BASIS OF 
HAEMATOPOIETIC AND MESENCHYMAL STROMA 
INTERACTION.  
4.1 INTRODUCTION 
In the previous chapter we have provided evidence that MSC induce in vitro the differentiation of 
three populations of myeloid cells according to the differential expression of Gr-1.  
In particular, CD11b+ Gr-1- cells exhibit a profile compatible with M0 type of macrophages, as 
defined by the up-regulation of both M1 and M2 markers and the ability to suppress the proliferation 
of T cells. Since NOS2 is one of the principal mediators of the immunosuppressive ability of mouse 
BM derived MSC [122] and macrophages, we investigated whether NOS2 could also regulate the 
ability of MSC to induce the differentiation of myeloid cells. Furthermore, NO, one of the metabolites 
produced by NOS activity, has recently been investigated also for its role as putative regulator of the 
HSC niche. Its inhibition causes an accumulation of HSPC progenitors in the BM, and an increase in 
the number of neutrophils in peripheral blood [369]. Accordingly, in vitro studies have demonstrated 
that NO can inhibit the differentiation of erythroid cells and induce instead myeloid differentiation in 
CD34+ cells [381].  
Several factors are known to up-regulate the expression of NOS2, in particular hypoxia and pro-
inflammatory cytokines, such as TNF-α and IFN-γ. Indeed, also the inflammatory environment has 
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emerged as potential regulator of HSPC niche activity, although it is not clear whether such regulation 
acts directly on HSC functions or on other cellular components of the HSC niche.  
In fact, several pieces of evidence indicate that also other niche components, such as osteoclasts, 
osteoblasts, neutrophils, macrophages, MSC precursors and the extracellular matrix [332] can 
modulate self-renewal and differentiation of HSPC.  
Taken altogether, our discovery that MSC are capable of differentiating myeloid cells, along with the 
notion that macrophages and MSC precursors interact in the HSC niche [262], led us to investigate 
several putative molecules involved in the regulation of haematopoietic differentiation as mediators of 
MSC ability to induce the differentiation of myeloid cells.  
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4.2 RESULTS 
4.2.1 Contact is required for MSC induced differentiation of CD11b+ Gr-1- cells 
To determine whether cell contact or soluble factors mediate MSC induced myeloid differentiation, 
BM cells were cultured with MSC either in contact or separated by a transwell membrane for 4 days.  
The percentage of CD11b+ Gr-1- cells was significantly reduced when BM was separated from MSC 
by a transwell membrane (7.1% ± 1.3% versus 50.6% ± 12.5% in BM+MSC, p=0.0003, Figure 
4.1B). However, the presence of MSC in the transwell cultures was still able to induce an increase in 
the percentage of CD11b+ Gr-1int-low cells as compared to BM cultured alone (22.3% ± 2.5% versus 
10.4% ± 1.6% in BM alone, p=0.0008, Figure 4.1B), thus suggesting that differentiation of this 
subset is mediated by a soluble factor. 
Analysis of the expression of F4/80 and Gr-1 revealed that when BM was cultured separated from 
MSC, the percentage of CD11b+ Gr-1- F4/80+ cells was reduced (2.19% versus 40.8% of BM+MSC), 
whereas the percentage of CD11b+ Gr-1high and Gr-1int-low was increased (33.8% versus 17.6% of 
BM+MSC) (Figure 4.1).  
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FIGURE 4.1. MSC induced differentiation of myeloid cells depends on cell contact. BM was cultured 
alone or with MSC (ratio 5:1) either in contact (BM+MSC) or separated by a transwell membrane 
(BM+MSC t/w) for 4 days. A. Contour plots represent the proportion of CD11b+ Gr-1high, CD11b+ Gr-1int-low 
and CD11b+ Gr-1- cells in the live gate, and expression of F4/80 versus Gr-1 in the CD11b+ gate. B. 
Percentage of Gr-1high, Gr-1int-low and Gr-1- in CD11b+ cells. Mean of 3 independent experiments, ± SD * 
p<0.05 *** p<0.001 **** p<0.0001 Unpaired t test.  
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4.2.2 MSC-induced differentiation of CD11b+ Gr-1- cells requires NOS2 
expression 
In order to investigate the effect of NOS2 in MSC-mediated differentiation of myeloid cells, short-
term co-culture experiments of BM cells and BM derived MSC isolated from WT or Nos2-/- mice 
were performed. 
BM derived MSC isolated from WT and Nos2-/- mice were plated overnight in a 24 well plate, and 
unfractionated WT BM cells were added for 4 days. In order to assess myeloid differentiation, cells 
were collected from the co-cultures and analysed for the expression of markers CD11b, Gr-1, F4/80, 
CD115, CD206, CD169 and CD68 (Figure 4.2).  
Nos2-/- MSC exhibited a reduced ability to induce an increase in the percentage of CD11b+ Gr-1- cells 
(16.6% ± 2.3% versus 30.8% ± 4.9% of BM WT+MSC WT, p=0.0020), but they induced an 
increased proportion of CD11b+ Gr-1high cells (71.9% ± 3.6% versus 58.8% ± 2.3% of BM WT+MSC 
WT, p=0.0009) as compared to WT MSC in the CD11b+ gated population (Figure 4.2B). 
Representative contour plots of Gr-1 versus CD11b are shown in Figure 4.2A. 
Analysis of macrophage markers F4/80, CD206, and CD68 confirmed a decrease in the proportion of 
macrophages obtained from BM cultured with Nos2-/- MSC. In particular, the percentage of CD11b+ 
F4/80+ cells was decreased in the co-cultures of BM cells and Nos2-/- MSC (27.8% ± 8.2% versus 
41.5% ± 8.7% in BM WT+MSC WT, p=0.0183, Figure 4.2C), as compared to BM cultured with WT 
MSC. A significant decrease was also detected in the percentage of CD11b+ CD206+ cells from BM 
cultured with Nos2-/- MSC (12.3% ± 3% versus 20.6% ± 2% in BM WT+MSC WT, p=0.0074 Figure 
4.2C). No difference was detected in the percentage of CD11b+ CD115+ cells (42.7% ± 13.7% versus 
45% ± 13.9% in BM WT+ MSC WT), CD169+ cells (1.5% ± 0.9% versus 2.3% ± 0.6% in BM 
WT+MSC WT) and CD68+ cells (11.8% ± 0.08% versus 16.8% ± 4.9% in BM WT+MSC WT) 
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between the two co-cultures. In particular, the expression of F4/80 and CD206 was decreased in the 
CD11b+ Gr-1- subset. Reduced, albeit not significant, was also the expression of markers CD115 and 
CD68 in the CD11b+ Gr-1- subset (Figure 4.2A).  
In order to rule out whether the lack of Nos2 could impair also the expansion of CD11b+ cells, we 
evaluated the percentage of CD11b+ cells recovered after the co-cultures. A 2-fold decrease in the 
percentage of CD11b+ cells collected at day 4 was documented in BM cultured with Nos2-/- MSC 
(5.3x106 ± 0.4x106 versus 8.4x106 ± 0.5x106, p=0.0016 versus BM+MSC WT, Figure 4.2D). 
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FIGURE 4.2. MSC induced differentiation of CD11b+ Gr-1- cells requires NOS2 expression. BM cells 
were cultured with MSC isolated from WT or Nos2-/- mice for 4 days. B. Percentage of Gr-1high, Gr-1int-low 
and Gr-1- in CD11b+ cells. Mean of 6 independent experiments, ± SD ** p<0.005 *** p<0.001 Unpaired t 
test. C. Percentage of CD11b+ F4/80+, CD115+, CD206+, CD169+, and CD68+ cells, within the CD11b+ cells 
population. Mean of 6 independent experiments, ± SD * p<0.05 ** p<0.005 Unpaired t test. D. Absolute 
number of CD11b+ cells recovered from BM cultured with MSC WT or Nos2-/- for 4 days. Mean of 6 
independent experiments, ± SD ** p<0.005 Unpaired t test.  
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4.2.2.1 Nos2 is required on MSC but not on BM cells for myeloid differentiation 
We further asked whether a lack of Nos2 in the haematopoietic cells could also determine an 
impairment of myeloid differentiation. BM isolated from Nos2-/- or WT mice was co-cultured with 
MSC isolated from Nos2-/- or WT mice for 4 days. Analysis of Gr-1 and CD11b expression showed 
that the lack of Nos2 in BM cells did not influence the differentiation of myeloid cells induced by 
MSC (Figure 4.3). Nevertheless, a small decrease in the percentage of CD11b+ Gr-1- cells was 
detected in co-cultures of Nos2-/- BM with WT MSC as compared to WT BM cultured with WT MSC 
(23.4% versus 29.2% of BM WT+MSC WT, Figure 4.3A and B). A similar decrease was 
documented in co-cultures of NOS2-/- BM with Nos2-/- MSC as compared to WT BM cultured with 
Nos2-/- MSC (9.74% versus 12.2% of BM WT+MSC Nos2-/-, Figure 4.3A and B).  
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FIGURE 4.3. BM cells do not require Nos2 expression when differentiation is driven by MSC. BM cells 
isolated from WT or Nos2-/- mice were cultured with MSC isolated from WT or Nos2-/- mice for 4 days. A. 
Contour plots represent the CD11b and Gr-1 proportion in the live gate. B. Percentage of Gr-1high, Gr-1int-low 
and Gr-1- in CD11b+ gated population. A representative example of two independent experiments is shown. 
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4.2.2.2 Functional characterization of Nos2-/- MSC-induced myeloid cells 
On the basis of the impaired differentiation seen in the co-cultures of BM and Nos2-/- MSC, we 
further characterised the enzymatic and functional profile of CD11b+ cells obtained from culturing the 
BM with Nos2-/- MSC or WT MSC.  
CD11b+ cells isolated from co-cultures of BM cells with MSC WT and NOS2-/- were analysed for the 
expression of M1 and M2 macrophage functional markers by RT-PCR (Figure 4.4). A significant 2-
fold decrease in the expression of Cox2 and Nos2 was found in BM cultured in presence of Nos2-/- 
MSC (0.36±0.3, p=0.0106 and 0.37±0.24, p=0.0218 versus BM WT+MSC WT, respectively). A 2-
fold increase was documented in Marco expression in BM cultured with Nos2-/- MSC, but such 
variation was not significant (3.8±2.6 versus BM WT+MSC WT). Arg-1 and Ccl12 were down-
regulated in presence of Nos2-/- MSC as compared to WT MSC (0.28±0.16, p=0.0232 and 0.42±0.03, 
p=0.014 versus BM WT+MSC WT respectively). No significant difference was found in the 
expression levels of Il12b, Chi3l1 and Irf4 in the two cultures (0.58±0.5, 0.63±0.39, and 0.52±0.49 
versus BM WT+MSC WT). 
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FIGURE 4.4. CD11b+ cells isolated from BM and WT or Nos2-/- MSC co-cultures have a different M1-
M2 profile. Quantitative RT-PCR data of CD11b+ cells isolated from 4 days cultures of BM with MSC WT 
or Nos2-/-. Data are expressed as normalized to Hprt1 housekeeping gene, and compared to abundance in 
CD11b+ isolated from BM and MSC WT co-cultures. Mean of 3 independent experiments, ± SD. * p<0.05, 
Unpaired t test. Arg1, arginase-1; Ccl12, CC-chemokine ligand 12; Chi3l1, chitinase 3-like 1; Cox2, 
cyclooxygenase 2; Hprt1, hypoxanthine guanine phosphoribosyl transferase; Il12b, interleukin 12b; Irf4, 
interferon factor 4; Marco, macrophage receptor with collagenous structure; Nos2, nitric oxide synthase 2. 
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CD11b+ cells isolated from BM and MSC cultures can suppress activated T cells. As Nos2 and 
Arginase-1, mediators of M0 macrophages immunosuppressive ability, were remarkably down-
regulated in CD11b+ cells obtained from BM cultured with Nos2-/- MSC, we tested these cells for the 
suppression of T cell proliferation.  
After 4 days, BM cultured with MSC isolated from WT or Nos2-/- mice was collected and CD11b+ 
cells were isolated. The cells were plated at different percentages of the total number of cells in the 
cultures (12%, 6%, 3% and 1.5%), and let adhere for 4 hours. Concanavalin-A (ConA) activated 
splenocytes were added for 72 hours and proliferation was assessed by tritiated (3H) thymidine 
uptake. The proliferation of activated splenocytes was suppressed by CD11b+ cells isolated from BM 
cultured with Nos2-/- MSC until they were present as 3% of the total amount of cells in culture, 
whereas CD11b+ cells obtained from BM cultured with WT MSC were immunosuppressive even 
when they represented only 1.5% of the total cells in culture (50% of inhibition) (Figure 4.5). 
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FIGURE 4.5. CD11b+ cells isolated from BM cultured with WT or Nos2-/- MSC are immunosuppressive. 
BM cells were cultured with MSC isolated from WT or Nos2-/- mice for 4 days. CD11b+ cells were sorted 
from the cultures, and plated into 96 well flat bottom plate; cells were present at different percentages of the 
total number of cells in the cultures (12%, 6%, 3% and 1.5%). ConA stimulated splenocytes were then added 
for 72h, and 3H-thymidine was added for the last 18 hours of co-culture. Representative experiment from 3 
independent experiments; each column represents the mean±SD of triplicates. (cpm: count per minute). 
Results are expressed as the value obtained by subtracting the (CD11b+ cells+Splenocytes) value from the 
(CD11b+ cells+Splenocytes ConA) value.  
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4.2.2.3 Nos2-/- mice have a normal mononuclear phagocyte system 
In order to understand whether Nos2-/- mice had an intrinsic impaired ability to differentiate 
macrophages in steady-state, we analysed the proportions of BM and spleen mononuclear phagocyte 
cells in Nos2-/- and WT mice. Following the gating strategy proposed by the group of Frenette [262], 
neutrophils granulocytes are represented in the Gr-1+ CD115- gate (Figure 4.6A, gate I), monocytes 
are represented in the Gr-1+ CD115+ (gate II) and Gr-1low CD115+ gate (gate III), whereas the Gr-1- 
CD115int F4/80+ fraction consists of eosinophils (gate V) and macrophages (gate IV), which can be 
discriminated by forward and side scatter characteristics. No difference was seen in the percentage of 
granulocytes (WT=35.4%±1.97 versus Nos2-/-=34.14%±5.2%), monocytes (Gr-1high: 
WT=6.86%±1.43% versus Nos2-/-=8.24%±1.07%; Gr-1low: WT=2.17%±1.24% versus Nos2-/-
=1.86%±0.54%), eosinophils (WT=0.59%±0.1% versus Nos2-/-=0.59±0.25%) and macrophages 
(WT=4.58%±1.1% versus Nos2-/- =4.55%±0.86%) in BM of WT or Nos2-/- mice (Figure 4.6B). 
Following the definition of Geissmann group [163], CD11b+ cells (Figure 4.7A, gate A) were divided 
into Ly6G+ Ly6Cint-low (neutrophils, gate B), and Ly6G- cells. Ly6G- cells were subdivided into Ly6C- 
CCR2- CD115- resident monocytes (gate C), Ly6Cdim CCR2- CD115- monocytes (gate D), and Ly6C+ 
CCR2+ CD115+ inflammatory monocytes (gate E). No difference was documented in the percentages 
of CD11b+ cells (WT=45.87%±3.9% versus Nos2-/-=46.24%±6.3%), Ly6G+ Ly6Cint-low cells 
(WT=32.37%±3.06% versus Nos2-/-=31.92%±5.87%), Ly6C- CCR2- CD115- cells (WT=0.9%±0.02% 
versus Nos2-/-=1.07%±0.10%), Ly6Cdim CCR2- CD115- cells (WT=7.22%±0.34% versus Nos2-/-
=7.91%±0.73%) and Ly6C+ CCR2+ CD115+ cells (WT=4.11%±0.36% versus Nos2-/-=4.06%±0.80%) 
in WT or Nos2-/- mice (Figure 4.7B).  
Analysis of these populations in spleen of WT or Nos2-/- recipients showed no differences (data not 
shown). 
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FIGURE 4.6. Proportions of BM mononuclear phagocyte populations in naïve WT and Nos2-/- 
mice are similar. BM cells of naïve WT and Nos2-/- mice were analysed by FACS. A. Gating 
strategy. Alive Gr-1+ populations were divided into a CD115- fraction comprised of neutrophils (I) 
and CD115+ fraction of Gr-1high monocytes (II). The Gr-1low fraction was further subdivided into 
two populations: CD115+ Gr-1low monocytes (III) and an F4/80+CD115- population, which can be 
subdivided into SSChigh eosinophils (V) and SSCint/low macrophages (IV). B. Percentage of BM 
mononuclear phagocyte populations within the live gate (n=5 per group). 
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FIGURE 4.7. Proportions of BM mononuclear phagocyte populations in naïve WT and Nos2-/- 
mice are similar. BM cells of naïve WT and Nos2-/- mice were analysed by FACS. A. Gating 
strategy. Alive CD11b+ cells (A) were divided into Ly6G+ Ly6Cint-low (neutrophils, B), and Ly6G- 
cells. The Ly6G- gate was subdivided into Ly6C- CCR2- CD115- resident monocytes (C), Ly6Cdim 
CCR2- CD115- monocytes (D) and Ly6C+ CCR2+ CD115+ inflammatory monocytes (F). B. 
Percentage of BM mononuclear phagocyte populations within the live gate (n=5 per group). 
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4.2.2.4 Role of NOS2 in driving macrophage differentiation in vivo 
In the previous paragraphs we discussed how NOS2 expression is required on MSC but not on 
haematopoietic cells for driving macrophage differentiation. Therefore, in order to investigate the role 
of NOS2 expression on stromal cells in vivo, we chose two different approaches. The first approach 
was to investigate whether and how WT or Nos2-/- MSC could enhance early reconstitution of 
haematopoiesis in myeloablated WT recipients. The rationale of the second approach, in which 
myeloablated and clodronate-treated WT or Nos2-/- recipients received an adoptive transfer of WT 
BM cells, was studying the haematopoietic recovery in a NOS2 deficient mesenchymal stroma.  
In both approaches, macrophage differentiation of donor cells was studied, 10 or 14 days after the 
transfer respectively.  
4.2.2.4.1 Adoptive transfer of Nos2-/- MSC results in impaired macrophage differentiation of donor 
cells 
In order to study the role of stromal cells in supporting and inducing the differentiation of 
macrophages, we decided to assess the effect of MSC following HSC transplantation. Myeloablated 
WT Ly5.1+ C57Bl/6 received syngeneic WT Ly5.2+ BM cells either alone, with WT MSC or with 
Nos2-/- MSC. After 10 days, BM and spleen mononuclear phagocyte populations were analysed by 
FACS (Figure 4.8A).  
No significant difference was documented in the engraftment of donor CD45.2+ cells in the BM (BM 
alone=42.6%±3.24%, BM+MSC WT=33.55%±3.18% and BM+MSC Nos2-/-=34.63%±5.23%) or in 
the spleen (BM alone=43.36%±1.54%, BM+MSC WT=41.05%±1.34% and BM+MSC Nos2-/-
=31.3%±9.46%) of mice injected with BM cells alone or with MSC (Figure 4.8C).  
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Following the gating strategy previously described (Figure 4.8B), analysis of mononuclear phagocyte 
populations within the donor cells (CD45.2+) in the BM showed that there was no difference in the 
proportions of granulocytes (BM alone=67.44%±4.55%; BM+MSC WT=64.95%±5.16%; BM+MSC 
Nos2-/-=73.07%±10.55%), monocytes (Gr-1high: BM alone=1.1%±0.35%; BM+MSC 
WT=1.42%±0.16%; BM+MSC Nos2-/-=1.4%±0.62%; Gr-1low: BM alone=0.39%±0.04%; BM+MSC 
WT=0.45%±0.13%; BM+MSC Nos2-/-=0.53%±0.21%), and eosinophils (BM alone=0.32%±0.1%; 
BM+MSC WT=0.44%±0.16%; BM+MSC Nos2-/-=0.37%±0.04%) in the three different groups 
(Figure 4.9A). An increase in the proportion of macrophages was instead documented in mice that 
were adoptively transferred with both BM cells and WT MSC in comparison to the ones that received 
only BM cells (2.46%±0.71% versus 1.17%±0.31%), and such increase was not documented in mice 
injected with BM cells and Nos2-/- MSC (1.32%±0.44%) (Figure 4.8D). Analysis of the absolute 
numbers of these populations within the donor cells in the BM confirmed there was no difference in 
the proportions of granulocytes (BM alone=2.99x106±1.22x106; BM+MSC WT=2.16x106±3.35x105; 
BM+MSC Nos2-/-=2.88x106±1.24x106), monocytes (Gr-1high: BM alone=4.67x104±1.55x104; 
BM+MSC WT=4.66x104±1.87x103; BM+MSC Nos2-/-=5.83x104±4.28x104; Gr-1low: BM 
alone=1.74x104±7.51x103; BM+MSC WT=1.47x104±3.02x103; BM+MSC Nos2-/-
=2.19x104±1.5x104) and eosinophils (BM alone=1.49x104±9.58x103; BM+MSC 
WT=1.45x104±4.25x103; BM+MSC Nos2-/-=1.39±3.34x103) in the three groups (Figure 4.8E). An 
increase in the absolute number of macrophages was confirmed in mice that received both BM cells 
and WT MSC (8.04x104±1.75x104) as compared to mice injected with BM cells alone 
(5.07x104±1.77x104) or BM cells and Nos2-/- MSC (4.82x104±1.03x104) (Figure 4.8E). 
In mice injected with BM cells and MSC spleen mononuclear cells of donor origin exhibited a higher 
percentage of granulocytes (BM+MSC WT=32.3%±14.1%, BM+MSC Nos2-/-=44.97%±13.49% 
versus BM alone=19.76%±2.28%), Gr-1high monocytes (BM+MSC WT=10.71%±3.52%, BM+MSC 
Nos2-/-=9.19%±3.5% versus BM alone=3.78%±0.69%), and eosinophils (BM+MSC 
WT=0.21%±0.04%,BM+MSC Nos2-/-=0.18%±0.05% versus BM alone=0.08%±0.02%) as compared 
to mice that received only BM cells but no difference was observed between the groups receiving WT 
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or Nos2-/- MSC (Figure 4.8F). An increase in the percentage of Gr-1low monocytes (BM+MSC 
WT=2.67%±0.6% versus BM alone=1.02%±0.19% and BM+MSC Nos2-/-=1.67%±0.34%) and 
macrophages (BM+MSC WT=7.11%±1.18% versus BM alone=4.57%±0.59% and BM+MSC Nos2-/-
=5.24%±0.73%) was documented in the group injected with BM cells and WT MSC as compared to 
the other two groups (Figure 4.8F). Analysis of the absolute number of spleen phagocyte populations 
revealed instead that mice that received BM cells and WT MSC had a decreased number of 
granulocytes (BM+MSC WT=2.5x106±1.51x106 versus BM alone=4.58x106±1.14x106, BM+MSC 
Nos2-/-=6.84x106±2.45x106), monocytes (Gr-1high: BM+MSC WT=7.45x105±1.91x105 versus BM 
alone=8.59x105±1.73x105, BM+MSC Nos2-/-=1.37x106±5.31x105; Gr-1low: BM+MSC 
WT=1.91x105±6.9x104 versus BM alone=2.32x105±5.43x104, BM+MSC Nos2-/-
=2.47x105±4.11x104), eosinophils (BM+MSC WT=1.7x104±1.24x104 versus BM 
alone=1.78x104±7.82x103, BM+MSC Nos2-/-=2.73x104±6.68x103) and macrophages (BM+MSC 
WT=5.19x105±2.17x105 versus BM alone=1.05x106±2.37x105, BM+MSC Nos2-/-
=7.85x105±1.69x105) as compared to the other two groups (Figure 4.8G).  
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FIGURE 4.8. Nos2-/- MSC exhibit an impaired ability to promote macrophage repopulation.  
Ly5.1 WT recipients were irradiated with a split dosage of 800cGy, and subsequently injected with 
2*106 Ly5.2 WT BM cells, either alone (BM alone) or in combination with 0.2*106 Ly5.2 WT 
MSC (BM+MSC WT) or with 0.2*106 Ly5.2 Nos2-/- MSC (BM+MSC NOS2-/-). 10 days after the 
transfer, BM and spleen were analysed by FACS. A. Scheme of experiment. B. Gating strategy of 
BM mononuclear phagocytes. Within the CD45.2+ cells, the Gr-1+ populations were divided into a 
CD115- fraction comprised of neutrophils (I) and CD115+ fraction of Gr-1high monocytes (II). The 
Gr-1low fraction was further subdivided into two populations: CD115+ Gr-1low monocytes (III) and a 
F4/80+CD115- population, which can be subdivided into SSChigh eosinophils (V) and SSCint/low 
macrophages (IV). C. Percentage of engraftment of CD45.2+ donor cells in BM and spleen 
(n=5/group). 
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FIGURE 4.8. Nos2-/- MSC exhibit an impaired ability to promote macrophage repopulation.  
Ly5.1 WT recipients were irradiated with a split dosage of 800cGy, and subsequently injected with 
2*106 Ly5.2 WT BM cells, either alone (BM alone) or in combination with 0.2*106 Ly5.2 WT 
MSC (BM+MSC WT) or with 0.2*106 Ly5.2 Nos2-/- MSC (BM+MSC NOS2-/-). 10 days after the 
transfer, BM and spleen were analysed by FACS. D. Percentage of BM mononuclear phagocyte 
populations within the donor cells (CD45.2+) in the BM. (n=5/group) E. Absolute number of BM 
mononuclear phagocyte populations within the gate of CD45.2+ cells in the BM (n=5/group). F. 
Percentage of BM mononuclear phagocyte populations within the donor cells (CD45.2+) in the 
spleen. (n=5/group) G. Absolute number of BM mononuclear phagocyte populations within the 
gate of CD45.2+ cells (n=5/group) in the spleen. 
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4.2.2.4.2 Adoptive transfer of BM cells into myeloablated and macrophage-depleted Nos2-/- recipient 
results in impaired differentiation of macrophages 
In order to study the role of stromal NOS2 in driving the differentiation of macrophages, we studied 
the reconstitution of mononuclear phagocyte populations in Nos2-/- mice.  
Ly5.2+ WT or Nos2-/- recipients were lethally irradiated, treated with clodronate and then transplanted 
with WT Ly5.1+ BM cells. After 14 days, BM and spleen mononuclear phagocyte populations were 
analysed by FACS (Figure 4.9A).  
No significant difference was documented in the engraftment of donor CD45.1+ cells in the BM 
(WT=45.39%±9.37% versus Nos2-/-=55.24%±13.28%) or in the spleen (WT=32.53%±13.96% versus 
Nos2-/-=33.21%±10.54%) of WT and Nos2-/- mice (Figure 4.9B). Following the same gating strategy 
discussed for the previous approach (Figure 4.8B), analysis of mononuclear phagocyte populations 
within the donor cells (CD45.1+) in the BM showed that there was no difference in the proportions of 
granulocytes (WT=63.23%±6.21% versus Nos2-/-=57.49%±5.99%), monocytes (Gr-1high: 
WT=0.08%±0.08% versus Nos2-/-=0.04%±0.02%; Gr-1low: WT=0.43%±0.17% versus Nos2-/-
=0.35%±0.18%) and eosinophils (WT=0.18%±0.14% versus Nos2-/-=0.16%±0.07%) in WT and 
Nos2-/- recipients (Figure 4.9C). A significant difference was instead documented in the percentage 
of macrophages within donor CD45.1+ cells in WT recipients (WT=1.87%±0.48% versus Nos2-/-
=1.18%±0.22%, p=0.0047) as compared to Nos2-/- recipients (Figure 4.9C).  
Analysis of these populations within the recipient cells (CD45.2+) in the BM revealed no difference in 
the proportions of granulocytes (WT=69.1%±8.76% versus Nos2-/-=59.68%±8.88%), monocytes (Gr-
1high: WT=0.2%±0.04% versus Nos2-/-=0.21%±0.14%; Gr-1low: WT=0.34%±0.07% versus Nos2-/-
=0.47%±0.21%), eosinophils (WT=0.4%±0.21% versus Nos2-/-=0.78%±0.59%) and macrophages 
(WT=1.95%±1.71% versus Nos2-/-=1.8%±1.32%) in WT and Nos2-/- recipients (Figure 4.9D).  
 138 
Spleen mononuclear phagocyte populations were analysed in WT and NOS2-/- recipients. Analysis of 
these populations within the donor (CD45.1+) cells showed there was no significant difference in the 
percentages of granulocytes (WT=31.31%±4.35 versus Nos2-/-=34.26%±6.86%), monocytes (Gr-1high: 
WT=1.13%±1.08% versus Nos2-/-=0.62%±0.41%; Gr-1low: WT=1.42%±1.16% versus Nos2-/-
=1.06%±0.69%), eosinophils (WT=0.23%±0.21% versus Nos2-/-=0.3%±0.21%) and macrophages 
(WT=7.55%±3.95% versus Nos2-/-=5.81±2.67%) in WT or Nos2-/- recipients (Figure 4.9E). No 
difference was seen in the percentages of granulocytes (WT=7.49%±4.39% versus Nos2-/-
=8.46%±3.99%), monocytes (Gr-1high: WT=0.09%±0.12 versus Nos2-/-=0.15%±0.07%; Gr-1low: 
WT=0.42%±0.29% versus Nos2-/-=0.2%±0.11%), eosinophils (WT=0.46%±0.46% versus Nos2-/-
=0.31%±0.18%) and macrophages (WT=1.55%±0.97% versus Nos2-/-=0.67%±0.29%) within the 
recipient (CD45.2+) spleen cells of WT or Nos2-/- mice (Figure 4.9F). No difference was documented 
in the absolute numbers of mononuclear phagocyte populations within donor or recipient cells in BM 
or spleen of WT or Nos2-/- recipients (data not shown). 
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FIGURE 4.9. Macrophage reconstitution is impaired in Nos2-/- hosts. Ly5.2 WT or Nos2-/- 
recipients were irradiated with a split dosage of 800cGy, and received a clodronate injection i.p. 
one day previous to the transfer of 2*106 Ly5.1 WT BM cells. 14 days after, BM and spleen were 
collected and analysed by FACS. A. Scheme of experiment. B. Percentage of engraftment 
(CD45.1+ cells) in BM and spleen. C and E. Percentage of BM mononuclear phagocyte populations 
within the donor cells (CD45.1+) in BM (C) and spleen (E). (n=8/group) D and F. Percentage of 
BM mononuclear phagocyte populations within the host cells (CD45.2+) in BM (D) and spleen (F). 
(n=8/group) ** p < 0.05, Mann-Whitney U test. 
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4.2.3 Role of TNF-α in driving MSC-mediated myeloid differentiation  
We further analysed the profile of pro- and anti-inflammatory cytokines produced by BM cells and by 
MSC cultured alone or together. This step was fundamental to identify the mechanism underlying the 
interaction between MSC and myeloid cells. 
4.2.3.1 TNF-α is upregulated in MSC-induced myeloid cells  
Intracellular Th1 and Th2 cytokine staining of BM cells was assessed in the presence or absence of 
MSC. After 4 days of culture, no production of IL-12, IL-4 or IL-10 was detected in BM cultured 
either alone or with MSC (Figure 4.10). TNF-α and IFN-γ were instead increased in BM cultured 
with MSC as compared to the expression detected in BM cultured alone (TNF-α: MFI = 19.3±1.3 
versus MFI = 4.44±2.7 of BM alone; IFN-γ: MFI = 3.16±0.9 and MFI = 4.4±2.1 of BM alone, Figure 
4.10A). Such increase was significant only for TNF-α expression (p=0.0096 versus BM alone, Figure 
4.10C). TNF-α was expressed mainly by CD11b+ Gr-1- subset (Gr-1-: MFI = 21.4±3.3 versus Gr-1high: 
MFI = 10.4±0.5 and Gr-1int-low: MFI = 16.3±4.7, Figure 4.10B), whereas IFN-γ was mainly expressed 
by CD11b+ Gr-1int-low and CD11b+ Gr-1- subsets in BM cultured with MSC (Gr-1int-low: MFI = 4.3±2.5, 
Gr-1-: MFI = 4.8±2 and Gr-1high: MFI = 2.7±1, Figure 4.10B). No difference was observed in 
cytokine production whether cells were or not stimulated with PMA-ionomycin to increase the signal. 
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FIGURE 4.10. BM cells cultured alone or with MSC express TNF-α and IFN-γ, and TNF-α expression 
increases after co-culture. BM cells were cultured alone or with MSC for 4 days. Cytokine production was 
assessed by intracellular cytokine staining. A. Histogram plots represent various intracellular cytokine 
markers within the CD11b+ gated population (open histograms) against their matched isotype controls (filled 
histograms). Mean fluorescence intensity (MFI) of 5 independent experiments, ±SD, is represented in the 
histogram plots. B. Histogram plots represent TNF-α and IFN-γ expression within the CD11b+ Gr-1high gate 
(Gr-1 HIGH), CD11b+ Gr-1int-low gate (Gr-1 INT-LOW), and CD11b+ Gr-1- gate (Gr-1 NEG). MFI of 5 
independent experiments, ±SD, is represented in the histogram plots. C. Fold increase of the percentage of 
TNF-α expression in CD11b+ gated population.  
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The expression of pro- and anti-inflammatory cytokines was investigated through intracellular 
cytokine staining in BM derived MSC before and after co-culture with BM cells (Figure 4.11). Anti-
inflammatory cytokines IL-4 and IL-10 and pro-inflammatory cytokine IL-12 were not detected 
before and after co-culture. IFN-γ could be detected only after co-culture (MFI = 4.59), whereas the 
expression of TNF-α was detected before and after co-culture (MFI = 69.7 and MFI = 31.9, Figure 
4.11).  
Figure 4.11. BM derived MSC express TNF-α when cultured alone and after co-culture with BM. BM 
derived MSC were cultured alone or with BM for 4 days. Cytokine production was assessed by intracellular 
cytokine staining. Histogram plots represent various intracellular cytokine markers within the CD11b- gated 
population (open histograms) against their matched isotype controls (filled histograms). MFI of a 
representative experiment is shown in the histogram plots.  
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4.2.3.2 TNF-α upregulates Nos2 expression on MSC 
BM cells cultured alone express the pro-inflammatory cytokines TNF-α and IFN-γ, which are 
upregulated after culturing BM with MSC. Several studies indicate that TNF-α and IFN-γ regulate 
Nos2 expression in MSC and in macrophages [122]. Therefore, in order to confirm that these two 
cytokines are involved in the upregulation of Nos2 expression, we investigated their effect, alone or in 
combination, on MSC after 24 or 48 hours of stimulation.  
TNF-α, IFN-γ and their combination significantly upregulated Nos2 expression in MSC after 24 and 
48 hours (Figure 4.12). IFN-γ stimulation induced a 30-fold increase in Nos2 after 24 hours 
(0.2±0.09, versus 0.007±0.008 of MSC untreated at 24 hours, p=0.0187), and a 27-fold increase after 
48 hours (0.11±0.06, versus 0.004±0.004 of MSC untreated at 48 hours, p=0.0381). TNF-α 
stimulation induced a 1500-fold increase in the expression of Nos2 after 24 hours (10.06±3.7, versus 
0.007±0.008 of MSC untreated at 24 hours, p=0.0142), and a 1200-fold increase after 48 hours 
(5.2±1.7, versus 0.004±0.004 of MSC untreated at 48 hours, p=0.0098). The combination of the two 
cytokines determined a synergistic effect, determining a 9000-fold increase in Nos2 expression after 
24 hours (62.1±33.1, versus 0.007±0.008 of MSC untreated at 24 hours, p=0.0314) and a 5700-fold 
increase after 48 hours (24.1±13.9, versus 0.004±0.004 of MSC untreated at 48 hours, p=0.0400).  
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FIGURE 4.12. Nos2 expression in MSC is up-regulated by TNF-α or the combination of TNF-α and 
IFN-γ . Quantitative RT-PCR data of MSC in culture alone or treated with IFN-γ (20ng/ml), TNF-α 
(20ng/ml), or the combination of TNF-α and IFN-γ for 24 and 48 hours. Data are expressed as normalized to 
Hprt1 housekeeping gene. Mean of 5 independent experiments, ± SD. * p<0.05, ** p<0.005, Unpaired t test. 
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4.2.3.3 TNF-α signalling in MSC is fundamental to drive the differentiation of CD11b+ Gr-
1- cells 
TNF-α induces a remarkable upregulation of Nos2 expression in MSC, when present either alone or in 
combination with IFN-γ. These two cytokines have been detected in BM cells cultured alone or with 
MSC, and in particular TNF-α was significantly upregulated after co-culture with MSC. On the basis 
of these findings, we assessed the role mediated by TNF-α in MSC ability to drive myeloid 
differentiation by culturing BM cells with MSC lacking the expression of TNF receptor 1 and 2 
(Tnfr1/r2-/-). 
To this purpose, unfractionated BM cells were cultured with MSC obtained from WT or Tnfr1/r2-/- 
mice for 4 days. In order to assess whether the lack of expression of Tnfr on MSC could modify the 
ability to differentiate myeloid cells, expression of markers CD11b, Gr-1, F4/80, CD115, CD206, 
CD169 and CD68 was evaluated on cells collected after 4 days (Figure 4.13). Representative contour 
plots of expression of these markers are shown in Figure 4.9A. 
Analysis of the proportions of CD11b+ Gr-1high, Gr-1int-low and Gr-1- subsets in the gated CD11b+ 
population revealed a statistically significant higher percentage of CD11b+ Gr-1int-low cells (35.6% ± 
7.3% versus 22.7% ± 2.1% in BM WT+MSC WT, p=0.0428), and a significant decrease in the 
percentage of CD11b+ Gr-1- cells in presence of Tnfr1/r2-/- MSC (24.4% ± 7% versus 40.3% ± 5.9% 
in BM WT+MSC WT p=0.0136) (Figure 4.13B).  
F4/80 was significantly decreased in the cultures with Tnfr1/r2-/- MSC in the gated CD11b+ 
population (26.1% ± 12.9% versus 46.6% ± 9.1% in BM WT+MSC WT, p=0.0409, Figure 4.13C). A 
decrease in the percentage of CD206 (11.5% ± 8.3% versus 19.2% ± 8.3% in BM WT+MSC WT) and 
CD68 (12.4% ± 7.7% versus 16.4% ± 5.3% in BM WT+MSC WT) was also documented, although it 
was not significant (Figure 4.13C). The percentage of CD11b+ CD115+ cells was decreased in 
cultures with Tnfr1/r2-/- MSC (9.9%±2.2 versus 50.3%±8.8% in BM WT+MSC WT, p=0.0006, 
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Figure 4.13C). In particular, the decrease in CD115+ cells was identified on the total CD11b+ 
population, whereas for all other markers the decrease was detected in the CD11b+ Gr-1- subset 
(Figure 4.9A).  
The presence of Tnfr1/r2-/- MSC determined a reduced expansion of the myeloid cell population in 
comparison with WT MSC, as shown by the reduction in the absolute number of CD11b+ cells 
collected after co-culture (4.1x106 ± 1x106 versus 6.3x106 ±0.5x106 in BM WT+MSC WT, p=0.0296, 
Figure 4.13D).  
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FIGURE 4.13. MSC induced differentiation of CD11b+ Gr-1- cells requires Tnfr1/r2 expression. BM 
cells were cultured with MSC isolated from WT or Tnfr1/r2-/- mice for 4 days. B. Percentage of Gr-1high, Gr-
1int-low and Gr-1- in CD11b+ cells. Mean of 4 independent experiments, ± SD ** p<0.005 *** p<0.001 
Unpaired t test. C. Percentage of CD11b+ F4/80+, CD115+, CD206+, CD169+, and CD68+ cells, within the 
CD11b+ population. Mean of 4 independent experiments, ± SD * p<0.05 *** p<0.001 Unpaired t test. D. 
Absolute number of CD11b+ cells recovered from BM cultured with MSC WT or Tnfr1/r2-/- for 4 days. 
Mean of 4 independent experiments, ± SD * p<0.05 Unpaired t test.  
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4.2.3.3.1 CD11b+ cells isolated from BM cultured with WT or Tnfr1/r2-/- MSC have different 
M1-M2 profiles 
The M1-M2 profile of the CD11b+ cells obtained from the co-cultures of BM cells with Tnfr1/r2-/- 
MSC was analysed by quantitative RT-PCR (Figure 4.14). Il12b and Nos2 were significantly 
upregulated in BM cells cultured with Tnfr1/r2-/- MSC (2.1±0.6, p=0.0159 and 8.4±3.1, p=0.0135 
versus BM WT+MSC WT, respectively), whereas Marco was downregulated (0.2±0.2, p=0.0020 
versus BM WT+MSC WT). Arginase-1 was significantly upregulated in Tnfr1/r2-/- co-cultures 
(200.8±119.6, p=0.0444 versus BM WT+MSC WT), and Ccl12 and Chi3l1 were upregulated 
although not significantly (10.7±13.5 and 2±0.8, respectively).  
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FIGURE 4.14. CD11b+ cells isolated from BM cultured with WT or Tnfr1/r2-/- MSC have different M1-
M2 profiles. Quantitative RT-PCR data of CD11b+ cells isolated from 4 days cultures of BM with MSC WT 
or Tnfr1/r2-/-. Data are expressed as normalized to Hprt1 housekeeping gene, and compared to abundance in 
CD11b+ isolated from BM and MSC WT co-cultures. Mean of 3 independent experiments, ± SD. Arg1, 
arginase 1; Ccl12, CC-chemokine ligand 12; Chi3l1, chitinase 3-like 1; Cox2: cyclooxygenase 2; Hprt1, 
hypoxanthine guanine phosphoribosyl transferase; Il12b, interleukin 12b; Irf4, interferon factor 4; Marco, 
macrophage receptor with collagenous structure; Nos2, nitric oxide synthase 2. 
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4.2.3.4 Addition of TNF-α in BM and MSC co-cultures impairs the differentiation of 
macrophages 
Nos2 expression on MSC is required for induction of myeloid differentiation, and it is induced by the 
presence of TNF-α alone or in combination with IFN-γ. In order to further dissect the effect of TNF-α 
and IFN-γ on the co-cultures of BM and MSC, the two cytokines were used alone or in combination 
to treat MSC before or directly added to the co-cultures (Figure 4.15A).  
MSC were pre-treated for 24 hours with TNF-α, IFN-γ or their combination. BM cells were then 
added to pre-treated or untreated MSC, or to untreated MSC with the addition of the cytokines. A 
decrease in the percentage of CD11b+ Gr-1- cells was detected in the presence of TNF-α or TNF-α 
and IFN-γ either by pre-treating MSC (26.1% with TNF-α and 21.8% with TNF-α and IFN-γ versus 
36% in untreated) or directly adding the cytokines to the co-cultures (20.7% and with TNF-α and 
16.3% with TNF-α and IFN-γ versus 36% in untreated) (Figure 4.15A). Addition or pre-treatment 
with IFN-γ alone had no effect on the differentiation of the three main CD11b+ Gr-1 subsets induced 
by MSC (Figure 4.15A).  
As TNF-α addition to the co-culture induced a diverse induction of differentiation, we further 
investigated the expression of monocyte and macrophage markers in the co-cultures. The addition of 
TNF-α induced a higher percentage of CD11b+ Gr-1int-low cells (20.9% ± 6.6% versus 11.1% ± 3.1% in 
BM+MSC, p=0.0356) and a decrease in the percentage of CD11b+ Gr-1- cells in the CD11b+ 
population (25.1% ± 4.9% versus 45% ± 9.2% in BM+MSC, p=0.0089, Figure 4.15B). Analysis of 
F4/80, CD115 and CD206 revealed that addition of the cytokine induced a decrease in the percentage 
of CD11b+ F4/80+ cells (25.7% ± 7.8% versus 46.9% ± 5.5%, p=0.0044 versus BM WT+MSC WT), 
in the percentage of CD11b+ CD115+ (22.9%±14.1% versus 52.3%±9.5% in BM+MSC, p=0.0134), 
and in the percentage of CD206+ cells (11.2% ± 2.5% versus 20.8% ± 3.4% in BM+MSC, not 
significant) (Figure 4.15C). A non specific toxic effect by TNF-α could be excluded because cell 
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recovery was not impaired by the addition of TNF-α in the co-culture (6.2x106±1.9x106 versus 
6.6x106±1.9x106 of BM+MSC, Figure 4.15D). 
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FIGURE 4.15. Augmenting TNF-α in BM and MSC cultures impairs the differentiation of CD11b+ Gr-
1- cells. B. Percentage of Gr-1high, Gr-1int-low and Gr-1- in CD11b+ cells collected from BM cultured with 
MSC either alone or in presence of TNF-α. Mean of 4 independent experiments, ± SD * p<0.05 ** p<0.005 
Unpaired t test. C. Percentage of CD11b+ F4/80+, CD115+, and CD206+ cells, within the CD11b+ cells 
population collected from BM cultured with MSC either alone or in presence of TNF-α. Mean of 4 
independent experiments, ± SD, *p<0.05, ** p<0.005 Unpaired t test. D. Absolute number of CD11b+ cells 
recovered from BM cultured with MSC either alone or in presence of TNF-α for 4 days. Mean of 4 
independent experiments, ± SD.  
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4.2.4 Agrin is fundamental for MSC induced myeloid differentiation 
We previously showed that NOS2 expression from MSC is required for the induction of myeloid 
differentiation. In particular, we demonstrated that NOS2 expression could be up-regulated mainly by 
TNF-α, which is in turn up-regulated by BM cells cultured in presence of MSC. Nevertheless, 
differentiation of myeloid cells is not completely inhibited when BM cells are cultured with NOS2-/- 
or Tnfr1/r2-/- cells, and addition of TNF-α results in a similar impairment of myeloid differentiation. 
Therefore, other molecules might be involved in the interaction between haematopoietic and 
mesenchymal cells. 
Extracellular matrix proteins are fundamental for organizational and functional support of cell niches. 
In particular, agrin has recently been described as a critical MSC-derived signal controlling the 
survival and proliferation of HSC [332], and as a non-redundant molecule influencing myeloid cell 
development and function [336].  
On the basis of these notions, we investigated the ability of BM derived MSC isolated from agrin-
deficient mice to drive the differentiation of myeloid cells in vitro. 
4.2.4.1 Agrin is required for driving MSC-induced myeloid differentiation 
BM derived MSC isolated from WT and Musk-L;Agrn-/- mice were cultured with WT BM cells for 4 
days. BM derived MSC isolated from Musk-L;Agrn+/- mice were used as controls, as they share the 
same phenotype of WT mice [332].  
Cells collected from the co-cultures were analysed for expression of markers CD11b, Gr-1, F4/80, 
CD115, CD206, CD169 and CD68 (Figure 4.16). Contour plots of Gr-1 versus CD11b, F4/80, 
CD115, CD206, CD169 and CD68 of a representative experiment are shown in Figure 4.16A.  
 156 
Analysis of the expression of Gr-1 marker in the CD11b+ gated population revealed that Musk-
L;Agrn-/- MSC induced an increase in the percentage of CD11b+ Gr-1int-low cells (27.5% ± 4.9% versus 
8.6% ± 3.6% in BM WT+MSC WT, p=0.0059) and a decrease in the percentage of CD11b+ Gr-1- 
cells (15.9% ± 2.2% versus 37.2% ± 6.5% in BM WT+MSC WT, p=0.0059) as compared to WT 
MSC (Figure 4.16B). Musk-L;Agrn+/- MSC also induced an increase in the percentage of CD11b+ Gr-
1int-low (22.3% ± 6.3%) cells and a decrease in CD11b+ Gr-1- cells (26.23% ± 7.4%), but the difference 
with BM cells cultured with WT MSC was not significant.  
Expression of markers F4/80, CD115, CD206 and CD68 in the CD11b+ gated population was 
significantly down-regulated in BM cells cultured with MSC from Musk-L;Agrn-/- mice (Figure 
4.16C). A 3-fold decrease was documented in the percentage of F4/80+ (15.2% ± 4.1% versus 41.9% 
± 8.1% in BM WT+MSC WT, p=0.0069), CD115+ (6.5% ± 1.1% versus 22.2% ± 7.7% in BM 
WT+MSC WT, p=0.0331), CD206+ (8.2% ± 2.3% versus 21.3% ± 2.9% in BM WT+MSC WT, 
p=0.0035), CD169+ (0.65%±0.15% versus 1.7%±0.25% in BM WT+MSC WT, p=0.0031), and 
CD68+ (7.9% ± 2.3% versus 17.8% ± 1.9% in BM WT+MSC WT, p=0.0050) cells in BM cells 
cultured with Musk-L;Agrn-/- MSC as compared to BM cells cultured with WT MSC (Figure 4.12C). 
The difference in the expression of these markers in BM cultured with WT or Musk-L;Agrn+/- MSC 
was not significant (Figure 4.16C). Expression of F4/80, CD206, CD169 and CD206 was mainly 
detected in the CD11b+ Gr-1- population, whereas CD115 was expressed by CD11b+ Gr-1high and 
CD11b+ Gr-1- cells (Figure 4.16A).  
The absolute number of CD11b+ cells recovered after 4 days of culture was decreased in BM cultured 
with Musk-L;Agrn-/- MSC (4.1x106 ± 0.5x106 versus 6.5x106 ± 0.8x106 in BM WT+MSC WT, 
p=0.0101) (Figure 4.16D). As expected, no difference in the recovery of CD11b+ cells was seen 
between BM cultured with WT or Musk-L;Agrn+/- MSC. 
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FIGURE 4.16. Expression of agrin is required for MSC-induced differentiation of myeloid cells. BM 
cells were cultured with MSC isolated from WT, Musk-L;Agrn-/- or Musk-L;Agrn+/- mice for 4 days. B. 
Percentage of Gr-1high, Gr-1int-low and Gr-1- in CD11b+ cells. Mean of 4 independent experiments, ± SD ** 
p<0.005 Unpaired t test. C. Percentage of CD11b+ F4/80+, CD115+, CD206+, CD169+, and CD68+ cells, 
within the CD11b+ cells population. Mean of 4 independent experiments, ± SD * p<0.05 ** p<0.005 
Unpaired t test. D. Absolute number of CD11b+ cells recovered from BM cultured with MSC WT, Musk-
L;Agrn-/- or Musk-L;Agrn+/- for 4 days. Mean of 4 independent experiments, ± SD * p<0.05 Unpaired t test.  
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4.2.4.1.1 CD11b+ cells isolated from BM cultured with WT or Musk-L;Agrn-/- MSC have 
different M1-M2 profiles 
The M1-M2 profile of CD11b+ cells isolated from BM cells cultured with WT, Musk-L;Agrn-/- and 
Musk-L;Agrn+/- MSC was investigated with RT-PCR (Figure 4.17). The analysis was run in 
comparison to the levels expressed by CD11b+ cells obtained from BM cultured with WT MSC. Cox2 
and Il-12b were up-regulated in cultures with Musk-L;Agrn-/- MSC, although not significantly 
(3.3±0.9 and 1.7±0.8, respectively). Musk-L;Agrn-/- MSC induced a significant down-regulation in the 
expression of Marco (0.09±0.1, p=0.0019 versus BM WT+MSC WT), and up-regulated the 
expression of Nos2 (65.1±29.97, p=0.0034 versus BM WT+MSC WT). Analysis of Arg-1, Ccl12, 
Chi3l1 and Irf4 expression revealed that co-cultures of BM cells with Musk-L;Agrn-/- MSC induced 
CD11b+ cells characterised by a higher expression of these markers (Figure 4.17). In particular, a 
300-fold increase and a 4-fold increase were detected in the levels of expression of Arg-1 
(239.8±103.1, p<0.0001 versus BM WT+MSC WT) and Chi3l1 (4.5±3.8, p=0.0137 versus BM 
WT+MSC WT) as compared to BM cultured with WT MSC. Ccl12 and Irf4 were up-regulated in 
presence of Musk-L;Agrn-/- MSC, although not significantly (6.5±3.8 and 2.4±0.5 versus BM 
WT+MSC WT, respectively). 
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FIGURE 4.17. CD11b+ cells isolated from BM and MSC WT or Musk-L;Agrn-/- co-cultures have a 
different M1-M2 profile. Quantitative RT-PCR data of CD11b+ cells isolated from 4 days cultures of BM 
with MSC WT, Musk-L;Agrn-/- or Musk-L;Agrn+/-. Data are expressed as normalized to Hprt1 housekeeping 
gene, and compared to abundance in CD11b+ isolated from BM and MSC WT co-cultures. Mean of 3 
independent experiments, ± SD. * p<0.05, ** p<0.005, **** p<0.001, Unpaired t test. Arg1, arginase 1; 
Ccl12, CC-chemokine ligand 12; Chi3l1, chitinase 3-like 1; Cox2, cyclooxygenase 2; Hprt1, hypoxanthine 
guanine phosphoribosyl transferase; Il12b, interleukin 12b; Irf4, interferon factor 4; Marco, macrophage 
receptor with collagenous structure; Nos2, nitric oxide synthase 2. 
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4.2.4.1.2 Nos2 expression in Agrin-deficient MSC is strongly downregulated 
We then investigated whether Nos2 and agrin expression on MSC were correlated.  
MSC obtained from WT or Musk-L;Agrn-/- mice were examined for the expression of Nos2 with or 
without TNF-α stimulation for 24 hours. MSC isolated from Musk-L;Agrn+/- were used as control. 
RT-PCR data show that Nos2 expression is significantly impaired in MSC derived from mice that are 
null for Agrin (0.16±0.1, p=0.0002 versus MSC WT), being downregulated 6 times (Figure 4.18). 
After TNF-α stimulation, a 288-fold decrease in Nos2 expression is detected in Musk-L;Agrn-/- MSC 
as compared to WT MSC (10.7±1.4 versus 3076±85.6 in MSC WT, p=0.0004) (Figure 4.18).  
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FIGURE 4.18. Musk-L;Agrn-/- MSC express less Nos2 and are less responsive to TNF-α for Nos2 up-
regulation. Quantitative RT-PCR data of MSC isolated from WT or Musk-L;Agrn-/- mice, in culture alone 
or treated with TNF-α (20ng/ml) for 24 hours. Data are expressed as normalized to Hprt1 housekeeping 
gene, and compared to abundance in untreated MSC WT. Mean of 3 independent experiments, ± SD. *** 
p<0.001, Unpaired t test. 
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4.2.5 C3 complement is required for driving the differentiation of CD11b+ Gr-
1int-low cells 
The complement cascade is a fundamental first line of defence during infections and inflammation. 
Recent investigations shed a new light on the role of complement in regulating HSPC mobilization 
and egress from the niche. In particular, a lack of expression of C3 in niche stromal cells impairs 
normal recovery of haematopoiesis after transplantation [354]. Furthermore, a recent study suggests 
that another complement factor, C5a, favours the recruitment of myeloid cells with 
immunosuppressive properties (MDSC) into solid tumours [382]. Taken altogether, these data 
prompted us to investigate whether a lack of C3 complement component on MSC could determine an 
impaired myeloid differentiation. 
BM derived MSC isolated from WT or C3-/- mice were cultured with WT BM cells. Representative 
contour plots of Gr-1 versus CD11b and F4/80 are shown in Figure 4.15A. A decreased percentage of 
CD11b+ Gr-1int-low cells was found in the co-cultures of BM cells with C3-/- MSC (16.5% ± 2.5% 
versus 29.2% ± 4.9% in BM WT+MSC WT, p=0.0035) (Figure 4.19B). Analysis of F4/80 showed no 
difference between BM cells cultured with WT or C3-/- MSC (Figure 4.19A), as confirmed by a 
similar percentage of CD11b+ Gr-1- cells in both cultures (45.5% ± 13.7% versus 32.9% ± 16.5% in 
BM WT+MSC WT, Figure 4.19B). To understand whether lack of expression of C3 on 
haematopoietic cells could determine an impaired myeloid differentiation, BM cells isolated from C3-
/- mice were co-cultured either with MSC from WT or C3-/- mice. No difference was seen in the co-
cultures (data not shown), further confirming that myeloid differentiation requires expression of C3 
on stromal cells and not on haematopoietic cells. 
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FIGURE 4.19. C3-/- MSC ability to induce CD11b+ Gr-1int-low cells is impaired. BM cells isolated from WT 
mice were cultured alone or with MSC from WT or C3-/- mice. A. Contour plots represent the CD11b and 
Gr-1 proportion in the live gate, and the F4/80 versus Gr-1 proportion in the CD11b+ gate. B. Percentage of 
Gr-1high, Gr-1int-low and Gr-1- in CD11b+ gated cells. Mean of 3 independent experiments, ± SD ** p<0.005 
Unpaired t test.  
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4.2.5.1 The role of soluble factors in MSC-induced CD11b+ Gr-1int-low cells 
Since C3-/- MSC are less able to induce the differentiation of CD11b+ Gr-1int-low cells, we analysed the 
expression of several soluble factors produced by these cells by ELISA. In particular, the production 
of cytokines GM-CSF and IL-6 were investigated on the basis of their ability to expand a myeloid 
population characterised by expression of CD11b and differential expression of Gr-1 [259]. 
In order to mimic the experimental settings in which BM cells are cultured together with MSC for 4 
days, supernatants were collected from BM derived MSC isolated from WT or C3-/- mice plated for 
24, 48, 72 and 96 hours. GM-CSF was not produced by WT or C3-/- MSC (data not shown), whereas 
IL-6 was produced by WT MSC but not from C3-/- MSC (Figure 4.20B).  
The next step was to investigate the amount of complement C3 produced by WT BM cells, WT or C3-
/- MSC, either in co-culture or alone at 24, 48 and 96 hours (Figure 4.20A). MSC produced C3 in 
increasing amounts with time, whereas BM cells from WT mice and C3-/- MSC did not express it. The 
levels of expression of C3 from BM cells cultured with MSC were similar to the ones detected in 
MSC WT alone, thus suggesting that MSC cannot induce production of C3 from BM cells.  
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FIGURE 4.20. C3-/- MSC do not produce C3 and IL-6. A. BM cells isolated from WT mice were cultured 
alone or with MSC isolated from WT or C3-/- mice for 4 days. Supernatants were collected at 24, 48 and 96 
hours, and tested for the production of C3 with ELISA. Mean of 2 independent experiments, ±SD. B. MSC 
from WT or C3-/- mice were cultured alone as described in Materials and Methods for 4 days. Supernatants 
were collected at 24, 48, 72 and 96 hours, and tested for the production of IL-6 with ELISA. Mean of 2 
independent experiments, ±SD. 
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C3-/- MSC induced a decreased percentage of CD11b+ Gr-1int-low cells when cultured with BM cells, 
and did not produce C3 and IL-6 as compared to MSC WT. Therefore we investigated the effect of 
addition of C3 or IL-6 to co-cultures of BM cells derived from WT or C3-/- mice with C3-/- MSC 
(Figure 4.21). Cytokines were added at day 1 and day 3. Although a small increase in the percentage 
of CD11b+ Gr-1int-low cells could be detected with the addition of C3 or IL-6, the amount was not 
restored to the levels expressed from BM cells cultured with WT MSC (Figure 4.21).  
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FIGURE 4.21. Addition of C3 or IL-6 to BM and MSC C3-/- co-cultures does not determine an increase 
in the percentage of CD11b+ Gr-1int-low cells. BM cells isolated from WT or C3-/- mice were cultured with 
MSC isolated from WT or C3-/- mice or 4 days either without or with the addition of C3 (150ng/ml) or IL-6 
(150ng/ml). Contour plots represent the CD11b and Gr-1 proportion in the live gate. A representative 
example of 2 independent experiments is shown. 
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4.3 DISCUSSION 
In this chapter, we describe the investigations on the mechanisms involved in MSC-induced myeloid 
differentiation. We have observed that macrophages are induced through cell contact, whereas the 
differentiation of immature myeloid cells is mediated by soluble factors (Figure 4.1). We studied 
therefore the role of some candidate molecules involved in haematopoietic niche functions. 
Several studies have investigated the role of NO in different settings, such as immunosuppression, 
tumour progression, and HSC self-renewal. In our in vitro system, the lack of NOS2 in the stromal 
compartment, but not in haematopoietic cells (Figure 4.3), impaired the ability of MSC to expand and 
differentiate the macrophage population, and induced a higher proportion of granulocytes (Figure 
4.2). The myeloid population induced by Nos2-/- MSC showed a slightly reduced ability to suppress 
the proliferation of mitogen-induced splenocytes, and a concomitant lower expression of M1 and M2 
markers as compared to myeloid cells induced by WT MSC (Figure 4.5 and 4.4).  
Interestingly, we found that Nos2-/- mice did not have constitutive significant abnormalities in the 
proportions of mononuclear phagocyte populations (Figure 4.6 and 4.7) as compared to WT mice 
both in BM and spleen. Although NOS2 may not indeed have any substantial effect, in the in vivo 
steady-state condition there can be pathways compensating for the defect. Therefore, we thought to 
test the role of NOS2 during myeloid reconstitution adopting two different strategies.  
The adoptive transfer of WT MSC induced a higher percentage of macrophages in BM donor cells, 
but not in spleen, whereas such ability was impaired in Nos2-/- MSC (Figure 4.8D and 4.8F). In 
contrast with the known ability of MSC in favouring HSC engraftment, no difference was 
documented between mice adoptively transferred with BM alone or with WT or Nos2-/- MSC (Figure 
4.8C). Such discrepancy can find a potential explanation in the different experimental systems used. 
The engraftment enhancing effect of MSC on HSC engraftment was observed using human MSC in 
NOD/SCID mice after six weeks from transplant [63]. An effect on early HSC engraftment was 
 168 
documented twelve days after syngeneic transplantation when murine MSC were injected intra-femur 
[64]. These results might suggest that, in early phases of reconstitution, MSC preferentially induce the 
repopulation of short-term progenitors (mature myeloid cells) in which NOS2 may play a 
fundamental role. Alternatively, but not exclusively, the myeloid population, supported by MSC, 
could be one involved in HSC long-term survival [262].  
Further work is required to confirm whether MSC have a favouring activity on HSC long-term 
engraftment, and whether such activity requires early reconstitution of mature myeloid cells in the 
early stages of engraftment.  
The selective effect of MSC on BM but not on spleen macrophage repopulation could be explained by 
the intrinsic tissue macrophage sensitivity to the irradiation dose. Therefore, in order to eliminate any 
confusing effect given by the WT recipient environment, and to eliminate the competition with host 
tissue macrophages, Nos2-/- recipients were treated with clodronate, irradiated and then received WT 
BM cells (Figure 4.9). Whilst WT recipients promoted early macrophage repopulation in BM 
(Figure 4.9), such ability was impaired in NOS2 deficient hosts. These data suggest that a defect in 
the haematopoietic environment of Nos2-/- mice exists, and impacts on donor macrophage 
differentiation. We cannot exclude that other cells (endothelial cells or pericytes) contribute to the 
macrophage defect via NOS2 deficiency . 
These in vivo experiments have not addressed which population in the unfractionated BM is 
interacting with MSC although the in vitro data suggest to be a committed myeloid progenitors (CMP 
or GMP).  
As Nos2 expression on MSC is mainly up-regulated by TNF-α, or its combination with IFN-γ (Figure 
4.12), we hypothesized that TNF-α produced by BM cells in culture with MSC (Figure 4.10) could 
drive the up-regulation of Nos2, and in turn the differentiation of macrophages. However, the high 
concentrations used to assay the role of these cytokines in MSC up-regulation of NOS2 cannot reflect 
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their physiological relevance in inducing myeloid differentiation ability. When added to the co-
cultures, the same concentrations gave the paradoxical effect of impairing macrophage differentiation 
(Figure 4.15), confirming their inappropriateness. Further experiments are needed to understand the 
role of BM derived TNF-α in the co-cultures, and whether macrophage differentiation is impaired by 
blocking or neutralising its effect. However, the impaired differentiation ability seen in Tnfr1/r2-/- 
MSC seems to indicate that TNF-α might play a role (Figure 4.13). Further investigation is therefore 
required to understand how other forms of TNF-α (such as trans-membrane TNF-α) on BM cells 
could mediate such effect, possibly corroborating the importance of cell contact in MSC-induced 
macrophage differentiation. 
Agrin-deficient MSC were also shown to induce a reduction in CD11b+ cells absolute number, in 
particular in the macrophage subset, and, similarly to the effect of Tnfr1/r2-/- MSC, they induced a 
higher proportion of early myeloid cells (CD11b+ Gr-1int-low) (Figure 4.16). Such effect was not 
unexpected, as agrin deficiency has been shown to correlate with impaired development of monocytes 
and macrophages, but not of neutrophils [336]. Although agrin-deficient MSC had a lower expression 
of Nos2, the existence of a relationship between agrin and NO has not been demonstrated yet (Figure 
4.17). However, in the neuromuscular junction, NOS activity is required for agrin-induced 
aggregation of postsynaptic acetylcholine receptors at the embryonic neuromuscular junction in vivo 
[383]. It has been suggested that an increase in NO production is part of the agrin/MuSK signal 
transduction pathway, but such hypothesis has not yet been confirmed [384].  
Whilst NOS2, TNFR1/R2 and agrin seemed to play a crucial role in MSC induced differentiation of 
macrophages, complement C3 was found to be necessary to drive the differentiation of immature 
myeloid cells (Figure 4.19). However, adding back C3 to the co-cultures did not restore the 
differentiation of this subset (Figure 4.21). Further investigation is therefore required to determine the 
soluble factor mediating the differentiation of CD11b+ Gr-1int-low cells. 
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These results could be interpreted in light of a possible role of BM MSC in driving macrophage 
differentiation in the haematopoietic BM niche, whereby several molecules involved in HSPC 
regulation can modulate such activity.  
The inflammatory environment has been shown to produce contrasting effects on HSPC functions. 
TNF-α has been associated with apoptosis and inhibition of HSC self-renewal [385, 386]. On the 
other hand, TNF-α signalling through TNFR1 appears to be fundamental for the maintenance of HSC 
functions [347]. Another inflammatory component, represented by the complement system, has been 
postulated as one of the major players in HSPC mobilization. C3 cleavage fragments enhance the 
responsiveness of HSPC to a CXCL12 gradient, thus promoting retention of these cells in the BM 
[387, 388].  
Hypoxia is another important regulator of niche activity, whereby low oxygen levels play a 
fundamental role in the maintenance of self-renewal for dormant HSC [358]. Together with 
inflammatory cytokines, hypoxia has been associated with up-regulation of NOS2 and ROS levels, 
which also have a role in regulating dormancy and mobilization of HSC [369].  
MSC-macrophage interaction in the niche is fundamental to control the retention of HSPC in the BM 
[261, 262]. In this perspective, we could argue that hypoxic and/or inflammatory microenvironments 
can shape the ability of MSC to differentiate myeloid cells, thus resulting in a differential modulation 
of HSPC self-renewal and mobilization. 
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CHAPTER 5. 
MSC-INDUCED MYELOID DIFFERENTIATION: 
IDENTIFICATION OF THE CELLULAR PLAYERS  
5.1 INTRODUCTION 
In the previous chapters we have described the ability of MSC to expand and differentiate 
unfractionated BM into three subsets of CD11b+ cells according to differing expression of Gr-1. In 
this section, our aims have been directed at identifying, amongst the haematopoietic hierarchy, the 
cellular target(s) of MSC driven myeloid differentiation.  
Intimately linked to this question, is the debatable origin of MSC and whether its source of origin 
impacts on their functions. In fact, there is still no consensus regarding the definition of stromal cells, 
which have been isolated from several tissues and given various names, such as fibroblasts, reticular 
cells, and mesenchymal stem/stromal cells. Several lines of evidence show that BM derived MSC 
share the same phenotype and immunosuppressive functions of the commonly defined fibroblasts [13, 
14]. Furthermore, a number of studies indicate that an interaction between MSC and macrophages 
exists also in peripheral tissues. In particular, stem cell niches present in the skin, kidney and liver are 
supported by the interaction between MSC and tissue-macrophages.  
Therefore, it was fundamental to understand whether the phenomenon we observed using cells of BM 
origin can also be reproduced: 1. using MSC from other tissues, 2. using haematopoietic cells at 
different differentiation stages. The information would be invaluable to understand the dynamics of 
tissue homeostasis in normal and inflammatory conditions. 
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5.2 RESULTS 
5.2.1 MSC target committed myeloid progenitors but not primitive HSC 
In an effort to understand the target cells of MSC-induced myeloid differentiation, FACS sorted HSC, 
common myeloid progenitors (CMP) and granulocyte/macrophage progenitors (GMP) were cultured 
with MSC in the usual conditions. Isolated megakaryocyte/erythroid progenitors (MEP) and 
unfractionated BM were used as negative or positive control of differentiation, respectively. 
Unfractionated BM cells were stained for Lineage (Lin), IL-7Rα, c-kit, Sca-1, CD16/32 (FcγR), 
CD34 and fetal liver kinase 2 (Flk2, FLT3). Because the expression of IL-7Rα chain marks the 
common lymphoid progenitors (CLP) and other downstream lymphoid progenitors, IL-7Rα positive 
cells were excluded, as well as all the Lineage positive cells. Following the isolation method proposed 
by Weissman group [160], c-kit+ and Sca-1- cells were subdivided in CD16/32low CD34+, CD16/32low 
CD34-, and CD16/32high CD34+ populations (MEP, CMP, GMP respectively). HSC were instead 
defined as c-kit+ Sca-1+ Flk-2- cells (Figure 5.1A). Analysis of the sorted populations revealed a high 
purity (83.3% of MEP, 94.1% of CMP, 100% of GMP and 100% of HSC) (Figure 5.1B).  
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FIGURE 5.1. Sorting of myeloid progenitors in mouse BM. A. BM cell suspension was prepared as 
described in Materials and Methods. The IL-7Rα-Lin- Sca-1-c-Kit+ fraction of BM cells was subdivided into 
CD16/32low CD34+, CD16/32low CD34-, and CD16/32high CD34+ populations (MEP, CMP, GMP 
respectively), whereas the IL-7Rα-Lin-Sca-1+c-Kit+ was subdivided into Flk2-Sca-1+ (HSC). B. Re-analysis 
of the sorted CD16/32low CD34+ (MEP), CD16/32low CD34- (CMP), and CD16/32high CD34+ (GMP) 
populations.  
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Sorted HSC, CMP, GMP and MEP were co-cultured with MSC for 4 days and cells collected and 
stained for expression of CD11b, Gr-1, F4/80 and CD115 (Figure 5.2). The presence of MSC in the 
cultures induced the differentiation of the three CD11b+ subsets from CMP and GMP, but not HSC 
and MEP (Figure 5.2A, left panel). 
Analysis of the Gr-1high, Gr-1int-low and Gr-1- subsets in the gated CD11b+ population revealed that co-
cultures of CMP and MSC induced a 2-fold decreased proportion of Gr-1high cells in comparison to 
unfractionated BM cultured with MSC (24% ± 6.9% versus 41.8% ± 10.8% in BM+MSC, p=0.0283), 
and a 2-fold increased percentage of Gr-1- cells as compared to unfractionated BM cultured with 
MSC (60.1% ± 8.9% versus 35% ± 12.8% in BM+MSC, p=0.0345) (Figure 5.2B). No statistically 
significant difference was found between GMP or unfractionated BM cultured with MSC (Figure 
5.2B). 
A 2-fold increase was documented in the percentage of CD11b+ F4/80+ cells in the co-cultures of 
CMP and MSC, in comparison to BM cultured with MSC (63.6% ± 9.8% versus 36.8% ± 13.7% in 
BM+MSC, p=0.0352) (Figure 5.2C and Figure 5.2A, middle panel). Furthermore, analysis of the 
percentage of CD115+ cells in the gated CD11b+ population showed that CMP cultured with MSC 
were able to induce a higher percentage of CD115+ cells as compared to BM cultured with MSC 
(85.8% ± 1.3% versus 38.6% ± 18.9% in BM+MSC, p=0.0155) (Figure 5.2C and Figure 5.2A, right 
panel). No statistically significant difference was documented between the co-cultures of MSC with 
GMP or with unfractionated BM (Figure 5.2C). 
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FIGURE 5.2. Committed myeloid progenitors, but not primitive HSC, generate myeloid cells when 
cultured with MSC. Unfractionated BM or sorted CMP, GMP, MEP and HSC were co-cultured with MSC 
for 4 days. A. Contour plots represent the CD11b and Gr-1 proportion in the live gate, and the expression of 
F4/80 and CD115 in the CD11b+ gated population. ND= not determined.  
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FIGURE 5.2. Committed myeloid progenitors, but not primitive HSC, generate myeloid cells when 
cultured with MSC. Unfractionated BM or sorted CMP, GMP, MEP and HSC were co-cultured with MSC 
for 4 days. B. Percentage of Gr-1high, Gr-1int-low and Gr-1neg in CD11b+ cells. Mean of 4 independent 
experiments, ± SD * p<0.05 Unpaired t test. C. Percentage of CD11b+ F4/80+ and CD115+ cells in the 
CD11b+ gated population. Mean of 4 independent experiments, ± SD * p<0.05 Unpaired t test.  
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To further confirm the hypothesis that committed cells would have an impaired differentiation ability 
as compared to myeloid precursors, we evaluated the ability of CD11b+ sorted cells from BM and 
from spleen of C57Bl/6 mice to differentiate into the three subsets of CD11b+ cells after culture with 
MSC. 
Unfractionated or CD11b+ sorted BM or spleen cells were cultured with MSC and myeloid 
differentiation analysed (Figure 5.3). A 4-fold decrease in the percentage of CD11b+ Gr-1- cells 
(8.74% versus 35% of unfractionated BM+MSC control in the live gated population) and a 2.5-fold 
increase in the percentage of CD11b+ Gr-1high cells (60.1% versus 24% of unfractionated BM+MSC 
control) were documented in the cultures of MSC and CD11b+ cells isolated from the BM. 
No differentiation was recorded in co-cultures of unfractionated spleen and MSC (Figure 5.3), whilst 
CD11b+ splenocytes showed minimal ability to differentiate, with only 16.8% of CD11b+ cells 
detected after the co-culture (Figure 5.3).  
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FIGURE 5.3. MSC do not differentiate spleen or BM CD11b+ cells. Unfractionated or CD11b+ BM or 
spleen cells were cultured with MSC for 4 days. Contour plots represent the CD11b and Gr-1 proportion in 
the live gate. A representative example of 3 independent experiments is shown. 
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5.2.2 MSC from peripheral tissues have the ability to differentiate myeloid cells 
We asked whether MSC isolated from skin and kidney glomeruli (mesangial cells) could drive the 
differentiation of myeloid cells from unfractionated BM. 
MSC isolated from the skin of C57Bl/6 mice exhibited a similar phenotype of BM derived MSC, with 
a proportion of PDGFR-α+/Sca-1+ cells of 40.2%. Cells did not express c-Kit, and the percentage of 
CD90+ cells was 80% (Figure 5.4A). 
In order to test their immunosuppressive activity, escalating concentrations of skin MSC were 
cultured with ConA-stimulated splenocytes (Figure 5.4B). The proliferation of activated splenocytes 
was completely abolished when skin stromal cells were present up to a 1:80 ratio, with a 6-fold 
reduction of proliferation still detectable at a 1:160 ratio.  
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FIGURE 5.4: Characterization of skin MSC preparation. A. FACS dot plots of skin MSC. Proportion of 
CD45- cells is represented in the live gate, and the proportions of PDGFRα+ Sca-1+ cells and CD90+ c-Kit+ 
cells are represented in the CD45- gate. A representative example from 3 independently derived preparations 
of skin MSC is represented. B. Skin MSC were plated at 5x104 cells/well, with 1:2 serial dilutions, and 
splenocytes were added at 5x105 cells/well and stimulated with 3µg/ml of ConA for 3 days. 3H-thymidine 
was added for the last 18h. The figure reports a representative experiment, and each column represents the 
mean±SD of triplicates of cultures. (cpm: count per minute). Results are expressed as the value obtained by 
subtracting the (Skin MSC+Splenocytes) value from the (Skin MSC+Splenocytes ConA) value.  
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We then assessed the ability of skin MSC and mesangial cells to induce the differentiation of 
unfractionated BM cells. Both cells were able to induce the differentiation of the three myeloid 
subsets (Figure 5.5B).  
However, the recovery of CD11b+ cells was different between BM cultured with cutaneous MSC or 
mesangial cells and BM MSC (Figure 5.5C). In particular, skin MSC induced a 2-fold increase in the 
expansion of CD11b+ cells as compared to BM cultured alone (2.4x106 ± 0.6x106 versus 0.7x106 ± 
0.09x106 of BM alone, p=0.0058), but such expansion was reduced when compared to the effect of 
BM MSC (6.1x106 ±0.8x106 in BM+MSC, p=0.0031). Similarly, mesangial cells induced an 
expansion of CD11b+ cells (1.5x106 ±0.15x106, p=0.0018 versus BM alone) but it was lower than that 
produced by BM MSC (p=0.0007 versus BM+MSC). 
The proportion of the myeloid subsets was quantitatively different using different MSC preparations. 
Mesangial cells induced a pattern of differentiation similar to the one induced by BM derived MSC, 
whereas skin MSC induced a 2-fold increase in the percentage of CD11b+ Gr-1int-low cells (38.7% ± 
12.6% versus 12.4% ± 1.1% in BM+MSC, not significant), and a 2-fold decrease in the percentage of 
CD11b+ Gr-1- cells as compared to BM cultured with BM MSC (26.8% ± 2.4% versus 52.1% ± 1.6% 
in BM+MSC, p=0.0065, Figure 5.5B).  
The phenotype of the myeloid components was further characterised by F4/80, CD115 and CD206 
expression. A 4- and a 2-fold decrease in the percentage of CD11b+ Gr-1- F4/80+ cells was 
documented in the co-cultures of BM with skin MSC and mesangial cells compared to BM MSC 
(13.3% and 23% versus 46.3% of BM MSC, respectively) (Figure 5.5). Notably, little or no 
expression of CD115 was detected in the co-cultures of BM with skin MSC or mesangial cells. 
Mesangial cells were able to induce only 8.76% of CD11b+ Gr-1- CD115+ cells, whereas no 
expression of CD115 was detected in CD11b+ cells from the cultures with skin MSC. A 3-fold 
reduction in the percentage of CD11b+ Gr-1- CD206+ cells was documented in BM cultured with skin 
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MSC or mesangial cells, as compared to BM cultured with BM MSC (6.56% and 6.98% versus 
21.7%, respectively). 
FIGURE 5.5. MSC of peripheral tissues are able to induce the differentiation of CD11b+ Gr-1- cells. BM 
was cultured with MSC isolated from BM or skin or mesangial cells (kidney MSC) for 4 days. A. Contour 
plots represent the CD11b and Gr-1 proportion in the live gate, and the expression of F4/80, CD115 and 
CD206 in the CD11b+ gated population. Data are representative of 2 independent experiments.  
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FIGURE 5.5. MSC of peripheral tissues are able to induce the differentiation of CD11b+ Gr-1- cells. BM 
was cultured with BM or skin-derived MSC or mesangial cells (kidney MSC) for 4 days. B. Percentage of 
Gr-1high, Gr-1int-low and Gr-1- in CD11b+ cells. Mean of 2 independent experiments, ± SD * p<0.05 ** 
p<0.005 *** p<0.001, Unpaired t test. C. Absolute number of CD11b+ cells recovered from BM cultured 
alone, with MSC, with skin MSC or with mesangial cells for 4 days. Mean of 2 independent experiments, ± 
SD. ** p<0.005 *** p<0.001, Unpaired t test.  
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The next step was to understand whether the CD11b+ induced cells from the co-cultures of BM cells 
and MSC isolated from peripheral tissues shared a similar M1-M2 profile with CD11b+ cells obtained 
from BM cultured with BM MSC.  
CD11b+ cells obtained from the co-cultures were isolated and RT-PCR analysis was performed on 
RNA extracted from these cells (Figure 5.6). Cox2 expression was similar in all of the co-cultures. 
Il12b expression from co-cultures of BM with skin MSC was similar to the expression induced by 
MSC, whereas mesangial cells induced a 2-fold increase in the expression of Il12b. A 2-fold increase 
and a 2-fold decrease were documented in the expression of Marco from CD11b+ cells isolated from 
BM cultured with skin MSC or mesangial cells, respectively. Nos2 was up-regulated by 20-folds and 
80-folds in BM cultured with skin MSC and mesangial cells, respectively, as compared to the 
expression induced by BM MSC.  
The M2 markers Arg-1 and Ccl12 were highly up-regulated in BM cultured with skin MSC (40-folds 
and 25-folds increase, respectively). Mesangial cells induced a similar expression of Arg-1 and Ccl12 
to the one induced by BM MSC.  
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FIGURE 5.6. M1-M2 profile of CD11b+ cells from MSC cultures. Quantitative RT-PCR data of CD11b+ 
cells sorted from 4 days cultures of BM with MSC isolated from BM or skin or mesangial cells (kidney 
MSC). Data are expressed as normalized to Hprt1 housekeeping gene, and compared to abundance in 
CD11b+ isolated from BM cultured with BM MSC. A representative example of 2 independent experiments 
is shown. Arg-1, arginase 1; Ccl12, CC-chemokine ligand 12; Cox2, cyclooxygenase 2; Hprt1, hypoxanthine 
guanine phosphoribosyl transferase; Il12b, interleukin 12b; Marco, macrophage receptor with collagenous 
structure; Nos2, nitric oxide synthase 2. 
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5.3 DISCUSSION 
In this chapter, the cellular players involved in the interaction between myeloid cells and MSC were 
investigated.  
Common myeloid progenitors (CMP), and granulocyte/macrophage progenitors (GMP), but not HSC 
or megakaryocyte/erythrocyte progenitors (MEP) were able to differentiate into macrophages when in 
contact with MSC (Figure 5.2). The results were not surprising, as several studies have shown that 
MSC can maintain long-term culture-initiating cell frequency and HSC primitive profile via 
mechanisms involving cell contact [389, 390].  
Consistent with these data, CD11b+ cells obtained from either the BM or the spleen of WT mice have 
an impaired ability to differentiate into macrophages (Figure 5.3). Spleen myeloid cells, such as 
marginal zone and red pulp macrophages, are probably already fully differentiated, hence unable to 
respond to MSC-derived differentiation stimulus. Furthermore, myeloid cells isolated from spleen and 
cultured with MSC seemed to loose the expression of CD11b after 4 days of culture.  
The lack of differentiation ability seen in the CD11b+ Gr-1int-low subset after co-culture with MSC 
could be explained by two possibilities. Firstly, CD11b+ Gr-1int-low are induced by MSC to have a fully 
committed phenotype that would impede the further differentiation into other types of myeloid cells. 
Secondly, the Gr-1int-low subset represents an immature myeloid population the survival of which 
depends on soluble factors provided by stromal cells. Further investigation is required to elucidate this 
issue.  
We observed that not only BM derived, but also skin MSC and mesangial cells were able to drive the 
differentiation of myeloid cells. Mesangial cells represent the stromal component of kidney glomeruli, 
and have been defined as specialised pericytes of the glomeruli [391]. Their osteogenic and 
adipogenic differentiation capabilities, along with their self-renewal capacity, led some investigators 
 187 
to define them as mesenchymal stem cells [392]. The ability to differentiate mature and immature 
myeloid populations adds therefore on to the list of common features shared between MSC of BM 
origin and those isolated from peripheral tissues (Figure 5.4 and [14]), thus revealing new 
perspectives in the functional notion of tissue mesenchyma.  
 Taken together, these data suggest a scenario in which tissue MSC can recruit and promote the 
maturation of myeloid precursors that recirculate in peripheral blood. 
However, the composition of the three myeloid subsets differs with the source of MSC. This is in line 
with the current notions on tissue-specific macrophages, which are characterised by different histo-
morphological features and functions. The differences documented in BM cells and cutaneous MSC 
or mesangial cells co-cultures could therefore account for a different ability of these cells to 
differentiate tissue specific macrophages. Further investigation is required to understand the impact of 
this in vitro property in the physiology of the recruitment and differentiation of peripheral tissue-
specific macrophages.  
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 CHAPTER 6. 
GENERAL DISCUSSION 
The findings presented in this thesis highlight a new role for stromal cells in the differentiation of 
circulating progenitors into macrophages in peripheral tissues. Myeloid progenitors differentiate into 
granulocytes and macrophages when in contact with or in proximity to MSC from different tissue 
sources. The molecular mechanisms underlying this effect appear to differ depending on the myeloid 
subset. Whilst NOS2 contribute to macrophage differentiation, complement C3 fraction drives the 
generation of early myeloid cells. Nos2-/- recipients are haematologically normal under steady-state 
conditions, yet they show a significant impairment in the ability to reconstitute macrophages in the 
BM after irradiation and transplantation of WT BM cells. Although limited to in vitro evidence, we 
showed that BM cells from Nos2-/- mice could differentiate into macrophages when in contact with 
WT MSC, thus suggesting that there is a defect in the haematopoietic environment of Nos2-/- mice.  
We have shown that MSC mediated Nos2 expression is dependent on TNF-α and IFN-γ, thus 
indicating that inflammatory molecules play an important role. Similarly, MSC immunomodulatory 
activity is susceptible to environmental cues. In fact, two opposing functional profiles have been 
identified for MSC immune regulation, whereby different TLR stimulation polarises MSC towards a 
pro- or alternatively an anti-inflammatory activity [135].  
During inflammation, cells of the innate immune system infiltrate tissues and their activation results 
into the release of chemokines and cytokines. Innate immunity is not only critical for removing dead 
cells and fight infections, but also to ignite a series of processes that limit inflammation and, as a 
consequence, promote tissue repair. Macrophage polarization has been shown to have a fundamental 
role in this, as inhibition of the transcription machinery driving the reprogramming of macrophage 
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function leads to impaired tissue regeneration [145]. Under these circumstances, ‘licensed’ tissue 
MSC may be instrumental at orchestrating resolution of inflammation not only by suppressing 
immune effectors, but also – and possibly more importantly – by recruiting and activating cellular 
networks of ‘innate (M2 macrophages) and adaptive (TREGS) immune tolerance’ [393]. Therefore, in 
the early stages of inflammation, MSC-induced differentiation of immature neutrophils and 
macrophages could be fundamental to initiate such a process by increasing the number of myeloid 
cells susceptible to acquire this anti-inflammatory profile at the site of inflammation.  
The interaction between MSC and macrophages is also central in the BM niche to regulate HSPC 
mobilization and egress [262]. However, the nature of MSC-macrophage interaction as ‘inflammatory 
unit’ in the stem cell niche has never been addressed or surmised. The notion of ‘stem cell niche’ 
traditionally refers to an environment that assures stem cell self-renewal and dormancy, and regulates 
differentiation. However, very recent results have suggested it may also be ‘immunoprivileged’ 
because TREGS have been identified in discrete areas of the BM niche [394]. On the other side, it has 
been observed that inflammation, transplantations, bleeding, infection and chemotherapeutic agents 
stress the dormant HSC and induce it to proliferate and differentiate. Therefore, it is plausible that the 
immunomodulatory activity of MSC in the BM niche may be subject to inflammatory cues enabling 
them to regulate HSC responses to stress.  
There is also evidence that the modalities by which MSC control inflammation might overlap with 
those regulating stem cell quiescence. Several metabolic pathways have been identified that can 
control T cell proliferation and that prominently involve the depletion of amino acids like tryptophan 
and arginine [378]. Similar mechanisms have been identified to regulate HSC self-renewal. 
Furthermore, m-TOR independent pathways, involving lipid and nucleotide metabolism, restrict HSC 
entry into cell cycle [395]. Dormant and self-renewing HSC reside in hypoxic niches, whereby they 
generate energy by maintaining a high rate of glycolysis, whereas the differentiated progeny has 
opposite metabolic needs. Finally, fibroblast growth factors have been extensively documented to act 
as metabolic regulators [396]. 
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These considerations suggest the existence of common pathways between inflammation and tissue 
repair in which the interaction between tissue MSC and myeloid cells play a crucial role. Our 
observation that MSC can differentially drive the generation of myeloid cells with different functions 
depending on the environmental signals is therefore a step forward in understanding tissue 
homeostasis through inflammation.  
It should be noted that a parallel can be drawn also between the stem cell and the tumour niche in 
which much more information about the interaction between inflammation and the cancer self-
renewing process is available. For the vast amount of chemokines and cytokines released by tumour 
cells, tumour has indeed been defined as ‘a wound that never heals’. Tumour cells hijack normal 
tissue niches for their own survival by reconfiguring the host microenvironment. In solid tumours, 
cancer cells are embedded in a framework of tumour associated macrophages and fibroblasts that 
foster their growth and promote immune evasion by inducing an immunosuppressive environment. In 
the field of haematopoietic malignancies, it is also well established that leukaemia cells exploit the 
niche ability to maintain HSC quiescence to evade the anti-proliferative and anti-apoptotic effects of 
chemotherapeutic agents, thus accounting for disease relapse. 
New tools and investigations are therefore required along the concept that inflammation is 
intrinsically linked to tissue repair. Our data on the ability of tissue MSC to drive the differentiation of 
circulating progenitors into tissue macrophages are possibly fundamental to produce vital information 
in stem cell biology and cancer treatment.  
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CHAPTER 7. 
FUTURE PLANS 
We have observed that MSC are able to induce the differentiation and expansion of three different 
subsets of myeloid cells. These observations may have profound implications for understanding the 
biology of the interaction between haematopoietic and mesenchymal stroma. However, the 
fundamental step is to investigate whether such phenomenon really occurs in vivo.  
Since we have identified a number of molecules that appear to be selectively involved in the 
differentiation of CD11b+ cell subsets, we can address whether the absence of these molecules 
determines an impairment of myeloid subsets differentiation in vivo. 
In order to do this, lethally irradiated CD45.2 WT recipients will receive a congenic CD45.1 BM 
transplantation and adoptive transfer of MSC from WT or knockout (Tnfr1/r2-/-, C3-/- and Musk-
L;Agrn-/-) mice. The relative abundance of the three different subsets induced by WT or knockout 
MSC will be evaluated in peripheral blood, BM and peripheral organs after 3, 7 and 10 days post-
transplantation. 
In order to understand whether the deficiency of NOS2 in the haematopoietic niche impairs not only 
the early reconstitution of macrophages but also the long term engraftment of HSPC, we will study 
the proportions of mononuclear phagocyte populations and their progenitors (HSC, CMP and GMP) 
in BM and spleen 10, 20 and 30 days post-transplantation of WT BM cells into clodronate-depleted 
and lethally irradiated Nos2-/- mice. 
Furthermore, we will investigate if and how the different proportion of macrophages found in the BM 
niche of WT and Nos2-/- recipients modulates the mobilization and egress of HSPC under 
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physiological and inflammatory conditions (G-CSF induced mobilization or infection). The 
proportion of stem cells and neutrophils will be evaluated in peripheral blood and BM under such 
conditions. 
In order to further unravel the mechanism involved in MSC-induced differentiation of myeloid cells, 
and to identify if there is a common pathway impairing the ability of Nos2-/-, Tnfr1/r2-/- and Musk-
L;Agrn-/- MSC to differentiate macrophages, we will perform a proteomic analysis on MSC isolated 
from WT and from knockout mice. If a discrete number of effector molecules arise, their precise 
involvement in MSC driven myeloid differentiation will be validated by means of the most 
appropriate technology, such as knockout models, RNA interfering or metabolic inhibitors.  
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Summary
The properties of mesenchymal stem cells (MSC) have
been widely investigated during the last decade, from their
differentiation capacity to their immunosuppressive effect
on any type of immune cell. These properties have been
successfully harnessed for the treatment of inflammatory
diseases such as graft versus host disease (GvHD). Differ-
ent mechanisms have been proposed for their immunosup-
pressive properties, although it seems likely that they are
used in concert. The inflammatory environment to which
MSC are exposed plays a pivotal role in activating their
functions.
Conversely, the interplay of MSC with the immunore-
gulatory networks recruited during inflammation is funda-
mental to the delivery of immunosuppression. Since other
types of terminally differentiated stromal cells share these
properties, it is plausible that stemness is not a required
feature. Therefore these functions may be involved in the
physiological control of acute inflammation in various tis-
sues. These notions highlight the importance of investigat-
ing the role of stromal cells as modulators of immune re-
sponses.
Mesenchymal stem cells (MSC) are multipotent pro-
genitor cells of stromal origin, originally isolated from
adult bone marrow and subsequently from other tissues in-
cluding in both adult and foetal life [1–9]. Even though
MSC are defined according to their ability to differentiate
into various tissues of mesodermal origin (osteocytes,
chondrocytes, adipocytes), there are unconfirmed reports
that they can also differentiate into endothelial cells [10],
as well as neural cells [11], and cells of endodermal origin
[12].
The identification of MSC with the use of specific
markers remains elusive. They are commonly described
as expressing CD73, CD105, CD90 and negative for the
haematopoietic (CD45) and vascular (CD31) markers [13].
In mouse MSC markers of embryonic origin such as
SSCA-1 [14] and SSCA-4 [15] have been identified, but
more recently the co-expression of PDGFRα and Sca-1
[16] appears to be particularly effective at selectively
identifying MSC because the vast majority of cells with
progenitor activity resides in this subset. The efforts at de-
tecting markers of human MSC have not delivered consist-
ent results, but have indicated that they may preferentially
express markers of neuronal lineage like low-affinity nerve
growth factor receptor-1 (LNFGR1) [17] and ganglioside
GD2 [18]. Although these markers have not been entirely
confirmed, the notion of the neuroepithelial origin of MSC
has recently been supported by an elegant study showing
that Sox1+ neuroepithelial cells supply the earliest wave of
MSC differentiation during embryogenesis [19].
Pre-MSC type cells with characteristics of pluripotency
have been isolated in the bone marrow or in foetal/perinatal
tissues. Good examples are multipotent adult progenitor
cells (MAPC), which differentiate into various lineages in
vitro using defined cytokine combinations, and when trans-
planted they directly contribute to haematopoiesis in vivo
and generate long-term repopulating haematopoietic stem
cells and the full repertoire of haematopoietic progenitors
[20].
The relative ease with which MSC can be isolated from
adult tissues and the lack of ethical concern have probably
been the main reason for their popularity. MSC have been
successfully tested for their ability to protect from a variety
of tissue injuries both in experimental [21–23] and clinical
[24] settings.
Key words: Mesenchymal; stem cells; immune responses;
immunoregulation; graft-versus-host disease; autoimmune
diseases
The immunosuppressive activity of
MSC
A further aspect that makes MSC of particular interest
is the finding that they exert immunoregulatory activities.
MSC from various species (humans, rodents and primates)
can suppress the response of T cells to mitogenic and poly-
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clonal stimuli [25, 26] and to their cognate peptide [27].
Such an effect is not cognate dependent because it can still
be observed using MSC from third-party donors fully mis-
matched for the MHC haplotype of the responder T cells
[28] or MSC which are constitutively negative for MHC
molecule expression [27]. MSC-induced unresponsiveness
lacks any selectivity, as it similarly affects memory and
naïve T cells [27] as well as CD4+ and CD8+ subsets [29].
The characterisation of MSC-induced anergic T cells
showed that the inhibitory effect of MSC is directed mainly
at the level of T cell proliferation. T cells stimulated in the
presence of MSC are arrested at the G1 phase as a result
of cyclin D2 downregulation. The expression of CD25 and
CD69 markers of T cell activation is completely unaffected
by MSC co-culture, and inhibition of T cell effector func-
tions can be reversed by MSC removal [29]. Whilst MSC
induce an unresponsive T cell profile, they can prevent the
apoptosis of activated T cells [30], indicating that MSC-
mediated immunosuppression results from an induced divi-
sion arrest anergy.
The effects of MSC on immune responses are not con-
fined to T cells. Although they are susceptible to recogni-
tion and lysis by IL-2 activated cells and natural killer (NK)
cells in vitro, due to their low expression of HLA class I
[31, 32], MSC have been demonstrated to be capable of in-
hibiting the proliferation of interleukin-2 (IL-2) or IL-15
stimulated NK cells [31–33]. Whilst there is agreement on
the immunosuppressive ability of MSC on NK cells, their
influence on NK cell-mediated cytotoxicity remains con-
troversial. Initial data suggested that MSC could inhibit the
cytolytic activity of IL-2 activated NK cells [33], but more
recent studies have shown that lysis of HLA I positive allo-
geneic targets by freshly isolated NK cells is not inhibited
by MSC [31]. NK cells’ cytokine production is also influ-
enced by MSC, which are able to induce the release of IFN-
γ [32, 34] and TNF-α [34].
The effect of MSC on B cell proliferation remains con-
troversial. Studies in the mouse [29] and humans [35]
showed that MSC inhibit B cell proliferation, inducing a
block in G0/G1 phase of the cell cycle. MSC have also
been shown to inhibit the differentiation of B cells to an-
tibody secreting cells [35, 36] as well as downregulating
CXCR4, CXCR5 and CCR7 chemokine receptors [35]. In
contrast, other studies have suggested that human MSC
promote the proliferation and differentiation of B cells
from healthy donors and patients with systemic lupus
erythematosus [37]. Although apparently in contradiction,
the opposing results of these studies can be reconciled
by the different conditions in which B cells have been
stimulated. As a result of different B cell stimulation, the
secreted cytokines could in fact polarise MSC towards a
proinflammatory phenotype. This concept is well estab-
lished for other cell types with regulatory functions, such
as monocytes/macrophages [38].
The immunosuppressive properties of MSC can also
target antigen-presenting cells (APC). The same effects ex-
erted on cell cycle progression in T cells have been docu-
mented to affect monocytes [39]. MSC inhibit the differen-
tiation of monocytes or CD34+ haematopoietic progenitors
into mature dendritic cells (DC) [40]. DC precursors ex-
posed to MSC lose their ability to stimulate alloresponses
and acquire regulatory features producing large amounts of
interleukin-10 [41].
Besides their effect on immune cells, MSC exhibit an
antiproliferative activity in vitro on different tumour cell
lines, whereas in vivo they facilitate tumour engraftment
and growth [42]. Since MSC contribute to the stem cell
niche, these findings indicate that MSC can also provide
the niche for cancer stem cells [43] and may influence the
course of malignant diseases not only by creating an im-
munosuppressive environment within the tumour but also
protecting tumour cells from apoptosis and facilitating its
spread [44].
Mechanisms involved in the
immunosuppressive effect
The mechanisms by which MSC exert their antiproliferat-
ive effect have still to be fully elucidated, although sever-
al candidate molecules have been proposed that are likely
to act in concert and/or in alternate fashion depending on
the environmental conditions to which MSC are exposed.
Studies in both animal and human systems have shown
that, although the effect requires an initial cell contact
phase, the ultimate signal is mediated by several factors,
which include transforming growth factor β-1 (TGF-β1)
[26], indoleamine 2,3-dioxygenase (IDO) [45],
prostaglandin E2 (PGE2) [41], nitric oxide (NO) [46], heme
oxygenase-1 (HO-1) [47], and insulin-like growth factor-
binding proteins [48].
The role of these molecules is different in the mouse
and in humans, as in human MSC the effect of IDO is
prominent, whereas in murine MSC NO seems to play a
major role.
Transforming growth factor β-1 (TGF-β1) and hepato-
cyte growth factor (HGF) were the first molecules to be de-
scribed as mediators of the immunosuppressive properties
of MSC [26]. Recently it has been proposed that TGF-β
gene expression is modulated in a contact-dependent mech-
anism by MSC [49].
Indoleamine 2,3-dioxygenase (IDO) is one of the im-
munosuppressive mechanisms believed to control T cell
responses to autoantigens and alloantigens [50, 51], be-
cause its activity causes tryptophan depletion and kynuren-
ine synthesis, capable of inhibiting the growth and function
of immune cells by depleting nutrients and/or direct toxic
activity of their catabolites [52]. IDO has been observed to
be produced by MSC under inflammatory conditions such
as exposure to IFNγ, and has been implicated in the inhib-
ition of T-cell [45], NK-cell [32] and activated B-cell [33]
proliferation.
Another mediator with immunosuppressive potential
secreted by MSC is prostaglandin E2 (PGE2). Inhibitors of
PGE2 synthesis mitigate the overall human MSC suppress-
ive effects [32, 41], with IDO as a synergistic partner [32].
It has been shown that MSC-derived PGE2 is involved in
skewing an inflammatory environment into an antiinflam-
matory environment, altering the cytokine secretion profile
of dendritic cell subsets (DC1 and DC2) and T-cell subsets
(Th1, Th2, or Tregs) [41].
Nitric oxide (NO) is synthesised by the inducible iso-
form of the NO synthase (iNOS), which is induced in MSC
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by contact with activated CD4+ or CD8+ lymphocytes [46].
The proliferation of T cells is inhibited by NO-mediated
suppression of phosphorylation of Stat5, a transcription
factor crucial for T cell activation and proliferation [53].
Sato et al. have shown that iNOS–/– MSC are less effective
in suppressing T cell proliferation than wild type MSC, and
this is demonstrated also by the blocking effect of N-nitro-
L-arginine methyl ester, a specific inhibitor of the iNOS, on
MSC immunomodulatory potential [46].
It has also been shown that HLA-G, a nonclassical
MHC class I, is involved in immunomodulation by MSC
[54]. Dendritic cells, NK, and T cells present inhibitory re-
ceptors that interact with both the membrane-bound and
the soluble isoform of HLA-G, which are expressed by hu-
man MSC. The soluble isoform HLA-G5, secreted by MSC
after IL-10 stimulation, can inhibit the cytolitic activity of
NK and CD8+ T cells, shift the T cell response to a Th2
cytokine profile and induce the expansion of regulatory T
cells [55]. Taken together these data suggest that all these
factors may be involved, depending on the environmental
conditions to which MSC are exposed, and are crucial for
their antiproliferative activity.
Stem/progenitor cells exhibit a particularly active tran-
scriptional activity that might account for the several prop-
erties described in undifferentiated cells, including immun-
osuppression [56]. However, it has been shown that the
immunosuppressive effect of MSC is not a property con-
fined to mesenchymal progenitor cells, but is rather a func-
tion exerted by most mesenchymal cells including those
terminally differentiated. This has been demonstrated on
primary articular human chondrocytes [57] and fibroblasts
from synovial joints, lung and skin [30, 58].
All the immunosuppressive activities described so far
are not a constitutive property of MSC. For the MSC to in-
hibit immune responses, they need to be “licensed”. In fact,
Jones and colleagues showed that only the supernatants ob-
tained from co-cultures of stromal cells and activated T
cells displayed an immunosuppressive effect when added
to secondary cultures of proliferating T cells [30]. The
immunosuppressive function of MSC is elicited by IFN-γ
[33] and other proinflammatory cytokines such as TNF-α,
IL-1α, or IL-1β [59].
MSC-mediated immunosuppression is not exclusively
the result of a direct inhibitory effect but involves the re-
cruitment of other regulatory networks. MSC act in concert
with monocytes because the magnitude of the effect seems
to be proportional to the number of monocytes in culture
[60, 61]. Furthermore, MSC can also activate and expand
regulatory T cells (Tregs) [62], although Tregs themselves are
not required as a unique component to effect MSC immun-
osuppressive activity [27].
These findings suggest a crosstalk between MSC and
the environment whereby first inflammatory monocytes ‘li-
cense’ MSC to acquire their immunosuppressive proper-
ties, and in turn MSC skew the inflammatory environment
into an antiinflammatory environment both directly and
through the effect on immunoregulatory circuits involving
monocytes and Tregs.
Clinical applications
The tissue repair function and the inhibitory effect on the
cell cycle on immune and nonimmune cells are properties
that lend themselves to therapeutic exploitation, and there
are a variety of disorders for which the use of MSC has
been proposed. One of the first preclinical studies in ba-
boons transplanted with allogeneic skin grafts showed that
the in vivo administration of donor MSC to MHC-mis-
matched recipient prolonged the survival of third-party
skin grafts [25]. On the same lines are the findings in islet
transplantation. The use of MSC has been tested in a rat
model of streptozotocin-induced diabetes with a view to
producing haematopoietic chimerism in concomitance with
allogeneic islet transplantation [63].
Further preclinical studies have shown that MSC could
be successfully exploited in autoimmune diseases. MSC
can ameliorate experimental autoimmune encephalomyel-
itis (EAE), reducing central nervous system inflammation
and demyelination through the induction of peripheral T
cell tolerance [64], and reduce the relapse rate of EAE im-
pairing pathogenic T and B cell responses directed against
the immunising antigen [65]. Whilst a first report on cell
therapy for collagen induced arthritis (CIA) using MSC
showed that their use was not beneficial in curing arthritis,
suggesting that activation of the TNFα inflammatory path-
way in the injured tissues might reverse their immunomod-
ulatory effect [66], it has recently been demonstrated that a
single injection of allogeneic MSC in a CIA model can pre-
vent the occurrence of irreversible damage to bone and car-
tilage [67]. On the basis of their ability to skew the inflam-
matory environment to an antiinflammatory environment,
MSC have also been investigated in sepsis [68] and colitis
[69]. Activated MSC can induce in vivo the production of
higher amounts of IL-10 from macrophages [68, 69] by re-
leasing PGE2, thus preventing neutrophils from migrating
into tissues and causing oxidative damage [68].
The most studied therapeutic application for MSC is
graft-versus-host disease (GvHD), a severe condition that
develops after allogeneic haematopoietic stem cell trans-
plantation (HSCT). The clinical efficacy of MSC in GvHD
was initially observed in a 9-year-old boy suffering from
steroid-resistant grade IV acute GvHD who received hap-
loidentical third-party MSC [70]. Subsequently a phase II
trial involving 55 patients with the same condition demon-
strated that the infusion of MSC could significantly im-
prove overall survival [71]. A previous multicentre phase
I/II clinical trial in which MSC were given at the time
of HSCT before any sign of GvHD produced a different
outcome, no difference being observed in the incidence
of GvHD between the group receiving MSC and the con-
trols [72]. The discrepancies might be explained by the
findings of the preclinical studies. Initial studies reported
that a single infusion of MSC at the time of the transplant
did not prevent the development of GvHD in MHC-mis-
matched donor-recipient pairs [73]. The work of Tisato and
colleagues, although confirming the ineffectual activity of
MSC injected in a single dose at the beginning of HSCT,
showed that GvHD could be totally prevented by multiple
doses [74]. Polchert et al. observed that MSC could sig-
nificantly increase the survival rate of recipient mice only
Review article Swiss Med Wkly. 2010;140:w13121
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 3 of 6
when given at day +2 or +20 when IFN-γ levels are at
their peak, MSC efficacy being dependent on the presence
of IFN-γ in the environment [75]. Timing is therefore es-
sential for MSC to exert their inhibitory effect, due to the
need for the appropriate inflammatory environment to ‘li-
cence’ the MSC. The role of IFN-γ [33, 59] and of the in-
flammatory environment [30] in activating MSC had also
been previously described in vitro, as already discussed.
Another suggested role for the inflammation derived from
in vivo studies [23, 74, 76] is the recruitment of MSC. IFN-
γ might be able to cause the accumulation of antigen-spe-
cific T cells at the site of inflammation by inducing MHC
molecule expression on the endothelium [77]. IFN-γ could
therefore promote accumulation of MSC and recruitment
of antigen-specific T cells at the same site, retaining sup-
pressive and effector cells in the same anatomical compart-
ment [78].
Besides their use to modulate immune responses, MSC
have been employed to promote tissue repair. It is likely
that the antiproliferative and antiapoptotic activity of MSC
on parenchymal cells [42] effect a cytoprotective action
that preserves residual stem cells from further destruction
thus favouring their recovery and spontaneous tissue repair.
The anti-inflammatory activity also favours the generation
of antiinflammatory macrophages, which are crucial for
promotion of tissue repair [79]. MSC has therefore been
used to promote the expansion and development of islet β-
cells in diabetes therapy. Repeated transplantation of hu-
man MSC-induced repair of pancreatic islets and renal
glomeruli in NOD/scid mice suffering from STZ-induced
diabetes [80]. By coinjecting sex mismatched bone marrow
cells (BMC) and syngeneic or allogeneic MSC it was pos-
sible to demonstrate that tissue repair was not the result of
trans-differentiation but rather the consequence of an endo-
genous repair process initiated by the graft and the suppres-
sion of T cell-mediated immune response against newly
formed β-cells by donor MSC [81]. A recent field of in-
vestigation is represented by the therapeutic potential of
MSC in acute renal failure [82] in which a paracrine activ-
ity mediated by MSC appears to play the main role in tis-
sue repair [23]. Similarly, in a model of bleomycin-induced
pulmonary fibrosis, inflammation and collagen deposition
were significantly reduced after MSC administration via a
mechanism involving IL-1 receptor antagonist [22].
Conclusions
The immunosuppressive properties of MSC have aroused
keen interest in the last few years. Current data indicate that
MSC utilise a number of synergistic mechanisms to non-
specifically control immune responses and activate further
immunosuppressive circuits to boost MSC action. In vitro
and in vivo studies have suggested that the inflammatory
environment is crucial to enable MSC to exert their anti-
proliferative and antiapoptotic effects, thus highlighting the
importance of dissecting the molecular features of the mi-
croenvironment to maximise the therapeutic impact. This
notion is also important in improving our understanding of
the function of tissue stroma as effector of innate tolerance
to rapidly modulate immune response and, with overlap-
ping mechanisms, to protect tissue progenitors from dying,
activate their self-renewal programme and contribute to tis-
sue repair.
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